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Altered lung tissue bioenergetics is an important and early step in the 
pathogenesis of acute lung injury (ALI), one of the most common causes of admission to 
medical ICUs. A wealth of information exists regarding the effect of ALI on specific 
mitochondrial and cytosolic processes in isolated mitochondria, cultured endothelial cell, 
and intact lungs. However, the interdependence of lung cellular processes makes it 
difficult to quantify the impact of a change in a single or multiple cellular process(es) on 
overall lung tissue bioenergetics. Integrating bioenergetics data from isolated 
mitochondria and intact lung is necessary for determining the functional significance of 
targeting a specific cellular process for prognostic and/or therapeutic purposes. Thus, the 
main objective of my dissertation was to develop and validate comprehensive, 
thermodynamically-constrained models of mitochondrial and lung tissue bioenergetics, 
and to use these models to predict the impact of ALI-induced changes in mitochondrial 
and cytosolic processes on lung tissue bioenergetics. For Aim 1, I developed an 
integrated model of the bioenergetics of mitochondria isolated from rat lungs, which 
incorporates the major biochemical reactions and transport processes in lung 
mitochondria. The model was validated by assessing its ability to predict experimental 
data not used for parameter estimation. The model provides important insights into the 
bioenergetics of lung mitochondria and how they differ from those of mitochondria from 
other organs. For Aim 2, I developed and validated an integrated computational model of 
lung tissue bioenergetics. The model expanded the computational model developed under 
Aim 1 by accounting for glucose uptake and phosphorylation, glycolysis, and the pentose 
phosphate pathway. The model was then used to gain novel insights into how lung tissue 
glycolytic rate is regulated by exogenous substrates, and assess differences in the 
bioenergetics of isolated mitochondria isolated from lung tissue and those of 
mitochondria in intact lungs. For Aim 3, the models developed under Aims 1 and 2 were 
used to quantify the impact of previously measured changes in specific mitochondrial 
processes in a rat model of clinical ALI on lung mitochondrial and tissue bioenergetics. 
To the best of our knowledge, the two computational models are the first for lung 
mitochondrial and tissue bioenergetics. These models provide a mechanistic and 
quantitative framework for integrating available lung tissue bioenergetics data, for testing 
novel hypotheses regarding the role of different cytosolic and mitochondrial processes in 
lung tissue bioenergetics and the pathogenesis of ALI, and for identifying potential 
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Chapter 1 : Introduction and background 
1.1 Clinical motivation  
Acute lung injury (ALI) and its most severe form acute respiratory distress 
syndrome (ARDS) are a major cause of morbidity and mortality in medical intensive care 
units (ICU) [1, 2]. ARDS occurs in ~200,000 patients in the U.S. per year and carries a 
mortality rate of 30-40% despite the best supportive care [3]. 
One reason for this high mortality rate is the lack of a clinical means for early 
detection of ALI/ARDS [2]. For instance, Herasevich et al. revealed that bedside 
providers are unable to detect ALI early enough in 70% of ALI patients [4], which delays 
the administration of available treatments at a time when interventions are most effective. 
Another reason for the high mortality rate is the lack of effective therapies. Several 
potential pharmacologic therapies have been evaluated in clinical trials for the treatment 
of ALI/ARDS [1]. These treatments include glucocorticoids, surfactants, inhaled nitric 
oxide, antioxidants, protease inhibitors, and a variety of other anti-inflammatory 
treatments. Unfortunately, to date none of these pharmacologic treatments has proven to 
be effective. As a result, existing treatments are mostly supportive. For example, one 
essential therapy is lung-protective mechanical ventilation with high oxygen (O2) 
concentrations to reverse hypoxemia (i.e. low blood O2) and hypoxia (low tissue 
oxygenation) associated with ALI/ARDS. Even though this therapy can help restore 
blood O2 level to close to its normal level, it has serious side effects [1, 2]. For instance, 




due to oxidative stress [5], and exacerbates lung injury associated with common causes of 
clinical ALI/ARDS [6, 7]. Furthermore, the positive pressure used in mechanical 
ventilation may lead to over-distention of the alveoli and as a result may cause 
mechanical injury to the epithelial cells and exacerbate lung injury. Recent advances 
including PEEP (positive end-expiratory pressure) and lung-protective ventilation have 
significantly reduced the risk of mechanical injury [8, 9] and improved outcomes.  
Thus, there is an urgent need for a clinical means for early detection of 
ALI/ARDS and novel treatments options for ALI/ARDS. As such, the long-term goal of 
this work is to develop a mechanistic and quantitative approach to identify novel cellular 
targets for therapeutic and/or prognostic purposes in patients with ALI/ARDS. 
1.2 Etiology, pathophysiology, and pathogenesis of clinical ALI/ARDS 
Clinical ALI/ARDS can be due to a direct or indirect insult to the lung [2, 3]. The 
most common direct insult is pneumonia. Less common direct insults include inhalation 
injury, pulmonary contusions, reperfusion injury, fat emboli, and near drowning. The 
most common indirect insults include sepsis, severe trauma, and shock. Less common 
indirect insults include multiple blood transfusions, burns, head injury, drug overdose, 







Figure 1.1: Pathogenesis of ALI/ARDS. Reproduced from reference [2]. 
 
As shown in Figure 1.1 and Figure 1.2 [2, 3], cardinal features of clinical 
ALI/ARDS include compromised lung alveolar-capillary barrier and pulmonary edema, 
which leads to impaired gas exchange and hypoxemia, multi-organ failure, and often 
death. Clinical criteria for ALI/ARDS include bilateral pulmonary infiltrate on chest 
radiographs reflective non-cardiogenic pulmonary edema, and hypoxemia as measured by 
the ratio of partial pressure of arterial O2 (PaO2) and fraction of inspired O2 (FiO2). 
Normal PaO2/FiO2 is ~500 mmHg as compared to PaO2/FiO2 ≤ 300 mmHg for ALI and ≤ 
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Figure 1.2: The injured alveolus in the acute phase of ALI (right) compared to normal 
alveolus (left). Reproduced with permission from [3], Copyright Massachusetts Medical 
Society.  
 
There is sufficient evidence that enhanced reactive oxygen species (ROS) 
generation and inflammation play a key role in the pathogenesis of ALI/ARDS [2]. 
Neutrophils accumulate in lung microvasculature in response to the pulmonary insult and 
become activated. As a result, a number of toxic mediators are released from neutrophils, 
including oxidants, leukotrienes and proteases (Figure 1.2). These mediators can cause 
damage to lung endothelial and epithelial cells and eventually lead to cell death including 




1.3 Hyperoxia-induced ALI/ARDS 
Several animal models of clinical ALI/ARDS have been developed to further 
understand the pathogenesis of ALI/ARDS [11, 12]. As mentioned above, prolonged 
exposure to high O2 (hyperoxia) can lead to lung injury consistent with clinical ALI. 
Crapo et al. [12, 13] demonstrated that the extent of hyperoxia-induced ALI is dependent 
on O2 concentration and exposure duration. They provided a detailed description of 
histologic and morphometric changes in lungs of rats exposed to 100% O2 hyperoxia. 
Specifically, they observed no structural or functional changes in lungs of rats exposed to 
100% O2 for up to 40 hours. However, the lungs of rats exposed to 100% O2 for 60 hours 
showed significant cellular and functional changes, including loss of capillary endothelial 
cells and cell surface, infiltration of phagocytic leukocytes, and an increase in the 
thickness of air-blood barrier. Longer exposure periods resulted in additional loss of 
endothelial cells, compromised microvascular capillary permeability, severe hypoxemia 
and death within 64 to 72 hours.  
Although the mechanisms that lead to pulmonary hyperoxic injury are not fully 
understood, there is ample evidence that the deleterious effects of high O2 are the result 
of increased formation of ROS such as superoxide •
2(O )
 , hydrogen peroxide ( 2 2H O ) and 
hydroxyl radical ( •OH  ). Excessive ROS can readily react with tissue structures and 
macromolecules (e.g. DNA, proteins, lipids) and cause damage to the lung endothelial 
and epithelial cells.  
Cellular antioxidant mechanisms can detoxify ROS via enzymatic (e.g. 
superoxide dismutase, SOD (MnSOD and CuZnSOD); catalase, CAT; glutathione (GSH) 




Superoxide can be efficiently catalyzed into H2O2 by intra- and extra-matrix SODs [14], 
and the resulting H2O2 can then be reduced to water by CAT, the GSH system, or the 
TRX system. GSH is one of the most abundant cellular antioxidants. It exists in both 
cytosol and mitochondria. The pentose phosphate pathway and the GSH redox cycle are 
the major sites for GSH synthesis [15]. Up-regulation of the cytosolic GSH redox cycle 
has been shown to protect the lung cells from oxidant injury, including key mitochondrial 
enzymes [13, 16]. However, during the pathogenesis of ALI/ARDS, uncontrolled 
increase of ROS production is suggested to overwhelm the capacity of antioxidant 
mechanisms, resulting in oxidative stress with damage to lipids, proteins and DNA [17].  
1.4 Lung mitochondrial and tissue bioenergetics 
Altered lung tissue bioenergetics (i.e. cellular capacity for ATP production) play a 
key role in the pathogenesis of hyperoxia induced ALI/ARDS. The following is a brief 
summary of the key substrates and cellular processes that affect lung mitochondrial and 
tissue bioenergetics. 
Glucose is the major energy substrate for lung. Even though fatty acids and amino 
acids can also be oxidized by lung, their contributions for the lung energy metabolism are 
relatively small compared to that for glucose [18]. Gluconeogenesis does not occur in 
lung, and glycogen stores are limited so that glycogenolysis is not prevalent, and the lung 
depends primarily on the circulation for its glucose needs for energy production [18]. 
Mitochondria are the major site of energy production in lung, accounting for 85% 
of ATP production in the whole organ, while glycolysis accounts for the other 15% of 
ATP production [18]. Glycolysis and the pentose phosphate pathway (PPP) are two key 




PPP, with some of the generated ribose 5-phosphate (R5P) subsequently used for the 
synthesis of nucleotides  [18]. Unused R5P reenters the carbohydrate pool [18, 19]. In 
glycolysis, glucose is broken down to pyruvate and lactate through a series of enzymatic 
reaction processes with two ATP molecules consumed at hexokinase (HK) and 
phosphofructokinase (PFK) catalyzed reaction processes, and subsequently four ATP 
molecules are generated at phosphoglycerate kinase (PGK) and pyruvate kinase (PK) 
catalyzed reaction processes. Therefore, there is a net production of two ATP molecules 
for each glucose that is consumed via glycolysis. All the generated lactate and some of 
the pyruvate are released into the blood from the cytosol [18]. Most of the generated 
pyruvate enters the mitochondria to generate the majority of lung tissue ATP via the 
coupled processes of pyruvate oxidation and the reactions of tricarboxylic acid (TCA) 
cycle, electron transport chain (ETC) and oxidative phosphorylation (OxPhos). 
Specifically, in mitochondria, pyruvate is oxidized by pyruvate dehydrogenase 
(PDH) to produce acetyl-CoA (ACoA), which enters the TCA cycle to generate the 
reducing equivalents or the coenzyme electron donors NADH and FADH2 (reduced 
forms of pyridine nucleotide and flavin adenine dinucleotide). NADH and FADH2 then 
enter the ETC at complex I and complex II, respectively, passing electrons to UQ to form 
UQH2. At complex III, UQH2 passes two electrons to cytochrome c (UQH2 oxidized, 
cytochrome c reduced). Cytochrome c is then oxidized by O2 at complex IV to form 
water. At the same time, protons are pumped from the mitochondrial matrix into the 
intermembrane space at complexes I, III and IV, generating proton gradient (ΔpH) and 
membrane potential (ΔΨ) across the inner membrane. Using the energy provided by the 




ATP at complex V. Mitochondrial membrane potential (ΔΨ) is a key component in the 
bioenergetics that controls ATP production and mitochondrial redox status, and is 
associated with apoptosis (programmed cell death). A change in ΔΨ is indicative of 
mitochondrial dysfunction, and the collapse of ΔΨ is an early sign of apoptosis. 
The outer mitochondrial membrane (OMM) has the voltage-dependent anion 
channels (VDACs) that allow free passage of ions and metabolites (respiratory substrates, 
phosphates, and adenine nucleotides) into and out of the mitochondrion, while the inner 
mitochondrial membrane (IMM) is impermeable to most ions and metabolites. Several 
transporters, including metabolite carriers, inorganic phosphate carrier (PIC) and adenine 
nucleotide translocase (ANT), exist in the IMM to facilitate the transport of specific ions 
and metabolites into and out of the mitochondrial matrix. 
1.5 Role of lung mitochondrial dysfunction in the pathogenesis of 
hyperoxia-induced ALI/ARDS 
As mentioned above, prolonged exposure to hyperoxia leads to ALI/ARDS [2].  
Rats exposed to > 95% O2 environment develop ALI and die within 64-72 hours from 
lung injury [5]. Rat exposure to hyperoxia is a well-established animal model of human 
ALI/ARDS that can reproduce the cardinal features of clinical ALI/ARDS, including 
epithelial injury, neutrophilic infiltration and edema accumulation. There is ample 
evidence that oxidative injury causes an increase in the rate of ROS production plays a 
key role in the pathogenesis of hyperoxia-induced lung injury [5, 17]. The mitochondrial 
ETC is the main source of ROS under hyperoxic conditions [17]. As shown in Figure 1.3, 
excess mitochondria ROS cause damage to mitochondrial proteins, membranes and 




cardiolipin and increase the release of cytochrome c, and initiate mitochondria 
permeability transition pore (PTP) opening, mitochondria swelling, outer-membrane 
rupture, and eventually cell death [14]. 
 
 
Figure 1.3: Overview of the diverse roles of mitochondrial ROS [17]. Figure reproduced 
from [17] with permission from Portland Press. 
 
 
A wealth of information exists regarding bioenergetic cellular processes measured 
in mitochondria isolated from rat lungs, cultured pulmonary endothelial cells, and intact 
rat lungs, and the effects of prolonged exposure to hyperoxia on these processes [7, 18, 
20-24]. Audi et al. demonstrated 50% decrease in complex I activity in lungs of rats 




(77%) and complex II (63%) activities in lung homogenates of rats exposed to >95% O2 
for 48 hrs [26]. The decrease in complex I activity could be attributed to the oxidation of 
cardiolipin [10], which is important for electron transfer in the ETC. Besides, 7 out of the 
45 complex I subunits are encoded by mtDNA, which is known to be highly sensitive to 
mitochondrial ROS damage [26].  
Mitochondrial dysfunction is associated with energy deficiency since 
mitochondria are the major site of ATP production, accounting for 80-85% of ATP in 
lung tissue [18]. Even though cytosolic glycolysis can partially compensate for the lost 
ATP production in mitochondria, it is not enough to maintain the lung ATP level [16]. 
Bongard et al. [16] demonstrated that inhibition of mitochondria complex I decreased the 
whole lung tissue ATP level by ~60% and compromised microvascular permeability as 
measured by an increase in pulmonary vascular endothelial filtration coefficient (Kf, a 
sensitive measure of endothelial barrier function) by 262%, consistent with the need for 
ATP to maintain the barrier function of endothelial cells. Moreover, they demonstrated 
that the decrease in lung tissue ATP and the increase in Kf can be reversed by adding 
coenzyme Q1 (CoQ1). The oxidized form of CoQ1 can be reduced to CoQ1H2 by cytosolic 
enzyme NADPH-quinone oxidoreductase 1 (NQO1) and by complex I. CoQ1H2 then 
enters mitochondria, passes electrons to complex III, and hence bypass complex I to 
restore mitochondrial bioenergetics [16]. These results suggest that altering mitochondrial 
bioenergetics can reproduce one of the cardinal features of ALI, and hence are consistent 
with an important role for mitochondrial bioenergetics in the pathogenesis of ALI. 
Furthermore, the results suggest that manipulation of mitochondrial pathways are 




Pulmonary edema formation and clearance are regulated by changes in osmotic 
pressure [27]. For edema clearance processes, Na+ is transported from lung alveolar fluid 
into pulmonary circulation, and as result an osmotic gradient is created. The alveolar 
fluid can then be reabsorbed by this osmotic gradient. The active transport of Na+ 
requires energy, and hence is ATP dependent via the Na,K-ATPase. The Na,K-ATPase 
pump is a key transporter of Na+ and thus is important for lung edema clearance. For 
instance, Lecuona et al. demonstrated that Na,K-ATPase activity is significantly inhibited 
in acute lung injury, resulting in edema in interstitial space [28]. Moreover, a study by 
Factor et al. suggested that over-expression of Na,K-ATPase in rats improved alveolar 
fluid clearance and protected rats against hyperoxia-induced ALI as measured by the 
increase in the time these rats survived in >95% O2 environment [29]. Overall, the 
requirement of ATP for edema clearance underscores the importance of bioenergetics in 
the progression of lung diseases, including ALI.   
1.6 Computational models of lung and other tissue mitochondrial 
bioenergetics 
There is a wealth of data on the bioenergetics of lung tissue at the molecular, 
cellular and whole organ levels, and on the impact of lung injury on mitochondrial 
enzymes, transporters and macromolecules [7, 16, 18, 20-24]. However, quantitative 
integration of such data is difficult, and the interdependence of lung cellular processes 
makes it difficult to quantify the impact of a change in a single or multiple cellular 
process(es) on overall lung tissue bioenergetics. Integrated computational modeling has 
been used to describe mitochondrial and tissue bioenergetics of other organs, including 




[30-34]. However, to the best of our knowledge, no such model exists for bioenergetics 
of lung tissue or isolated lung mitochondria.  
The first computational model of energy metabolism was developed by Garfinkel 
et al. in 1960s for Ehrlich ascites tumor cells, and was subsequently used to model energy 
metabolism in dog and rat hearts [30, 35, 36]. Figure 1.4 shows a block diagram of their 
energy metabolism model, which incorporates key reactions in glycolysis and key 
mitochondrial pathways. Each enzyme was formulated in the simplest terms that can 
explain their in situ kinetics [30]. Their model was able to provide regulatory insights of 
anoxic perfused rat heart [30] and ischemic metabolism in dog heart [35].  
 
 
Figure 1.4: Block diagram of the metabolic processes included in the first model of 
energy metabolism. Arrow indicates direction of metabolic flux. BOH: NAD-linked 
substrate. Figure was reproduced from reference [37] with permission from Elsevier. 
 
Subsequently, with the development of fast computing platforms, more detailed 
computational models of mitochondrial function with complex kinetics were developed 




kinetics of electron transfer and proton translocation by ETC, ATP synthesis by complex 
V, and passive proton leak in their model. Later, Ca2+ and Na+ were included in a model 
by Magnus et al. to study their interactions with cellular energy metabolism in pancreatic 
beta cells [40]. Their model simulations agreed well with experimental data of 
mitochondrial Ca2+ uptake and the influence of Ca2+ alterations on mitochondrial oxygen 
consumption and ATP synthesis in pancreatic beta cells. A series of models of oxidative 
phosphorylation (OxPhos) were developed by Korzeniewski et al. to study the control 
mechanisms of OxPhos and energy production in skeletal muscle during exercise (change 
in energy demand) [34, 41-44]. 
 
 
Figure 1.5: Scheme of the mitochondrial model structure by Holzhütter et al. [39].  
Left: Schematic representation of the reactions in whole model. Right: Reaction scheme 
of the respiration chain. Reproduced with permission from Elsevier. 
 
In 2003, Cortassa et al. introduced a detailed computational model of the TCA 




mitochondria respiration and energy balance in cardiomyocytes mediated by Ca2+ 
regulations of mitochondrial dehydrogenase enzymes [38, 45]. In another study, Cortassa 
et al. integrated cardiac electrophysiology (electrical activity of the cardiomyocyte and 
the molecular and cellular processes that govern their signaling) and cardiac contraction 
into a model of the mitochondrial bioenergetics of cardiomyocytes to study how energy 
demand is matched by mitochondria in response to increased workload [33].  
Beard and coworkers improved the fidelity of computational models of 
mitochondrial bioenergetics by applying thermodynamic principles in the modeling of 
reaction and transport fluxes [32, 46, 47]. Using experimental data of isolated enzymes 
and transporters, Beard and coworkers developed detailed mechanistic models for key 
enzymes and transporters accounting for the effects of pH, ionic strength, and cation 
binding and buffering. For example, detailed mechanistic models have been developed 
for citrate synthase [48], isocitrate dehydrogenase [49] and succinyl-CoA synthetase [50] 
and key transporters such as monocarboxylate transporter [51]. Recently, Dash and 
colleagues developed and parameterized detailed kinetic models for mitochondrial cation 
transporters, including Ca2+ uniporter (CU), Na+/Ca2+ exchanger (NCE) and Na+/H+ 
exchanger to study regulations of mitochondrial cation homeostasis [47, 52-55]. These 
models not only provide foundation for integrated computational models at the cellular 
level, but also facilitate understanding of how OxPhos and ATP synthesis is regulated in 
skeletal muscle and heart during ischemia and exercise, and how energy metabolism 
breaks down under pathophysiological conditions [56-61] 
Critical bioenergetics regulation questions have been addressed using integrated 




have focused on the question of how mitochondrial ATP synthesis is controlled. Potential 
mechanisms such as feed-forward control and feedback control were tested (see above). 
Moreover, models were developed to explain metabolic oscillation during heart ischemia 
[62-64]. Mitochondrial ROS production and scavenging have been incorporated into 
mitochondrial bioenergetics models to study the role of ROS in the progression of 
diseases [65, 66]. Recently, electron microscopy showed that mitochondria are not 
uniformly distributed in cardiomyocytes [67], some mitochondria are aggregated into 
different sizes of columns. The impact of this mitochondrial heterogeneity on 
bioenergetics was investigated using a mitochondrial computational model that accounts 
for mitochondrial heterogeneous arrangement [67]. 
Computational models of mitochondrial and tissue bioenergetics have been 
developed for organs such as heart, liver and skeletal muscle [33, 34, 40-44, 56-61, 68]. 
However, such computational models are not available for lung bioenergetics. In contrast 
with skeletal muscle, heart and liver cells which utilize fatty acids as the main oxidative 
fuel, rat lung cells use glucose as the main energy source. In addition, lung cells are 
mostly non-excitable, and thus are postulated to behave very differently from excitable 
cells such as cardiac and skeletal muscle cells [69]. Therefore, new computational models 
of lung mitochondrial and tissue bioenergetics are needed. Such models would provide 
new insights into lung energy production under physiological and pathological 
conditions, including ALI/ARDS. 
1.7 Objective and specific aims 
There is ample evidence that altered lung tissue bioenergetics is an important and 




studies in lung isolated mitochondrial, cultured endothelial cell, lung tissue homogenate, 
and intact lung have demonstrated ALI/ARDS-induced changes in multiple lung tissue 
mitochondrial and cytosolic metabolic processes that are pertinent to overall lung tissue 
bioenergetics [1, 18]. 
 
Figure 1.6: Sample data on different levels of biological complexities 
 
However, it is difficult to integrate bioenergetics data from different levels of 
biological complexities and infer functional outcome relying on experiments alone. 
Integrating bioenergetics data from isolated mitochondria, cultured endothelial cells, and 
whole-organ through computational modeling (Figure 1.6) is necessary for determining 
the functional significance of targeting a specific cellular process for prognostic and/or 
therapeutic purposes. To that end, the key objective of my dissertation work is to develop 
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achieved through the following specific aims:  
 Specific Aim 1: Develop and validate an integrated computational model of 
the bioenergetics of mitochondria isolated from rat lungs.  
Rationale: The isolated mitochondrial preparation is widely used for evaluating 
lung tissue mitochondrial bioenergetics under physiological conditions and the impact of 
ALI/ARDS on specific mitochondrial enzymes, including mitochondrial ETC complexes 
and TCA cycle enzymes. Such a preparation is important for studying the lung tissue 
mitochondrial bioenergetics independent of cytosolic changes, including glucose uptake, 
glycolysis, and substrate availability. However, interpretation of the data is not straight 
forward since the transport processes and reaction processes are interdependent. Also, 
substrate availability and experimental environment such as buffer pH and temperature 
affect experimental results. Therefore, a computational model of lung mitochondrial 
bioenergetics is essential to interprete the isolated mitochondria experimental data. 
Objective: To develop and validate a model of lung mitochondrial TCA cycle and 
electron transport system that governs oxidative phosphorylation. The proposed model 
will provide a mechanistic and quantitative framework for 1) integrating new and existing 
data regarding lung tissue mitochondrial bioenergetics, 2) assessing the impact of a 
change in one or more mitochondrial processes on overall mitochondrial bioenergetics, 
and 3) predicting the ability to counter the effects of hyperoxia-induced ALI/ARDS on 
lung tissue mitochondrial bioenergetics by targeting specific mitochondrial processes. 
Furthermore, the proposed model is an important step towards the development and 
validation of a comprehensive thermodynamically-constrained computational model of 




 Specific Aim 2: Develop and validate an integrated computational model of 
lung tissue bioenergetics.  
Rationale: Even though mitochondria have been identified as a primary and early 
target of hyperoxia-induced ALI/ARDS, there are other potential contributing factors in 
the cytosol that may be associated with the progression of hyperoxia-induced ALI/ARDS. 
For instance, although ~85% of cellular ATP is produced in mitochondria [18], glycolysis 
is important for tissue bioenergetics since it can partially compensate for the decrease in 
lung mitochondrial ATP generation. Furthermore, the pentose phosphate pathway in the 
cytosol is important for defending against oxidative stress by generation of NADPH, 
which is a required electron donor for regeneration of the antioxidant GSH. The isolated 
perfused rat lung preparation allows us to control composition of lung perfusate and 
ventilation gas, and to directly manipulate specific key pathways pertinent to lung tissue 
bioenergetics. Previous studies [18, 21, 70, 71] using isolated perfused rat lung 
preparation, provide a wealth of information regarding lung tissue bioenergetics, such as 
glucose uptake, lactate and pyruvate production rate, ATP content, surface NADH and 
FAD, oximetry, etc.  
Objective: To develop and validate a computational model of rat lung tissue 
glucose utilization and intermediary metabolism using existing and new data. The model 
will account for the major processes that determine lung tissue bioenergetics, including 
glucose uptake and phosphorylation, glycolysis, the pentose phosphate pathway, pyruvate 
oxidation, the Krebs cycle, and oxidative phosphorylation. The model developed under 
Aim 1 will be the foundation of this lung model. The model will then be used to evaluate 
the impact of hyperoxia-induced changes in key mitochondrial and cytosolic processes 




 Specific Aim 3: Quantify the impact of hyperoxia-induced changes in specific 
mitochondrial processes on lung mitochondrial and tissue bioenergetics. 
Rationale: Published data suggest that specific mitochondrial and cytosolic 
processes pertinent to lung tissue bioenergetics, such as mitochondria complexes I and II, 
are significantly impaired in hyperoxia-exposed rats, and that these processes are 
important to lung hyperoxic lung injury and protection from this injury. The 
computational models will be important for determining the potential of these processes 
as targets for therapeutic purpose. 
Objective: To use the computational models under Aims 1 and 2 for quantitative 
integration and interpretation of data from isolated mitochondria and isolated perfused 
lungs of rats exposed to hyperoxia for 48 hrs as a model of clinical ALI/ARDS. To this 
end, published data about specific cytosolic and mitochondrial processes pertinent to lung 
tissue and mitochondrial bioenergetics (e.g., complexes I, II, IV, mitochondrial 
membrane potential, oximetry, lactate and pyruvate production, etc.) collected from 
isolated rat lung mitochondria, lung tissue homogenate, and isolated perfused lungs of 
rats exposed to >95% O2 for 48 hrs as a model of clinical ALI/ARDS will be used. The 
expected outcomes will allow us to determine the functional impact (e.g. effect on lung 
tissue bioenergetics) of changes in each of these processes. This would help in 





Chapter 2 : Computational Model of the Bioenergetics of 
Isolated Lung Mitochondria 
2.1 Introduction 
Mitochondrial respiration accounts for 80–85% of total lung ATP, and 
mitochondrial dysfunction plays a key role in the pathogenesis of acute and chronic lung 
diseases. There is ample information regarding the impact of lung injury on 
mitochondrial enzymes, transporters, and other macromolecules. The objective of Aim 1 
was to develop and validate an integrated computational model of the bioenergetics of 
isolated lung mitochondria. The model incorporates the major biochemical reactions and 
transport processes in lung mitochondria. A general framework was developed to model 
those biochemical reactions and transport processes. Intrinsic model parameters such as 
binding constants were estimated using previously published isolated enzymes and 
transporters experimental data describing their kinetics. Extrinsic model parameters such 
as maximal reaction and transport velocities were estimated by fitting the integrated 
bioenergetics model to published and new tricarboxylic acid cycle and respirometry data 
measured in isolated rat lung mitochondria. The integrated model was then validated by 
assessing its ability to predict experimental data not used for the estimation of the 
extrinsic model parameters. For example, the integrated bioenergetics model was able to 
predict reasonably well the substrate and temperature dependency of mitochondrial 
oxygen consumption, kinetics of the NADH redox status, and the kinetics of 
mitochondrial accumulation of the cationic dye rhodamine 123 (R123), driven by 
mitochondrial membrane potential, under different respiratory states. The latter required 




mitochondrial uptake and release of R123 from buffer under different respiratory states. 
The integrated bioenergetics model provides important insights into the bioenergetics of 
lung mitochondria and how they differ from those of mitochondria from other organs for 
which similar models have been developed. To the best of our knowledge, this model is 
the first for the bioenergetics of isolated lung mitochondria. The results of this Aim, 
including model development and validation, are published in the journal PLoS One 
(Zhang et al. Jun 11;13(6):e0197921, 2018). 
2.2 Experimental Methods 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated 
otherwise. All treatment protocols and procedures for animals were approved by the 
Institutional Animal Care and Use Committees of the Zablocki Veterans Affairs Medical 
Center, the Medical College of Wisconsin, and Marquette University. 
2.2.1 Isolation of rat lung mitochondria: 
Adult male Sprague-Dawley rats (320-360g) were anesthetized (pentobarbital 
sodium 50-100 mg/kg, ip) and the lungs were rapidly exposed and cleared of residual 
blood with 50 ml cold perfusion solution (physiologic saline buffered with 10 mM 
HEPES, pH 7.4, and containing 5.5 mM glucose) via the right ventricle. The lungs were 
then removed from the chest, and the trachea, large airways and large vessels were 
removed, after which the peripheral lung was placed in an ice-cold homogenization 
buffer (pH 7.4) containing 10 mM HEPES, 200 mM mannitol, 70 mM sucrose, 1 mM 
EGTA, 2% fatty acid-free BSA, and protease inhibitor cocktail Set III (50 μl/g lung 




homogenized using a Teflon pestle. The resulting homogenate was then centrifuged 
(Sorvall Superspeed RC-5B, Norwalk, CT) at 2,000 × g and 4°C for 15 minutes. The 
supernatant was transferred to a clean tube and centrifuged at 17,800 × g at 4°C for 15 
minutes.  The resulting supernatant was discarded and the remaining pellet was 
resuspended in 5 ml ice-cold homogenization solution and centrifuged at 17,800 × g at 
4°C for 15 minutes. The supernatant was discarded and the final pellet was resuspended 
in 0.3-4 ml ice-cold buffer (same as the homogenization buffer without BSA or the 
protease inhibitor cocktail) and stored on ice to be used for the respirometry and 
membrane potential studies described below. Mitochondrial protein was determined 
using the Pierce BCA protein assay with bovine serum albumin as the standard. 
Mitochondrial yield was ~2 mg/rat lung. 
2.2.2 Mitochondrial oxygen consumption: 
Mitochondrial oxygen consumption (respiration) was measured polarographically 
at 23°C with a Strathkelvin 782 2-Channel Oxygen System (Strathkelvin Instrument). 
Briefly, 0.55 ml respiration buffer (130 mM KCL, 5 mM K2HPO4, 20 mM MOPS, 0.1 
mM EDTA, 0.001 mM Na4P2O7 and 0.1% BSA, pH 7.2) was transferred to the reaction 
chamber. After 2 minutes, 0.55 mg mitochondrial protein (1 mg/ml) was transferred to 
the 0.55 ml reaction chamber. Stock solution containing respiratory substrates (pyruvate 
(10 mM) + malate (5 mM), glutamate (10 mM) + malate (5 mM), or succinate (7 mM) at 
pH 7.2) was introduced into the reaction chamber using a Hamilton syringe. Once the 
oxygen consumption rate reached steady state (state 2), ADP (100 M or 50 M) was 
added to stimulate the rate of oxygen utilization (state 3). State 4 was measured as the 




respiratory control index (RCI) for pyruvate + malate, malate + glutamate, or succinate 
was then calculated as the ratio of state 3 and state 4 respiratory rates. The rate of 
uncoupled oxygen consumption was measured in the presence of the uncoupler carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP, 2 µM).  
For a subset of experiments, maximal complex IV activity was measured at 30°C 
using the complex IV substrate tetramethyl-p-phenylenediamine (TMPD, 0.3 mM) as a 
direct artificial electron donor in the presence of antimycin A (1 M, complex III 
inhibitor). Ascorbate (1.3 mM) was also added to the medium to maintain TMPD in its 
reduced form. Furthermore, the integrity of the mitochondrial outer-membrane was 
assessed by evaluating the ability of exogenous cytochrome c (10 M) added to the 
medium to stimulate oxygen consumption.  
2.2.3 Mitochondrial membrane potential: 
As previously described [72], mitochondrial membrane potential (m) studies 
were performed at room temperature (23°C) using a Photon Technology International 
(PTI) QuantaMaster spectrofluorometer (HORIBA Scientific, Edison, New Jersey) that 
monitored and recorded the R123 fluorescent signal (503/527 nm excitation/emission 
wavelength) continuously over time. Briefly, a cuvette containing 1 ml of the buffer (pH 
7.2), R123 (200 nM), and either pyruvate (10 mM) + malate (5 mM) or succinate (7 mM) 
as respiratory substrate was placed in the cuvette holder of the spectrofluorometer. After 
2 minutes, mitochondrial protein (1 mg/ml) was added, and then once the R123 
fluorescent signal had reached steady-state (state 2), ADP (100 M or 50 M) was added 
to evaluate the ADP-stimulated depolarization of m. The maximum uncoupled m 




are low (≤ 200 nM), quenching effects are negligible [73]. Hence, the R123 fluorescent 
signal was converted to R123 concentration by assuming a linear relationship between 
R123 medium concentration and fluorescent signal. 
2.3 Model Development 
2.3.1 Model Structure 
The integrated model of bioenergetics of isolated lung mitochondria was 
developed based on the thermodynamic and kinetic properties of the mitochondrial 
metabolic reactions and transporters [46, 56, 68]. As shown in Figure 2.1, the model 
consists of three regions: the extra-mitochondrial region (buffer), the mitochondrial 
matrix region, and the inter-membrane space (IMS) region. Moreover, the model 
accounts for the dynamics of forty state variables, including thirty-seven metabolite 
concentrations in the matrix and buffer regions, two ion concentrations (matrix H+ and 
buffer H+ concentrations), and mitochondrial membrane potential (m). Volumes of the 
three regions along with initial concentrations of metabolites are given in Table 2.1.  
 
Table 2.1: General model parameter values for isolated mitochondria model 
Parameter Value Source 
Mitochondria matrix volume (Vm) 1 l/mg mitochondria protein  [46, 74, 75] 
Mitochondria IMS volume (Vims) Assume to be 10% of Vm  
Total cytochrome c content 0.33 nmol/mg mitochondria [76] 
Total pyridine nucleotide content 
(NAD+NADH) 
1.73 nmol/mg mitochondria [76] 
Total flavin adenine dinucleotide 
concentration (FAD+FADH2) 
0.7 mM [66] 
Total adenine nucleotide content (ATP 
and ADP)  
6.4 nmol/mg mitochondria [76] 
Total coenzyme A content 
(SCoA+ACoA+CoA) 




Aspartate + glutamate concentration in 
mitochondria matrix 
12 mM [77] 
Total ubiquinone concentration 
(UQ+UQH2) 




Figure 2.1: Structure of the isolated lung mitochondrial bioenergetics model.   
The model consists of three regions (extra-mitochondrial buffer, mitochondrial matrix, 
and inter-membrane space (IMS)). Major reactions include TCA cycle reactions and 
electron transport chain reactions. Transport exists between mitochondrial matrix and 
IMS. Most of the metabolites are assumed to be freely permeable across mitochondria 
outer-membrane. The major biochemical species included in this model are: PYR: 
pyruvate, CoA: coenzyme-A, ACoA: acetyl-CoA, OXA: oxaloacetate, CIT: citrate, AKG: 
a-ketogluterate, SCoA: succinyl-CoA, SUC: succinate, FUM: fumarate, MAL: malate, 
GLU: glutamate, and ASP: aspartate, NAD and NADH: oxidized and reduced form of 
nicotinamide adenine dinucleotide, respectively, FAD and FADH2: oxidized and reduced 
form of Flavin adenine dinucleotide, respectively, ADP and ATP: adenosine triphosphate 
and adenosine diphosphate, respectively, UQ and UQH2: oxidized and reduced form of 
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Fifteen reaction fluxes are included in this integrated model, including ten 
reactions in the tricarboxylic acid cycle (TCA or Krebs cycle) and five reactions in the 
respiratory system (complex I-complex V). Unlike liver and kidney mitochondria, which 
can produce oxaloacetate (OXA) from pyruvate, pyruvate carboxylase activity is 
extremely low in lung mitochondria [78]. Thus, pyruvate carboxylase is not included in 
this model. In isolated mitochondria experiments, bovine serum albumin (BSA) was used 
to bind free fatty acids and their esters [79]. Therefore, fatty acid oxidation was not 
considered in this isolated mitochondrial model. All the reactions in the integrated 
bioenergetics model are listed in Table 2.2.  
 






1 PDH PYRm+CoAm+NADm ⇌ 
ACoAm+CO2+NADHm+Hm 
2 CITS ACoAm+OXAm ⇌ CITm+CoAm+ 2Hm 
3 CITDH CITm+NADm ⇌ AKGm+NADHm+CO2 
4 AKGDH AKGm+CoAm+NADm ⇌ SCoAm+NADHm+CO2 
5 SCAS SCoAm+GDPm+Pim ⇌ SUCm+GTPm+CoAm+Hm 
6 NDK GTPm+ADPm ⇌ GDPm+ATPm 
7 SDH SUCm+FADm⇌ FUMm+FADH2m 
8 FH FUMm = MALm 
9 MDH MALm+NADm ⇌ OXAm+NADHm+ Hm 
10 GOT ASPm+AKGm ⇌ GLUm+OXAm 
11 CI NADHm+UQm+Hm ⇌ NADm+UQH2m+ 4∆H 
12 CII FADH2+UQm ⇌ FADm+UQH2m 
13 CIII UQH2m+2CytCo ⇌ UQm+2CytCr+ 2∆H+ 2𝐻𝑖 
14 CIV 2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2∆H 





Additionally, the model includes ten transport processes to account for the 
exchange of key metabolic species between the mitochondrial matrix and IMS regions. 
The mitochondrial inner membrane is impermeable to most metabolites. Therefore, 
except for proton leak, the exchange of species between the mitochondrial matrix and 
IMS regions is assumed to be catalyzed by specific transporters, such as inorganic 
phosphate carrier (PIC) and adenine nucleotide translocase (ANT). The proton leak 
between the IMS and mitochondrial matrix regions is modeled using modified Goldman-
Hodgkin-Katz equation [46]. All the transporters in the model are listed in Table 2.3. 
 






1 PYRH PYRe + He ⇌ PYRm + Hm 
2 GLUH GLUe+ He ⇌ GLUm+ Hm 
3 DCC (MAL) MALe+Pim ⇌MALm+Pie 
4 DCC (SUC) SUCe+Pim ⇌ SUCm+Pie 
5 TCC MALe+ CITm ⇌ MALm+ CITe 
6 OME MALe+AKGm ⇌ MALm+AKGe 
7 GAE ASPe+ HGLUm ⇌ ASPm + HGLUe 
8 ANT ADPe + ATPm ⇌ ADPm + ATPe 
9 PIC Pie + He ⇌ Pim + Hm 
10 Hleak Hi ⇌ Hm 
 
The mitochondrial outer membrane (OMM) has VDACs that allow the transport 
of small molecules in and out of mitochondria [46]. Therefore, we assumed that the 
concentration differences of most of the metabolic species between the IMS and extra-




weight of about 12 KD, and hence too large to pass through the mitochondrial outer 
membrane under normal conditions, was assumed to exist only in the IMS region. 
2.3.2 Reaction and transport flux expressions: 
In the proposed integrated bioenergetics model, all enzymatic reactions are 
assumed to follow a generalized random-ordered rapid-equilibrium kinetic mechanism 
[80], which encompass all possible kinetic mechanisms as special cases. Thus, for each 
reaction, all pertinent substrates must bind to the enzyme together before the catalysis can 








    (2.1) 
where Si is i
th substrate, Pj is j
th product, Ns and Np are the number of substrates and 
products, respectively, and αi and βj are the corresponding stoichiometric coefficients. 
The general form of the reaction flux, J, accounting for the thermodynamic (Haldane) 
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  (2.2) 
where KSi and KPj are binding constants corresponding to substrates and products, 
respectively; [ ]iS and [ ]jP  are concentrations of substrate i and product j, respectively; 
Vmaxf  is the maximum forward reaction rate; and Keq is the apparent equilibrium constant 
for the reaction, which is the value of the equilibrium-state reaction quotient (i.e. ratio of 




thermodynamic conditions (i.e. temperature, ionic strength and pH). Detailed derivations 
of this general reaction flux equation and its various special cases are included in the 
Appendix. 
In the presence of cofactor pairs (e.g. NADH and NAD+, ATP and ADP, GTP and 
GDP, CoA and ACoA, or CoA and SCoA), the generalized reaction flux equation (2.2) 
can be modified appropriately so as to not include any interactive cofactor product terms 
[80]. The assumption is that the substrate and product represented as a cofactor pair bind 
with a given enzyme at the same binding site, in which case the resulting reaction flux 
equation does not include the corresponding substrate and product multiplication terms in 
the denominator of equation (2.2). Equation (2.2) can also be suitably modified to 
account for other reaction kinetic mechanisms (e.g. sequential-ordered mechanisms, ping-
pong mechanisms). The flux expressions of all the enzymatic reactions are included in 
Appendix. 
In this integrated bioenergetics model, all the transport processes across the 
mitochondrial inner membrane, with the exception of the proton leak, are catalyzed by 
specific metabolite transporters involving two different species (co-transporters and anti-
porters). For generality, a random-ordered rapid-equilibrium binding mechanism is 
assumed for all the transporters, i.e., the transporter can bind to the two species in an 
arbitrary order, similar to that described for a reversible two-substrate two-product 
enzymatic reaction. Thus, the general form of the transport flux expression is assumed to 
be the same as that for the reaction flux expression. The flux expressions for all the 




2.3.3 Accounting for the effect of pH on equilibrium constants: 
The proposed integrated bioenergetics model accounts for the pH dependence of 
the apparent equilibrium constants for proton-releasing reactions (2.3) and for proton-
consumption reactions (2.4) [68, 75, 81]:  
 
0Δ /0 7 710 10rG RTpH pHeq eqK K e
       (2.3) 
 
0Δ /0 7 710 10rG RTpH pHeq eqK K e
       (2.4) 
where 
0
eqK   is the reaction apparent equilibrium constant ( eqK  ) at pH of 7, and 
0
rG  R 
and T are the standard Gibbs free energy of the reaction at pH = 7, gas constant, and 
temperature, respectively. 
2.3.4 Accounting for the effect of temperature on enzymatic reaction and transport 
rates: 
To allow for model simulations at different temperatures, we account for the 
temperature effects on the maximal reaction and transport rates (Vmax’s and Tmax’s) using 







   (2.5) 
where T is the temperature, R2/R1 is the correction coefficient (i.e. the ratio of maximal 
reaction and transport velocities at temperature T2 and T1), and Q10 is the temperature 
coefficient which was set to 2.5. 
2.3.5 Dynamic mass balance equations 
The governing ordinary differential equations describing the dynamic changes in 




principle of mass balance. The change in the concentration of a given species within the 
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    (2.7) 
where ,m jJ  is the j
th reaction flux in the mitochondrial matrix and ,m e jJ   is the j
th transport 
flux between mitochondria matrix region and extra-mitochondria buffer region, mV  and 
eV  are the volumes of the mitochondrial matrix region and the extra-mitochondria region, 
respectively. For the extra-mitochondria region which does not include chemical 
reactions, the right hand side of (2.7) contains just transport fluxes. Detailed mass balance 
equations are included in Appendix IV. 
The rate of change of mitochondrial membrane potential (m) is given by 
equation (2.8) [46]: 
  
Ψ 1
4 2 4 3m CI CIII CIV CV Hleak ANT
imm
d
J J J J J J
dt C

        (2.8) 
where immC  is the capacitance of the inner mitochondrial membrane; CIJ , CIIIJ , CIVJ  and 
CVJ  are the reaction fluxes of complex I, complex III, complex IV and complex V, 
respectively; HleakJ  is the proton leak between the IMS and mitochondria matrix regions; 
and ANTJ  is the transport flux characterizing ATP/ADP exchange via the ANT. 
MATLAB function ‘ode15s’ (MathWorks Inc.) was used to solve the system of 




ordinary differential equations, where solution components vary on drastically different 
time scales [82]. Non-stiff ode solvers, such as ‘ode45’ and ‘ode23’, are unable to solve 
stiff problems, or are extremely slow. For a stiff system, ‘ode15s’ is more efficient than 
the non-stiff ode solvers.  
2.4 Model Parameter Estimation 
As described below, some model parameters were set at published values, while 
others were estimated from new and published data, including isolated enzyme and 
transporter kinetics (See Appendix), TCA cycle kinetics [78], and respirometry [76, 78]. 
2.4.1 Estimation of the intrinsic model parameters: 
The binding constants (K’s) of various substrates and products for enzymes and 
transporters were either set to published values [46, 83] or estimated using published 
kinetic data from isolated mitochondrial enzymes and transporters. Some of the isolated 
enzyme and transporter kinetic data were from heart, kidney or liver mitochondria due to 
the scarcity of such data from lungs. The assumption is that the binding constants are 
intrinsic model parameters, and hence their values should be organ-independent.  
For a given enzyme or transporter, the MATLAB function ‘fmincon’, a nonlinear 
program solver, was used with a least-squares objective function to estimate the values of 
the K’s from the published kinetic data for the enzyme or transporter by fitting the flux 
equation for a given enzyme or transporter reaction to pertinent kinetic data.  
Models of reaction and transport fluxes for various enzymatic reactions and 
metabolite transporters, parameter estimation results, as well as the kinetic data are 




2.4.2 Estimation of the extrinsic model parameters: 
With the binding constants (K’s) of the various enzymes and transporters known, 
a genetic algorithm (GA, MATLAB function ‘ga’) was then used to estimate the values 
of the extrinsic model parameters (i.e. Vmaxfs and Tmaxfs) of the integrated bioenergetics 
model that best fit new and published dynamic kinetic data (Figure 2.3-Figure 2.5) 
obtained from isolated lung mitochondria, including TCA cycle kinetics data [78], and 
respirometry data at different respiratory states [76, 78].  Thus, the resulting values of 
extrinsic model parameters are specific to isolated rat lung mitochondria.  
GA is a global parameter estimation algorithm that mimics the process of natural 
selection and can escape local minima [84]. In each iteration of GA, a population of 
parameters is generated, the fitness of each ‘individual’ (parameter) is evaluated based on 
the objective function, and ‘parents’ are selected at random to produce offspring for the 




reproduce, thus the population evolves towards the optimal solution. 
 
 
Figure 2.2 Flow chart of genetic algorithm. 
 
GA is suitable for optimization problems with a relatively large number (>10) of 
unknown parameters. For such optimization problems, GA can usually find better 
estimation of the best fit than ‘fmincon’ because of its ability to find global minimum. 
However, GA is usually more time-consuming than ‘fmincon’. For a simple parameter 
estimation problem with less than 5 unknown parameters, fmincon is usually more 
efficient in finding the optimal values for the model parameters. Therefore, fmincon was 
used for estimation of the intrinsic parameters for the flux of an enzymatic or transport 
reaction (Section 2.4.1), and GA was used for extrinsic parameter estimation at the 
mitochondrial level. 
For the integrated model extrinsic parameter estimation, the objective function ƒ 
used is:  
Initialize a population of 
parameter sets and evaluate their 
fitness functions
STOP
Check if the 
fittest individual 
meets criterion
Select parents, use cross-over 
and mutation to generate 
offspring
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    (2.9) 
where xi,j and Xi,j are the model solutions and the corresponding experimental data at the 
ith time point and jth data set, respectively. N is number of data points and M is the 
number of data sets used for the parameter estimation. 
2.5 Experimental and computational results 
2.5.1 Oxygen consumption 
Respirometry data were collected at room temperature (23o C). In order to collect 
enough information for parameter estimation of different substrate tranporters and 
enzymes, different combinations of metabolic substrates were used in experiments. For 
example, two combinations of complex I substrates (pyruvate + malate and malate + 
glutamate) were used to get enough information for relevent enzymes/transproters, such 
as pyruvate tranportor (PYRT), malate-pi exchanger (DCC) and glutamate-aspartate 
exchanger (GAE). Results are shown in Figure 2.3. Averaged time-course respirometry 
data (mean ± SE) are shown in the presence of complex I substrates pyruvate + malate 
(Figure 2.3A, n = 4), complex I substrates malate + glutamate (Figure 2.3B, n = 1), and 
complex II substrate succinate (Figure 2.3C, n = 4).  A summary of the oxygen 
consumption rates (OCR, nmol/min/mg) show higher states 2, 3 and 4 respiratory rates 
with complex II substrate (Figure 2.3F) compared to those with complex I substrates 
(Figure 2.3D and Figure 2.3E). Furthermore, the results show smaller respiratory rates, 
but higher respiratory control index (RCI, defined as the ratio of state 3 OCR to state 4 




also shows fits of the integrated bioenergetics model to the measured oxygen 
consumption kinetic data (solid lines, upper panels) and oxygen consumption rates (red 
bars, lower panels) generated using the values of the model parameters in Table 2.4, 
except for the value of the Tmaxf parameter describing the proton leak process (Tmaxf, LEAK), 
which was set at 40% of the value in Table 2.4. This is consistent with a less “leaky” and 
more coupled isolated rat lung mitochondria for the data in Figure 2.3 as compared to the 
data in Figure 2.4. Figure 2.10A and D, which provide a summary of the states 2 and 3 
oxygen consumption rates in Figure 2.4 and Figure 2.3, show the expected dependency of 
those rates on buffer temperature.  
 
 
Figure 2.3: Respirometry data at room temperature (23˚C).  
Rat lung mitochondria were incubated in 0.55 ml buffer containing 2 mM Pi, and 0.55 
mg mitochondria protein, buffer pH=7.2. Average oxygen concentrations in buffer are 
shown under state 2, state 3, state 4 and uncoupled state 3 using pyruvate (PYR) + malate 
(MAL) (n = 4, panel A), MAL + glutamate (GLU) (n = 1, panel B), or succinate (SUC) (n 
= 4, panel C) as substrates. ADP and FCCP was added to buffer at 3.5 min and 6.5 min, 
respectively. Symbols are experimental data (mean ± SE) and solid lines are integrated 














estimated value of the proton leak parameter Tmaxf, LEAK in Table 1 was increased by seven 
folds. Panels D, E, and F show average oxygen consumption rates (OCR, nmol/min/mg) 
under states 2, 3 and 4 using PYR + MAL (n = 4), MAL + GLU (n = 1), or SUC (n = 1) 
as substrates. Blue bars are experimental data (mean ± SE) and red bars are integrated 
model fits to the data.   
 
2.5.2 Estimated values of the unknown model parameters 
In what follows, all Figure and Table numbers with prefix “A” are found in the 
Appendix. Most of the intrinsic parameters of the integrated bioenergetics model, such as 
the binding constants (K’s) of the enzymatic reactions and transport processes, were 
estimated based on previously published isolated enzyme or transporter kinetic data 
shown in appendix using the MATLAB function “fmincon”. The solid lines 
superimposed on the data in the Figures are fits of corresponding enzyme/transporter 
models to the data in Appendix. Since the binding constants of the enzymatic reactions 
and transport processes are intrinsic model parameters, they are assumed to be tissue-
independent [75] . It is worth noting that the extrinsic model parameter Tmaxfs and Vmaxfs 
values estimated from the isolated enzyme and transporter kinetic data were not used in 
the integrated bioenergetics model since those parameters are expected to be dependent 
on the tissue source of mitochondria. 
With the K’s of the various enzymes and transporters known, the next step was to 
estimate the extrinsic parameters (i.e. Tmaxfs and Vmaxfs) of the integrated bioenergetics 
model using kinetic data from isolated rat lung mitochondria. Multiple datasets from 
isolated rat lung mitochondria were used, including previously published TCA cycle 
metabolite uptake/release dynamic data (Figure 2.5) and respirometry data at 30 
o
C 






C, Figure 2.3).  
 
 
Figure 2.4: Respirometry data (30˚C) (Evans et al. [78]).  
Rat lung mitochondria were incubated at 30˚C in 1.9 ml buffer containing 4 mM Pi, and 
0.7 mg mitochondria protein, buffer pH=7.4. Oxygen consumption rates (OCR, 
nmol/min/mg) were calculated under state 2 and state 3 conditions. Different metabolic 
substrates were used: (A) PYR + MAL, (B) SUC, (C) CIT + PYR and (D) PYR + AKG. 
Shaded areas are experimental data (mean ± SE) and solid lines are integrated model fits 
to the data. In the inset figures, the same experimental data are plotted as blue bars (mean 














Figure 2.5: Substrate-dependent responses of pyruvate (PYR) uptake, malate (MAL) 
uptake and citrate (CIT) production (Evans et al. [78]).  
Rat lung mitochondria were incubated at 30ºC in 1.0 ml buffer containing 4 mM Pi, and 
0.7 mg mitochondria protein, buffer pH = 7.4. Mitochondria were incubated in the 
presence of different substrate concentrations. Panel A, B and C: (A) mitochondria were 
incubated with 5 mM MAL ([MAL] = 5 mM) and different concentrations of PYR: 
[PYR] = 0 mM (red circle), [PYR] = 0.5 mM (green star), [PYR] = 1 mM (blue triangle), 
[PYR] = 5 mM (purple plus sign), [PYR] = 10 mM (cyan triangle). Panel D, E and F: 
mitochondria were incubated with fixed PYR concentration ([PYR] = 5 mM) and 
different concentrations of MAL: [MAL] = 0 mM (red circle), [MAL] = 0.5 mM (green 
star), [MAL] = 1 mM (blue triangle), [MAL] = 5 mM (purple plus sign), [MAL] = 10 
mM (cyan triangle). PYR uptake rate (A, D), MAL uptake rate (B, E) and CIT production 
rate (C, F) were measured over a 10-minute incubation period. Symbols are experimental 
data and lines are integrated model fits. 
 
 
As shown in Figure 2.5, mitochondrial pyruvate uptake, malate uptake, and citrate 
production/release were measured in isolated rat lung mitochondria by Evans et al. in the 
presence of 5 mM malate and varying pyruvate concentrations (top panel) or 5 mM 
pyruvate and varying malate concentrations (bottom panel) in buffer [78]. Results show 
that pyruvate uptake, malate uptake, and citrate release increased with increasing buffer 




concentration at 5 mM of pyruvate (bottom panel), and that those flux rates saturated 
when pyruvate and malate concentrations were greater than 5 mM.  
In addition to the TCA cycle metabolite uptake/release data, the study by Evans et al. 
also provided mitochondrial oxygen consumption rates using different metabolic 
substrates [78]. As shown in Figure 2.4, mitochondria oxygen consumption rates under 
states 2 and 3 were measured in the presence of different complex I substrates (pyruvate 
+ malate, -ketoglutarate (AKG) + pyruvate, and citrate + pyruvate) and complex II 
(succinate) substrates, with the buffer temperature set at 30 
o
C [78]. The data show that 
states 2 and 3 oxygen consumption rates tended to be higher in the presence of complex 
II substrate as compared to those in the presence of complex I substrates. However, only 
oxygen consumption rates are provided in this study, whereas key information such as 
length of state 3 and oxygen dynamic changes under state 3 conditions are lacking. Thus 
for additional information on rat lung mitochondria ETC for the estimation of pertinent 
extrinsic model parameters, we measured oxygen consumption (Figure 2.3) at 23 oC 
using pyruvate + malate or glutamate + malate as complex I substrates or succinate as 
complex II substrate. The resulting average oxygen concentration kinetic data under 
states 2, 3 and 4 were used along with the data in Figure 2.3 for estimating the extrinsic 
parameters of the integrated bioenergetics model. The uncoupled state 3 kinetic data in 
Figure 2.3 were simulated by increasing the estimated value of the proton leak parameter 
Tmaxf, LEAK by seven fold. 
Figure 2.3 and Figure 2.4 show different state 2 respiration rates. Since state 2 
respiration rates in Figure 2.3 are ~40% (after accounting for temperature effect) of those 




adjusted to account for those differences. Therefore, for the data in Figure 2.3, Tmaxf, LEAK 
was set at 40% of the value used to fit the data in Figure 2.4 (Table 2.4). However, for 
experimental data from the same study (Figure 2.4 and Figure 2.5), Tmaxf, LEAK was set to 
the same value.  
All of the extrinsic parameters (Table 2.4) of the integrated bioenergetics model 
were estimated by simultaneously fitting the integrated model solution to kinetic data 
from isolated rat lung mitochondria (Figure 2.3 -Figure 2.5) using genetic algorithm 
(MATLAB function “ga”). The estimated values of the extrinsic parameters of the 
integrated bioenergetics model are shown in Table 2.4. 
 
Table 2.4: Estimated value of the extrinsic parameters of the mitochondria model (30°C) 
Parameters Definition Value 
(nmol/min/mg) 
Vmaxf, PDH Maximum forward reaction rate of PDH 307 
Vmaxf, CITS Maximum forward reaction rate of CITS 4631 
Vmaxf, CITDH Maximum forward reaction rate of CITDH 531 
Vmaxf, AKGDH Maximum forward reaction rate of AKGDH 780 
Vmaxf, SCAS Maximum forward reaction rate of SCAS 5816 
Vmaxf, NDK Maximum forward reaction rate of NDK 4.33×10
6 
Vmaxf, SUCDH Maximum forward reaction rate of SDH 1.08×10
4 
Vmaxf, FH Maximum forward reaction rate of FH 6.4×10
3 
Vmaxf, MDH Maximum forward reaction rate of MDH 3.3×10
3 
Vmaxf, GOT Maximum forward reaction rate of GOT 975 
Vmaxf, CI Maximum forward reaction rate of CI 11 
Vmaxf, CII Maximum forward reaction rate of CII 220 
Vmaxf, CIII Maximum forward reaction rate of CIII 2.23×10
4 
Vmaxf, CIV Maximum forward reaction rate of CIV 0.27 
Vmaxf, CV Maximum forward reaction rate of CV 589 
Tmaxf, DCC(SUC) Maximum transport rate of DCC(SUC) 1699 
Tmaxf, DCC(MAL) Maximum transport rate of DCC(MAL) 22 
Tmaxf, OME Maximum transport rate of OME 1 
Tmaxf, TCC Maximum transport rate of TCC 81.3 
Tmaxf, PYRH Maximum transport rate of PYRH 96.6 
Tmaxf, PIC Maximum transport rate of PIC 2.4×10
4 




Tmaxf, GLUH Maximum transport rate of GLUH 5 
Tmaxf, GAE Maximum transport rate of GAE 646 
Tmaxf, LEAK Maximum rate of proton leak  36 
 
 
2.6 Model validation  
2.6.1 Measures of identifiability and estimatility of the extrinic parameters of the 
integrated model  
To assess the estimability (existence of model parameters to fit available 
experimental data) and identifiability (uniqueness of the model parameters to fit available 
experimental data) of the extrinsic parameters of the integrated bioenergetics model 
(Table 2.4), we estimated the parameters’ normalized sensitivity coefficients and a matrix 
of correlation coefficients between the model parameters. The normalized sensitivity 
coefficients provide information about the contribution of each of the extrinsic model 
parameters to the overall model solution. If a given model parameter is identifiable, its 
sensitivity coefficient should be relatively large. In addition, a parameter that has a 
relatively larger sensitivity coefficient indicates the parameter has more influence on 
model outputs.  While the correlation coefficient matrix provides information about the 
degree of interdependence between the various model parameters. For a given extrinsic 















  (2.10) 




integrated bioenergetics model fit, and θi is the estimated value of i






 was approximated using the central difference method with 0.1% change in i .  
The matrix of correlation coefficients between the model parameters was 
evaluated at the values in Table 1 that best fit the integrated model to the data (Figure 
2.5–Figure 2.3). The correlation coefficient (CCij) between the i
th parameter and jth 
parameter was determined using equation (2.11) [85]: 





CC for i j np
HH HH
     (2.11) 
where np is the number of model parameters, HH is the inverse of the product of the 
transpose of the Jacobian matrix and the Jacobian matrix evaluated at the values of the 
model parameters in Table 2.4 that best fit the integrated bioenergetics model to the data 





Figure 2.6: Normalized sensitivity coefficients of the integrated model extrinsic 
parameters. A parameter contribution to the model solution is proportional to its 
normalized sensitivity coefficient estimated using equation (2.10) 
 
 
Figure 2.6 and Figure 2.7 show the respective normalized sensitivity coefficients 
and matrix of correlation coefficients for the intrinsic parameters of the integrated model. 
For most of the intrinsic model parameters, the normalized sensitivity functions are 
relatively high, and the correlation coefficients are relatively low, consistent with a tight 




Figure 2.5.  
 
Figure 2.7: Matrix of correlation coefficients between the extrinsic parameters of the 
integrated model.  
Correlation coefficients range between -1 (perfect negative correlation) and +1 (perfect 
positive correlation) and are estimated using equation (2.11). A small positive or negative 




2.6.2 Model validation using Pharmacokinetic model for the cationic dye rhodamine 
123 (R123) 
To validate the integrated bioenergetics model, we assessed its ability to predict 
experimental data that were not used for estimating the values of the unknown model 
parameters. To that end, we measured mitochondrial membrane potential (m) using the 




















intensity increases linearly with dye concentration at low concentrations (<1 µM) in the 
buffer [73]. Thus, we converted the R123 fluorescence intensity to R123 concentration to 
compare with model simulated R123 concentration in the buffer.  
To simulate R123 dye disposition in isolated mitochondria, the integrated 
bioenergetics model was coupled with a modified version of a pharmacokinetic model by 
Gan et al. for the cellular uptake and mitochondrial accumulation of R123 [86]. Two 
additional state variables were needed, namely R123 concentrations in the mitochondria 
matrix  123
m
R  and in the extra-mitochondrial buffer 123
e
R . The process which 
accounted for the transport of R123 from the buffer to the matrix driven by an 
electrochemical gradient was modeled using the Goldman-Hodgkin-Katz equation [73].  
 


















  (2.12) 
where F is Faraday’ s constant, z is R123 valence, R is the gas constant, T is temperature, 
Ψm is the membrane potential and p is the permeability coefficient of the membrane 
which was set to 1.38 mol/(liter mitochondria)/s/M. 
The ordinary differential equations that describe the change in the concentrations 
of R123 in the matrix and buffer are: 
 







d R d R
V V J
dt dt
     (2.13) 
where 
APP
mV  and 
APP
eV  are the apparent volumes of mitochondrial matrix region (Vm) and 
extra-mitochondria buffer region (Ve), respectively [86]. For the model predictions in 
Figure 2.8, 
APP
mV  was set to 2.25 µl/mg mitochondria protein and 
APP
eV was set to that for 





Figure 2.8: Model validation using membrane potential data.  
Experiments were performed under the same experimental condition as in Figure 2.3. 
R123 buffer concentrations are shown (symbols). Either pyruvate + malate (PYR+MAL, 
blue, n = 4) or succinate (SUC, red, n = 4) was used as the metabolic substrate. Values are 
mean ± SE. Black lines in Panel A are model predictions using the estimated values of the 
model parameters in Table 2.4. Panel B shows integrated model predictions of the 
mitochondrial membrane potential with either PYR + MAL or SUC as the metabolic 
substrates and with the values of the model parameters set to those in Table 2.4. 
 
 
2.6.3 Model validation using ACoA and CoA steady state data (Evans et al. [78]) and 
dynamic NADH redox status data [76]. 
In addition to membrane potential data, we evaluated the ability of the integrated 
model to predict steady-state ACoA and CoA fractions at different malate concentrations 
[78], and kinetic NADH redox status data under different respiratory states [76]. Figure 
2.9A and B show the ability of the integrated bioenergetics model to predict quite well 


















Figure 2.9: Model validation using ACoA and CoA steady state (Evans et al. [78]) and 
dynamic NADH redox status data [76].  
Panel A. Rat lung mitochondria were incubated with fixed pyruvate concentration (5 
mM), and without or with 5 mM malate. Mitochondria density = 2.5 mg/ml. Other 
experimental conditions are the same as in Figure 2.3. ACoA and CoA steady-state 
concentrations were measured at the end of 10-min incubation time. Symbols are 
experimental data and solid lines are integrated model predictions under the same 
experimental conditions with the values of the model parameters set to those in Table 2.4. 
Panel B. Fluorescence of pyridine nucleotides (NADH) in isolated rat lung mitochondria. 
Mitochondrial density was 2.5 mg/ml. 2.5 mM MAL and 0.2 mM ADP were added to the 
buffer at 1 min and 2.2 min, respectively. Symbols are experimental data and solid lines 
are integrated model predictions under the same experimental conditions with the values 




We have developed and validated the first integrated mechanistic computational 
model of the bioenergetics of isolated lung mitochondria using new and previously 
published experimental data. As described below, this integrated model provides 
important insights into the bioenergetics of isolated lung mitochondria and how they 
differ from those of mitochondria from other organs. 
Similar computational models of mitochondrial bioenergetics have been 









muscles [41, 46, 56, 68, 75]. Such models differ from the current integrated model in 
many aspects, in part because of differences in mitochondrial bioenergetics and energy 
demand of lung tissue as compared to those of the heart and skeletal muscle. It is well 
known that mitochondrial content, major metabolic substrates, and control mechanisms 
vary widely between different organs. For instance, β-oxidation of fatty acids has been 
identified as the primary source of energy for heart under physiological conditions 
accounting for 70% of ATP production [87-89], whereas glucose is the primary source of 
energy for lung tissue and accounts for 80–85% of the total lung tissue ATP production 
under physiological conditions [18].  
Moreover, lung cells are mostly non-excitable, and thus are postulated to behave 
very differently from excitable cells such as cardiac and skeletal muscle cells [69]. For 
instance, the ATP demand for cardiac cells between resting state and maximal exercise 
state could increase by ~4 fold, while that for skeletal muscle cells could increase by as 
much as ~100 fold between resting state and maximal exercise state [61, 90]. Thus, key 
enzymes in existing computational models are modeled to be modulated by metabolic 
controllers, such as inorganic phosphate (Pi), ADP/ATP ratio, NADH/NAD+ ratio, etc. 
However, in lung mitochondria where the energy requirement is much more stable, such 
control mechanisms may not be as important. Furthermore, most existing computational 
models place emphasis on complex I substrate-dependent respiration [46, 75]. These 
differences were one of the reasons for the development and validation of an integrated 
model specific for the bioenergetics of isolated lung mitochondria.  
Another reason for developing a comprehensive integrated model for 




enzymes and transporters used in the existing heart and skeletal muscle models [41, 46, 
68]. Those equations are not feasible for an isolated lung mitochondrial model due to the 
scarcity of experimental data needed to estimate the values of the large number of 
unknown parameters in the individual flux expressions and in the integrated 
mitochondrial model [78]. In the present study, a simplified general flux equation that 
accounts for apparent binding constants was developed and utilized for all enzymatic 
reactions and metabolite transporters. As such, the number of unknown model parameters 
was minimized for the individual flux expressions as well as for the integrated 
bioenergetics model. Yet, the model incorporated major pathways associated with lung 
mitochondrial bioenergetics, including metabolite transports and oxidations, TCA cycle 
reactions, ETC reactions, and oxidative phosphorylation.   
2.7.1 Estimation of unknown model parameters, and integrated model predictions 
For intrinsic model parameters, such as binding constants, for major enzyme 
reactions and transport processes, their values were estimated using experimental data 
measured in isolated enzymes or fixed to published values, mostly from organs other than 
lungs due to lack of such data from lungs. The assumption is that for a given 
mitochondrial enzyme or transporter, intrinsic properties, such as binding constants, are 
organ-independent [46].  
With intrinsic model parameters known, a challenging aspect of the integrated 
bioenergetics model development was estimation of the values of the extrinsic 
parameters. To that end, we relied on previously published experimental data from 
multiple studies in isolated rat lung mitochondria as well as new data that were obtained 




Figure 2.3–Figure 2.5 and Figure 2.8-Figure 2.10, the model is capable of fitting (Figure 
2.3–Figure 2.5) and predicting (Figure 2.8–Figure 2.10) quite well all the data from 
isolated rat lung mitochondria with the same set of values for the extrinsic model 
parameters (Table 2.4).  
A genetic algorithm was used to estimate the values of the extrinsic model 
parameters that best fit the kinetic data in Figure 2.3–Figure 2.5. Even though GA is a 
global parameter estimation algorithm that does not require initial estimates for the model 
parameters, good initial estimates can significantly reduce the computational time needed 
to identify optimal values of the model parameters. Good initial estimates can be obtained 
from boundary conditions such as pyruvate uptake rate, citrate production rate, and 
malate production rate.  
For the TCA cycle experimental data measured by Evans et al. [78] and used for 
estimating the values of some of the model parameters, citrate formation was reported 
even when no exogenous pyruvate was added to the buffer medium (Figure 2.5C, F). In 
our integrated bioenergetics model, both pyruvate and malate are required to generate 
citrate. This resulted in a difference between model fits and experimental data when the 
pyruvate buffer concentration is zero. One possible explanation for this apparent 
inconsistency is that citrate measured at zero pyruvate buffer concentration, in the 
experiments by Evans et al., was from endogenous substrates, such as ACoA [78]. 
However, reported endogenous ACoA of ~1 nmol/mg mitochondria [78] is too small to 
account for the measured 40 nmol citrate. Since citrate formation was observed only after 
4 min of incubation time (as shown in Figure 2.5C, F), it is more likely that the source of 




acids from mitochondrial proteins [23]. Another potential source of medium pyruvate is 
the presence of some endogenous pyruvate in the isolated mitochondria.  
2.7.2 Identifiability and estimability of the extrinsic parameters 
Figure 2.6 shows that proton leak extrinsic parameter Tmaxf, LEAK has the largest 
normalized sensitivity coefficient among the 25 extrinsic model parameters of the 
integrated model. This could be because mitochondrial membrane leakiness not only 
affects oxygen consumption rate, RCI, and membrane potential, but also substrate 
consumption rate at state 2 since proton leak is the only pathway in this model for 
consumption of the energy provided by substrate oxidation under state 2 conditions (in 
the absence of ADP).  
The intrinsic model parameters for glutamate-hydrogen or glutamate-hydroxyl 
antiporter (GLUH), nucleoside diphosphokinase (NDK), fumarate hydratase (FH), and α-
ketoglutarate (2-oxoglutarate) malate exchanger (OME) reactions have the smallest 
normalized sensitivities coefficients (Figure 2.7). GLUH exists in rat liver mitochondria 
and heart mitochondria [91], but does not exist in rat brain mitochondria [91]. The 
existence of GLUH in rat lung mitochondria has not been confirmed, even though it was 
proposed that GLUH might be an important process for the replenishment of TCA cycle 
metabolites in the rat lung [92]. In the present study, the estimated GLUH activity and 
sensitivity are very low, indicating that GLUH is not required to fit the data in Figure 
2.3–Figure 2.5 or to predict the data in Figure 2.8-Figure 2.10. In contrast, glutamate 
oxaloacetate (GOT) is the major pathway for glutamate + malate-driven respiration. The 
GOT enzyme activity reported by Evans et al. [78, 92] (975 nmol/min/mg protein) is both 




2.3B. Since the NDK and FH reactions are running at near equilibrium, their 
corresponding extrinsic parameters are not identifiable without additional data.  
We also estimated the matrix of correlation coefficients between the extrinsic 
parameters (Figure 5) of the integrated bioenergetics model for the estimated parameters. 
The extrinsic parameter pairs with the highest positive correlation are those for 
PDH/PYRH and DCC (SUC)/SDH reactions. The extrinsic parameter pair with the 
highest negative correlation is that for TCC/CITDH reactions. Extrinsic parameters for 
equilibrium reactions such as NDH and FH have virtually no correlation with the 
extrinsic parameters of other reactions. 
2.7.3 Membrane integrity of isolated mitochondria  
Isolation of mitochondria from rat lung tissue is challenging due to the high lipid 
content and low mitochondria content [93]. For instance, cardiac myocyte mitochondria 
account for ~35% of cell volume, compared to 1–2% in pulmonary endothelial cells, 
which account for 50% of the cells in the lung [93]. Thus, a relatively high concentration 
of bovine serum albumin is required in the isolation buffer to bind free fatty acid and 
lipids. In addition, the integrity of lung mitochondrial membrane in the isolated 
mitochondria is highly dependent on the isolation protocol used. For the data from Evans 
et al. (Figure 2.4), the measured state 2 oxygen consumption rate was higher than that 
measured in the present study (Figure 2.3). This could be due to differences in the 
mitochondria isolation protocols used. Thus for the model fit to the data in Figure 2.4–
Figure 2.5, the value of the leak parameter (Tmaxf, LEAK, which accounts for state 2 
respiratory rate) was adjusted to account for differences in the measured state 2 





Figure 2.10: Effect of temperature and/or proton leak activity on mitochondrial 
respiration, membrane potential, and NADH concentration.  
Panel A (PYR+MAL) and Panel D (SUC) show integrated bioenergetics model 
simulation of the state 2 and 3 oxygen consumption rates (OCR) with different proton 
leak activities at different temperatures. Temperature was varied from 25 to 37 
o
C and 
leak activities were varied from 40% to 170% of Tmaxf, LEAK value in Table 2.4. Symbols 
are experimental data (mean ± SE) of Figure 2.3 and Figure 2.4. Panel B (PYR + MAL) 
and E (SUC) show corresponding simulated RCIs, which were calculated as the ratio of 
state OCR and state 2 OCR. Panel C and F show model predictions of membrane 
potential and NADH dynamic responses at different temperatures. 
 
 
Simulations in Figure 2.10 show the effect of temperature and proton leak activity 
(Tmaxf, LEAK) on mitochondrial oxygen consumption. With pyruvate + malate as metabolic 
substrates, both state 2 and state 3 oxygen consumption rates increase (Figure 2.10A), 
although the % increase in state 2 appears to be larger than that for state 3. As a result, 
there is an inverse relationship between proton leak activity and RCI (Figure 2.10B). In 
contrast, with succinate as the metabolic substrate, the state 3 oxygen consumption rate 
decreases as proton leak activity increases (Figure 2.10D) due to the collapse of 








using succinate as substrate.   
By altering the proton leak activity (Tmaxf, LEAK), the integrated model was capable 
of simulating a wide range of mitochondrial experimental data performed under different 
experimental conditions (temperature, mitochondria density, pH, etc.) with the same set 
of values for the other model parameters (adjusted for temperature and pH effects). 
Figure 2.10C and F show the effect of temperature on dynamic responses of membrane 
potential and NADH redox states at state 3. Figure 2.10C also shows that ADP is 
consumed faster at higher temperature. As a result, the length of state 3 decreases as 
temperature increases. 
2.7.4 Apparent functionally incomplete TCA cycle in isolated lung mitochondria 
Isolated rat lung mitochondria and heart mitochondria show different behavior 
under similar experimental conditions. For instance, isolated rat lung mitochondria with 
pyruvate + malate as respiratory substrates produce significantly higher citrate than 
isolated cardiac mitochondria [77]. For lung mitochondria with pyruvate + malate as 
substrates, citrate production rate accounts for ~80% of the pyruvate and malate uptake 
rate. In contrast, for heart mitochondria, the consumed pyruvate and malate rate is 
approximately equal to amounts of citrate, α-ketoglutarate, succinate, and fumarate 
production rates [77].  
The large citrate production rate in isolated rat lung mitochondria is consistent 
with an apparent functionally incomplete TCA cycle since most of the consumed carbon 
from pyruvate and malate is converted to citrate and released into the extra-mitochondrial 
buffer medium. Therefore, not enough substrate is left for the reaction to proceed beyond 




the CITDH reaction under physiological conditions, based on isolated enzyme 
experiments (KNADH = 4.7 M). Model predicted simulations (Figure 2.11) also show that 
the reaction fluxes of CITDH and AKGDH are very low compared with those for 
PYRDH and MALDH.  
 
 
Figure 2.11: Model predicted substrate-dependent responses of the steady state reaction 
and transport fluxes.  
3-Dimensional surface plots of key metabolic fluxes at steady-state as a function of buffer 
pyruvate (PYR) and malate (MAL) concentrations ranging from 0.5 mM to 10 mM 
obtained at the end of a 10-minute incubation period in isolated lung mitochondria. 
Simulations were performed under the same experimental conditions as in Figure 2.5 and 
Figure 2.4 with the values of the extrinsic model parameters set to those in Table 2.4.  
 
 
Additional evidence of the apparent functionally incomplete TCA cycle in 
isolated rat lung mitochondria is the relatively high pyruvate/oxygen ratio since pyruvate 
consumption rate (10 nmol/min/mg mitochondria protein, as shown in Figure 2.5) is 
comparable to oxygen consumption rate (12 nmol/min/mg mitochondria protein, as 
shown Figure 2.4) under the same experimental conditions with pyruvate + malate as 






NADH to be generated from each pyruvate (PYRDH, ICDH, MALDH and AKGDH), 
and 8 electrons to transfer to complex IV and reduce two molecules of oxygen. However, 
the data from Evans et al. (Figure 2.4 and Figure 2.5) show that only 1.2 oxygen 
molecules are consumed for each pyruvate molecule. The high pyruvate/oxygen ratio in 
experiments suggests that only around 2.4 molecules of NADH are produced for each 
pyruvate consumed, consistent with only two of the four dehydrogenases being 
functional. 
The observed large citrate production and the release to extra-mitochondrial 
buffer in isolated lung mitochondria with complex I substrate (pyruvate + malate) could 
be a means to ensure the availability of enough lipid synthesis for lung surfactant since 
citrate is an important source of acetyl units for ATP citrate lyase, an important step in 
fatty acid biosynthesis. The lung is an active organ that produces fatty acid to maintain 
lung surfactant balance, which is composed of approximately 90% lipids [94].  
It is well known that calcium ions (Ca2+) have a stimulating effect on key 
dehydrogenase enzymes in mitochondria [90]. Considering that not all of the 
dehydrogenase enzymes are active in isolated mitochondrial experiments (Figure 2.11), 
the effect of Ca2+ control on the TCA cycle and bioenergetics might be underestimated in 
isolated mitochondrial experiments. For example, Vinnakota et al. [90] showed that 
physiological and supra-physiological Ca2+ levels have no or only modest stimulatory 
effect on cardiac mitochondrial oxidative phosphorylation, respectively, in isolated 
mitochondria respiring on complex I substrates (pyruvate + malate), which is insufficient 
to explain the Ca2+ stimulating effect on oxidative phosphorylation in vivo in the heart. 




excess citrate production and release to buffer (Figure 2.5 and Figure 2.11) could provide 
an explanation for why the stimulating effect of Ca2+ on mitochondrial bioenergetics with 
pyruvate + malate as respiratory substrate is less evident in isolated cardiac mitochondria 
than mitochondria in vivo. In addition, significant NADH inhibition of the CITDH 
reaction at physiological conditions could be another mechanism behind the non-
stimulating effects of Ca2+ on mitochondrial bioenergetics in isolated cardiac 
mitochondria with pyruvate + malate as respiratory substrates. 
2.7.5 Rate-limiting steps in rat lung mitochondrial electron transport chain (ETC) 
In the present study, experimental data and model sensitivity analysis reveal key 
information regarding the limiting step(s) in the rat lung mitochondrial ETC. Consistent 
with a previous report [76, 78], states 2 and 3 oxygen consumption rates in the presence 
of succinate were higher than those measured in the presence of pyruvate + malate.  
In isolated heart mitochondria, simultaneous addition of complex I and complex II 
substrates increased state 3 oxygen consumption rate by up to 2-fold relative to that 
following the addition of complex I or complex II substrates alone [95]. In contrast to 
heart and liver mitochondria [95], our data show that convergent electron flow from both 
complex I and complex II substrates is not additive (i.e.  oxygen consumption rate with 
pyruvate + malate + succinate did not increase relative to that with succinate alone), 
indicating that in isolated rat lung mitochondria the rate limiting step(s) for the flow of 
electrons in the ETC is downstream from complexes I and II (sum of CI and CII reaction 
fluxes exceeded maximum reaction fluxes downstream CI and CII). Therefore, 
complexes III, IV, V and/or ANT could be the potential rate limiting step.  




uncoupler FCCP was added to the extra-mitochondrial buffer to increase proton leak 
from the inter-membrane space to the mitochondria matrix. In agreement with a previous 
rat lung mitochondria study [76], our data (Figure 2.3 and Table 2.5) show that the 
oxygen consumption rate at uncoupled state 3 did not increase relative to that of ADP-
stimulated state 3, suggesting that there is no excess ETC capacity over and above that 
for oxidative phosphorylation. Thus, electron flow under state 3 respiration is not limited 
by mitochondrial complex V or ANT.  It is more likely that complex III and/or complex 
IV are the rate limiting steps in rat lung mitochondria. 
Integrated model sensitivity analysis can reveal important information regarding 
rate limiting steps in mitochondrial ETC. A high sensitivity coefficient for a given 
parameter indicates that the model output is sensitive to the enzyme whose activity is 
described by that parameter. Therefore, an enzyme with a relatively high sensitivity 
coefficient is more likely to be the rate limiting step than an enzyme with a low 
sensitivity coefficient. Sensitivity analysis results (Figure 2.6) show that mitochondrial 
complex I and complex IV have much higher normalized sensitivity coefficients than 
complex III. One possible explanation is that with complex I substrates, there is excess 
electron transport capacity in ETC, and that mitochondrial electron flow is limited by 
complex I activity. However, when complex II substrate is present, electron flow from 
complexes I and II exceeds the maximum capacity of complex IV, and thus complex IV 
becomes the rate limiting step. 
To prove that mitochondrial complex IV is the rate limiting step, maximum 
complex IV activity was measured using the complex IV substrate TMPD  (artificial 




IV activity was measured by adding TMPD along with ascorbate to the medium in the 
presence of antimycin A. The measured oxygen consumption rates (OCR) are shown in 
Table 2.5, which also shows OCR in the presence of exogenous cytochrome C and 
succinate. The results in Table 2.5 show no significant difference between the oxygen 
consumption rates measured under state 3 conditions in the presence of succinate and 
those measured in the presence of TMPD + ascorbate or TMPD + ascorbate + 
cytochrome C. These results are consistent with those reported by Fisher et al. [76, 78]. 
 
Table 2.5: Complex IV activity (nmol/min/mg) 
Electron donor OCR (nmol/min/mg) 
Current study (30 oC) 
OCR (nmol/min/mg) 
Fisher et al. [76, 78], 28 oC 
TMPD+Ascorbate 65 ± 12 (n = 8) 50 ± 13 (n = 4-7) 
TMPD+Ascorbate+CytoC 73 ± 11 (n = 8) NA 
SUC+ADP 78± 11 (n = 8) 53 ± 9 (n = 4 -7) 
Values are mean ± SE. OCR, oxygen consumption rate; CytoC, cytrochrome c; TMPD, 
tetramethyl-p-phenylenediamine; NA, not available. 
 
 These results suggest that maximum complex IV activity is reached when 
succinate is used as the metabolic substrate, and that additional oxygen consumption 
cannot be stimulated by the addition of an uncoupler or complex I substrates to the 
surrounding medium. 
Release of cytochrome c due to the relatively leaky mitochondrial outer-
membrane could be a reason for the apparent low complex IV activity. If so, the addition 
of exogenous cytochrome c to the medium should markedly stimulate oxygen 
consumption. As shown in Table 2.5, adding exogenous cytochrome c had a small 
(12.5%) and insignificant effect (paired t-test, p = 0.11) on the measured rate in the 




the cytochrome c stimulated oxygen consumption can be regarded as a sign of intact 
outer-membrane in heart and muscle mitochondria [96], a 12.5% increase in oxygen 
consumption may suggest a slightly “leaky” mitochondrial outer-membrane.  
2.8 Conclusion and model limitations 
2.8.1 Conclusions 
The proposed integrated bioenergetics model is an important step towards the 
development and validation of a comprehensive thermodynamically-constrained 
computational model of isolated perfused rat lung tissue bioenergetics that includes 
cytosolic processes such as glycolysis. Such a model will be used to evaluate the impact 
of ALI- or ARDS-induced changes in one or more mitochondrial or cytosolic processes 
on overall lung tissue bioenergetics, and for assessing the impact of targeting specific 
processes for mitigating the impact of ALI and ARDS on lung tissue bioenergetics. 
2.8.2 Model limitations 
Cations such as calcium (Ca2+) and magnesium (Mg2+) play an important role in rat 
lung mitochondrial bioenergetics. In this integrated bioenergetics model, all the cation 
concentrations are assumed constant. Even though it is known that dehydrogenases are 
activated by Ca2+ at nM level (~100-300 nM), Fisher et al. reported that mitochondrial 
oxygen consumption rates are inhibited as Ca2+ concentration in mitochondria matrix 
increases to µM-mM ranges [76]. However, the detailed mechanism for this biphasic 
effect is not known. Therefore, additional studies and data from isolated rat lung 
mitochondria are required to incorporate cations into the current model.  




different cell types in the lung. Endothelial cells, which account for ~50% of all lung 
cells, are not rich in mitochondria [86]. However, other lung cell types including 
contractile (smooth muscle cells), phagocytic (alveolar macrophages) and epithelial cells 
are rich in mitochondria. Thus, the model and the estimated values of model parameters 
should be interpreted as a mechanistic description of the average mitochondrial 
bioenergetics of all lung cells. Although the question regarding the mitochondrial 
bioenergetics of specific lung cell types is important, understanding the bioenergetics of 
mitochondria isolated from lung tissue and alteration in those bioenergetics is important 





Chapter 3 : Computational Model of the Bioenergetics of 
Isolated Perfused Rat Lung 
3.1 Introduction 
 Altered lung tissue bioenergetics plays a key role in the pathogenesis of lung 
diseases. A wealth of information exists regarding the bioenergetic processes of 
mitochondria isolated from rat lungs, cultured pulmonary endothelial cells, and intact rat 
lungs under physiological and pathophysiological conditions [7, 16, 18, 20-24]. However, 
the interdependence of those processes makes it difficult to quantify the impact of a 
change in a single or multiple process(es) on overall lung tissue bioenergetics. For 
instance, although ~85% of cellular ATP is produced in mitochondria under physiological 
conditions [18], glycolysis is important for lung tissue bioenergetics since it can partially 
compensate for the decrease in lung tissue ATP when mitochondrial ATP generation is 
impaired [97].  
The objective of Aim 2 was to develop and validate an integrated computational 
model of isolated rat lung tissue bioenergetics using existing experimental data. Figure 
3.1 shows an overview of an isolated perfused rat lung system. The system allows us to 







Figure 3.1: Structure of isolated perfused rat lung system. 
 
The model of isolated perfused rat lung expands the integrated computational 
model of the bioenergetics of mitochondria isolated from rat lungs by accounting for 
glucose uptake and phosphorylation, glycolysis, and the pentose phosphate pathway. The 
model is used to gain novel insights into how lung tissue glycolytic rate is regulated by 
exogenous substrates such as glucose and lactate, and assess differences in the 
bioenergetics of mitochondria isolated from lung tissue and those of mitochondria in 
intact lungs. The results of Aim 2, including the development and validation of the model 
of the bioenergetics of the intact rat lung, are described in an accepted manuscript  
(Frontiers in Physiology: Mitochondrial Research). 
 
3.2 Model Development 
3.2.1 Model Structure 




reservoir + tubing region, the lung vascular (blood) region, the cytosolic region, inter-
membrane space (IMS) region, and the mitochondria matrix region. For all regions, the 
general forms of the reaction and transport fluxes are identical to those developed for the 




Figure 3.2: Structure of the isolated perfused rat lung bioenergetics model.  
The model consists of five regions: The reservoir + tubing region, the lung vascular 
(blood) region, the cytosolic region, the inter-membrane space (IMS) region, and the 
mitochondria matrix region. Major reactions include glycolysis, pentose phosphate cycle, 
TCA cycle, and electron transport chain reactions. Major biochemical species included 
include: GLC: glucose, G6P: glucose 6-phosphate, F6P: fructose 6-phospate, F16BP: 
Fructose 1,6-biphosphate, GAP: Glyceraldehyde 3-phosphate, BPG: 1,3-
Bisposphoglycerate, PEP: Phosphoenolpyruvate, PYR: pyruvate, LAC: lactate. ALA: 
alanine. CoA: coenzyme-A, ACoA: acetyl-CoA, OXA: oxaloacetate, CIT: citrate, AKG: 
a-ketogluterate, SCoA: succinyl-CoA, SUC: succinate, FUM: fumarate, MAL: malate, 
GLU: glutamate, and ASP: aspartate, NAD and NADH: oxidized and reduced form of 
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nicotinamide adenine dinucleotide, respectively, FAD and FADH2: oxidized and reduced 
form of flavin adenine dinucleotide, respectively, ADP and ATP: adenosine triphosphate 
and adenosine diphosphate, respectively, UQ and UQH2: oxidized and reduced form of 




Lung tissue is capable of oxidizing a wide range of substrates, including glucose, 
fatty acids, amino acids, and lactate [18, 21, 23]. However, glucose is by far the major 
substrate under physiological conditions [18]. Alanine, an amino acid, can also be an 
importance substrate, especially when glucose is low [23, 98]. Thus, glucose and alanine 
utilization and intermediary metabolism are accounted for in the proposed integrated lung 
tissue bioenergetics model. The model does not account for glycogen, which is low and 
relatively constant in lung tissue [23]. 
3.2.2 Reaction and transport fluxes 
The proposed integrated lung tissue bioenergetics model accounts for 70 state 
variables, including the concentrations of key metabolites in the mitochondrial matrix 
region and cytosol, as well as the mitochondrial membrane potential. Key reactions in the 
glycolytic pathway and pentose phosphate pathway are also included in this model (Table 
3.1).  
 
Table 3.1: Reactions in the isolated perfused rat lung model 
Reaction number Enzyme Reference reactions 
1 HK GLCc+ATPc ⇌ G6Pc+ADPc+Hc 
2 PGI G6Pc ⇌ F6Pc 
3 PFK F6Pc+ATPc ⇌ F16BP+ADPc+H+ 
4 ALD F16BPc ⇌ 2GAPc 
5 GAPDH GAPc+Pic+NADc ⇌ BPG+NADHc+Hc 
6 PGK BPGc + ADPc ⇌ PEPc+ATPc 
7 PK PEPc+ADPc+Hc ⇌ PYRc+ATPc 





9 G6PDH G6Pc + NADPc  ⇌ PG6c + NADPHc + Hc 
10 6PGD PG6c + NADPc ⇌ R5Pc + NADPHc + Hc + CO2 
11 GR GSSGc + Hc + NADPH ⇌ 2GSHc + NADPc+ 
12 GPx 2GSHc + H2O2c ⇌ GSSGc + 2H2O 
13 ATPase ATPc ⇌ ADPc + Pic+ Hc 
14 AK ATPc+ AMPc ⇌ 2ADPc 
15 AA PYRc ⇌ ALAc 
16 PDH PYRm+CoAm+NADm ⇌ ACoAm+CO2+NADHm+Hm 
17 CITS ACoAm+OXAm ⇌ CITm+CoAm+ 2Hm 
18 ICDH CITm+NADm ⇌ AKGm+NADHm+CO2 
19 AKGDH AKGm+CoAm+NADm ⇌ SCoAm+NADHm+CO2 
20 SCAS SCoAm+GDPm+Pim ⇌ SUCm+GTPm+CoAm+Hm 
21 NDK GTPm+ADPm ⇌ GDPm+ATPm 
22 SDH SUCm+FADm ⇌ FUMm+FADH2m 
23 FUM FUMm = MALm 
24 MDH MALm+NADm ⇌ OXAm+NADHm+ Hm 
25 GOT ASPm+aKGm ⇌ GLUm+OXAm 
26 CI NADHm+UQm+Hm ⇌ NADm+UQH2m+ 4∆H 
27 CII FADH2+UQm ⇌ FADm+UQH2m 
28 CIII UQH2,m+2CytCo+2Hm  ⇌ UQm+2CytCr+ 4∆H 
29 CIV 2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2∆H 
30 CV ADPm+Pim+Hm+3∆H ⇌ ATPm 
 
Thirteen trans-membrane transport processes (Table 3.2) are included in the 
model to account for the exchange of key metabolic species between the mitochondrial 
matrix and cytosol, and between the blood region and cytosolic region. We used the same 
reaction and transport flux expressions as in the isolated rat lung mitochondria [24].  
 
Table 3.2: Transports in the isolated perfused rat lung model 
Transport number Enzyme Reference reactions 
1 GLUT GLCb ⇌ GLCc 
2 PYRT PYRb + Hb ⇌ PYRc + Hc 
3 LACT LACb + Hb ⇌ LACc + Hc 
4 PIT Pib ⇌ Pic 
5 DCC (SUC) SUCm +Pic ⇌ SUCc+Pim 
6 DCC (MAL) MALm+Pic ⇌ MALc+Pim 




8 PYRH PYRc + Hc ⇌ PYRm + Hm 
9 PIC Pic + Hc ⇌ Pim + Hm 
10 ANT ADPc + ATPm ⇌ ADPm + ATPc 
11 GLUH GLUc+ Hc ⇌ GLUm+ Hm 
12 MAS NADHc + NADm ⇌ NADHm + NADc 
13 LEAK Hi ⇌ Hm 
 
Several glycolytic reactions are regulated by specific activators or inhibitors [99]. For 
instance, hexokinase (HK) is inhibited by its reaction product glucose-6-phosphate 
(G6P), phosphofructokinase (PFK) is known to be activated by cytosolic AMP and 
inhibited by cytosolic ATP and citrate [99, 100]. Those reaction fluxes are modified to 
account for such regulatory effects as described in Appendix V. 
3.2.3 Dynamic mass balance equations 
The governing ordinary differential equations describing the dynamic changes in 
the concentrations (C) of various chemical species in different regions (total 70 state 
variables) were derived based on the principle of mass balance. The changes in the 
concentration of species within each of the five regions are given by: 
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where Cx,j is the concentration of j
th species in region x, F is the flow rate, Jx,j is the jth 




and Vx is the volume of the region x. Subscripts r, b, c, m, and i denote reservoir region, 
blood region, cytosolic region, mitochondrial region, and inter-membrane space region, 
respectively. Detailed mass balance equations are included in Appendix VI. 
MATLAB function ‘ode15s’ (MathWorks Inc.) was used to solve the system of 
governing differential equations. 
3.3 Model parameter estimation 
The proposed integrated lung tissue bioenergetics model accounts for key 
metabolites in the mitochondrial matrix region and cytosol, as well as the mitochondrial 
membrane potential. Volumes of each region and general model parameters are listed in 
Table 3.3. 
 
Table 3.3: General model parameters for the isolated perfused lung model 
Parameter Value (units) Source 
Volumes 
Capillary vascular volume (Vb) 0.66 (ml) [12] 
Total tissue volume (Vc+Vm+Vi) 0.67 (ml) [12] 
Total lung volume 1.33 (ml) [12] 
Lung tissue cytosolic volume (Vc) 0.66 (ml) [86]* 
Mitochondria volume (Vm) 13.12 (μl) [86]* 
Inter-membrane space volume (Vi) 0.95 (μl) [46]* 
Lung wet/dry weight ratio 5.87 ± 0.24 [16] 
Average rat lung dry weight  0.227 (g) [16]** 
Metabolic pools 
Total flavin adenine dinucleotide 
concentration (FAD + FADH2) in 
mitochondria 
0.7 (mM) [66] 
Total pyridine nucleotide content 




Cytosolic NAD+ concentration  340 (M) [98] 
* Calculated based on Vm/Vc = 1/50 [86], and Vi/Vm = 0.0724 [46]. 






For the mitochondria matrix and IMS regions, the values of intrinsic (binding 
constants, K’s) and all extrinsic model parameters (Vmaxfs and Tmaxfs), except for the 
parameter describing mitochondrial membrane leakiness, were fixed to those estimated 
using our model of the bioenergetics of isolated lung mitochondria (Aim 1) [24]. For 
these regions, the values of the extrinsic model parameters, expressed in units of 
nmol/min/mg mitochondria protein in the model for isolated lung mitochondria, were 
converted to nmol/min/lung for the integrated lung model by multiplying each parameter 
by total mitochondria protein mass (Mmito) in the rat lung. The value of Mmito along with 
those for other unknown model parameters were estimated from the experimental data 
described below. For the lung model, the value of Tmaxf,,LEAK  was assumed to be equal to 
or lower than that estimated for isolated mitochondria [24], since the mitochondria 
isolation process could cause damage to mitochondrial membrane. Thus Tmaxf,LEAK was 
assumed to be an unknown parameter for the lung model. 
For the cytosolic region, the values of the intrinsic model parameters, such as 
binding constants of various substrates and products for different enzymes and 
transporters, were set to previously published values (see Appendix). The assumption is 
that the binding constants are intrinsic model parameters, and hence their values should 
be organ-independent [24, 46]. The values of the extrinsic model parameters (i.e., Vmaxfs, 
Tmaxfs) in Table 3.3 were estimated by fitting model solution to experimental data Figure 
3.3-Figure 3.5 from rat lung tissue bioenergetics using the genetic algorithm (MATLAB 
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where ,i jx  and ,i jX  are the model solutions and the corresponding experimental 
data at the ith time point and jth data set, respectively. N is the number of data points and 
M is the number of data sets used for the parameter estimation. Experimentally measured 
maximal enzyme activities  were used as initial guesses for the Vmaxfs of corresponding 
reactions in the glycolytic pathway [101]. A total of seventeen unknown extrinsic 
parameters were estimated from the experimental data in Figure 3.3-Figure 3.5 [16, 18, 
20, 21, 23]. 
 
Table 3.4: Estimated values of unknown parameters for the lung model (30 °C) 









Glycolytic pathway reactions 
Vmaxf, HK Maximum forward reaction rate of HK 279 705 ± 93.1 
Vmaxf, PGI Maximum forward reaction rate of PGI 3.70×10
4 4.2×104 ± 
3.7×103 
Vmaxf, PFK Maximum forward reaction rate of PFK 1.47×10
3 8.3×103 ± 
1.2×103 
Vmaxf, ALD Maximum forward reaction rate of ALD 1.43×10
3 5.72×103 ± 146 
Vmaxf, GAPDH Maximum forward reaction rate of 
GAPDH 
6.35×104 5.53×103 ± 864 
Vmaxf, PGK Maximum forward reaction rate of PGK 2.00×10
5 8.15×104 ± 
1×104 
Vmaxf, PK Maximum forward reaction rate of PK 1.89×10
4 1.83×104 ± 784 


















Vmaxf, AA Maximum forward reaction rate of AA 409 NA 
Tmaxf, GLUT Maximum transport rate of GLUT 534.12 NA 
Tmaxf, PYRT Maximum transport rate of PYRT 185.08 NA 
Tmaxf, LACT Maximum transport rate of LACT 9.08×10
3 NA 
Tmaxf, MAS Maximum transport rate of MA shuttle 4.43×10
3 NA 
Tmaxf, LEAK Maximum rate of passive proton leak 15.98 NA 
Mmito  
Average mass of mitochondria protein in 
rat lungs  
16.44 mg 
13.12 mg** 
*values are converted from µmol/g wet weight/min to nmol/min/lung. **Mitochondrial 
protein content is 1mg/1µL mitochondrial volume. NA = Not available. 
 
The following data sets (Figure 3.3–Figure 3.5) were used to estimate the values 
of the unknown model parameters (i.e. maximal reaction and transport velocities), related 
to the cytosolic reactions and plasma membrane metabolite transporters.  
 
 
Figure 3.3: Pseudo-steady state reaction fluxes used for parameter estimation. 
Panel A. Glucose (GLC) consumption rate [23] and total lactate (LAC) and pyruvate 
(PYR) production rates [20] of isolated rat lungs perfused with perfusate containing 5.5 
mM glucose. Red symbols are experimental data (mean ± SE, n = 4). Panel B. Pseudo-
steady state reaction flux of pentose phosphate pathway (PPP) measured at the end of 100 
min recirculation time [18]. G6PDH: glucose 6 phosphate dehydrogenase. Red symbol is 
experimental data calculated based on [18, 70]. Values are mean ± SE (n = 4). Panel C. 
Lung cyanide-sensitive oxygen consumption rate (OCR), calculated as lung OCR in the 
absence of potassium cyanide – OCR in the presence of potassium cyanide (complex IV 
inhibitor, 2 mM) of atelectatic isolated perfused rat lungs [102]. Values are mean ± SE (n 
= 6). For the model, lung OCR was calculated as half of reaction flux of complex IV. 
Panel D. Mitochondrial and cytosolic ATP production rate were estimated based on 
recovery of catabolic products from glucose [18]. Units were converted from µmol/hr/g 
dry weight to µmol/min/g dry weight. In model simulations, pseudo-steady state reaction 






For the perfusate glucose concentration of 5.5 mM, Figure 3.3 (panel A) shows 
the glucose consumption rate [23], and the production rates of pyruvate and lactate [20]. 
The data in Figure 3.3 (panel B) show the pseudo-steady state reaction flux of the pentose 
phosphate pathway. Audi et al. estimated the reaction flux of mitochondrial complex IV 
as the cyanide-sensitive oxygen consumption rate (OCR) calculated as the difference in 
isolated rat lung OCR measured in the absence of potassium cyanide (complex IV 
inhibitor, 2 mM) and that measured in the presence of potassium cyanide (Figure 3.3, 
panel C) [102]. The data in Figure 3.3 (panel D) show rat lung cytosolic ATP production 
rate and mitochondrial ATP production rate estimated by Fisher et al. based on glucose-






Figure 3.4: Effects of the perfusate GLC or LAC on rat lung GLC consumption and LAC 
production.  Panel A. Effect of perfusate glucose (GLC) concentrations on rat lung 
glucose consumption rate [23]. Lungs were isolated from male Sprague-Dawley rats 
(200-260 g) and perfused with different concentrations of D-glucose plus 5-3H-glucose 
and U-14C glucose. The labeled glucose, 5-3H-glucose, and U-14C glucose were used to 
measure glucose consumption and exogenous lactate production, respectively. The 
production rate of 3H2O was used as index of glucose consumption since more than 90% 
of 3H from glucose was recovered as 3H2O [23]. Values are mean ± SE (n = 3 or more for 
each glucose concentration). Lines are model fits to data. Panels B and C. Lung 
exogenous, endogenous, and total lactate (LAC) production rates as a function of 
perfusate glucose concentration [23]. Isolated rat lungs were perfused with different 
concentrations of D-glucose plus 5-3H-glucose and U-14C glucose. Perfusate samples 
were collected every 20 minutes for LAC measurement. Labeled LAC concentrations 
were derived from U-14C glucose; unlabeled LAC concentrations were derived from 
endogenous substrates such as amino acids [23]. In panel B, total LAC production is 
plotted as a function of recirculation time. In panel C, exogenous, endogenous, and total 
LAC production rates are plotted separately as a function of buffer GLC concentration. 
Values are mean ± SE (n = 6 or more for each GLC concentration). Lines are model fits 
to data. Panel D. Effect of perfusate LAC concentrations on lung GLC consumption rate 




perfusate containing 10 mM 5-3H-glucose and D-glucose. In addition, different 
concentrations of LAC were added to the perfusate before recirculation. 3H2O production 
rate was measured as an index of GLC consumption rate. 0.5 mM LAC had no effect on 
GLC consumption rate, but as buffer LAC concentrations increased to 2 mM, GLC 
consumption rate decreased to half compared to that under baseline conditions (no LAC). 
Symbols are mean values from 4–10 lungs, and lines are model fits to data. 
 
Kerr et al. evaluated the effect of perfusate glucose concentrations on the glucose 
consumption rate as well as lactate production rate in isolated perfused rat lungs [23]. The 
lungs were perfused with different concentrations of D-glucose along with labeled 
glucose (5-3H-glucose and U-14C glucose, each with specific activity of 0.1 mCi/mmol). 
The labeled glucose were used to measure lung glucose consumption rate, and to 
distinguish lactate production rate from glucose added to the perfusate (exogenous 
source) from that derived from endogenous substrates such as amino acids and glycogen 
[23]. Following the lung uptake of 5-3H-glucose, tritium (3H) is liberated during 
glycolysis to form 3H2O. Over 90% of the 
3H from glucose was recovered as 3H2O [23]. 
As such, the production rate of 3H2O was used as a measure of lung glucose consumption 
rate [23]. For a given perfusate sample, 3H2O was separated from 5-
3H-glucose by 
evaporation of the sample [71]. 14C labeled lactate measured in perfusate was derived 
from U–14C glucose and is referred to as exogenous lactate since it is derived from 
exogenous sources (i.e. glucose added to the perfusate). Lactate derived from U–14C 
glucose was separated from U–14C glucose by extraction with ether [23]. Endogenous 
lactate in a given perfusate sample was then obtained as the difference between total 
lactate in sample, measured enzymatically, and labeled lactate [23]. The resulting data are 
shown in Figure 3.4 (panels A–C). The data in Figure 3.4 show the amount of glucose 
consumed (panel A) and total lactate produced (panel B) as a function of recirculation 




relationship between the perfusate glucose concentration and the lung rate of glucose 
consumption, consistent with the saturability of glucose transporters [23]. The results in 
Figure 3.4 (panel C) show that the rate of endogenous lactate production is saturable at 
low perfusate glucose concentration, whereas the rate of exogenous lactate production is 
relatively linear over the range of perfusate glucose concentrations studied. In the model, 




















  (3.8) 
where JAA , JPK and JLACT  are the reaction/transport rates of alanine aminotransferase, 
pyruvate kinase, and lactate transport between blood and cytosol, respectively. 
Fisher and Dodia evaluated the effect of perfusate lactate concentrations on lung 
glucose consumption rate in isolated rat lungs perfused with perfusate containing 5-3H-
glucose and different D-glucose concentrations [21]. 3H2O production rate was measured 
as an index of glucose consumption rate. The data in Figure 3.4 (panel D) show that 0.5 
mM lactate had no effect on glucose consumption rate, but as perfusate lactate 
concentration increased to 2 mM, glucose consumption rate decreased to half as 
compared to that under baseline conditions (zero exogenous lactate). These data suggest 
that exogenous lactate has a regulatory effect on rat lung glycolytic rates [21, 103, 104].  
In another study, Fisher and Dodia measured the production rates of lactate and 
pyruvate in isolated perfused rat lungs as a function of O2 partial pressure (PO2) in lung 
ventilation/aeration gas mixture [20]. Gas mixtures containing %PO2 ranging from 




samples were then collected for lactate and pyruvate measurements. Figure 3.5 shows 
that lactate and pyruvate production rates were not significantly altered when PO2 in gas 
mixture was between 0.1% (0.76 mmHg) and 95% (~722 mmHg) [20]. However, as PO2 
was dropped to 0.006%, lactate production rate increased by ~ two-fold. These results 
suggest that rat lung can maintain normal metabolism for PO2 ≥ 0.1% [20].  
 
 
Figure 3.5: Effects of lung oxygen partial pressure (PO2) on lung LAC and PYR 
production. Lungs were isolated from male Sprague-Dawley rats (200–250 g) and 
perfused with 40 ml Krebs-Ringer bicarbonate buffer containing 10 mM glucose (GLC) 
and 3% bovine serum albumin [20]. Gas mixtures containing different % oxygen partial 
pressures (PO2; ranging from 0.006% to 95%) were used to ventilate the lungs and aerate 
the perfusate. Perfusate sample were collected for lactate (LAC) and pyruvate (PYR) 
measurements. Rat lung LAC production rate (panels A and D), PYR production rate 
(panels B and E), and LAC/PYR ratio (panels C and F) are plotted as a function of %PO2 
(top panels) or log (%PO2) (bottom panels) in gas mixture to show the model fit to data at 
low %PO2 [20]. Symbols are experimental data [20] and solid lines are model fits.  
 
 All of the extrinsic model parameters of the integrated lung tissue bioenergetics 






experimental data in Figure 3.3–Figure 3.5 using genetic algorithm (MATLAB function 
“ga”). The estimated values of the extrinsic model parameters are shown in Table 3.4 
3.4 Model validation 
To assess the estimability (existence of model parameters to fit available 
experimental data) and identifiability (uniqueness of the model parameters to fit available 
experimental data) of the extrinsic parameters of the integrated lung tissue bioenergetics 
model, we estimated the parameters’ normalized sensitivity coefficients and a matrix of 
correlation coefficients between the estimated model parameters. The normalized 
sensitivity coefficients provide information about the contribution of each of the extrinsic 
model parameters to the overall model solution. If a given model parameter is 
identifiable, its sensitivity coefficient should be relatively large. In addition, a parameter 
that has a relatively larger sensitivity coefficient indicates the parameter has more 
influence on model outputs.  While the correlation coefficient matrix provides 
information about the degree of interdependence between the various model parameters. 
For a given extrinsic model parameter, the normalized sensitivity coefficient was 














  (3.9) 
where E is the sum of squared difference between experimental data and the integrated 
lung tissue bioenergetics model fit, as defined by equation (3.9), and i  is the estimated 










method with 0.1% change in i .  
The matrix of correlation coefficients between the model parameters was 
evaluated at the estimated parameter values in Table 3.4 that best fit the integrated lung 
tissue bioenergetics model to the available experimental data. The correlation coefficient 
(CCij) between the i










  for i,j= 1,…,np (3.10) 
where np is the number of model parameters, HH is the inverse of the product of the 
transpose of the Jacobian matrix and the Jacobian matrix evaluated at the estimated 
values of the model parameters in Table 3.4 that best fit the model to the data in Figure 





Figure 3.6: Matrix of correlation coefficients between the extrinsic parameters of the 
integrated lung tissue bioenergetics model. 
Correlation coefficients range between -1 (perfect negative correlation) and +1 (perfect 
positive correlation) and are estimated using equation (3.10). A small positive or negative 
correlation coefficient between two parameters suggests small interdependence between 
those parameters. 
 
Figure 3.7 and Figure 3.6 show the respective normalized sensitivity coefficients 
and matrix of correlation coefficients for the extrinsic model parameters. For most of the 
extrinsic model parameters, the normalized sensitivity functions are relatively high, and 




those parameters that provide a good fit to the data in Figure 3.3–Figure 3.5. This 
suggests that the chosen experimental data has enough information to estimate the values 
of the unknown model parameters.  
 
Normalized sensitivity coefficient





































Figure 3.7: Normalized sensitivity coefficients of the extrinsic model parameters. 
A parameter contribution to the model solution is proportional to its normalized 
sensitivity coefficient estimated using equation (3.10). 
 
To validate the integrated lung tissue bioenergetics model, we assessed its ability 
to predict published experimental data that were not used for estimating the values of the 
unknown model parameters. To that end, we evaluated the ability of the model to predict 




Bongard et al. measured fractional ATP, ADP and AMP contents as a function of 






  (3.11) 
in isolated rat lungs following exposure to a single or combination of various treatments, 
including rotenone (complex I inhibitor, 20 μM), ubiquinol analog coenzyme Q1 
(oxidized artificial electron donor, 50 µM), or antimycin A (complex III inhibitor, 3.6 
μM) [16]. These treatments induced different degrees of change in lung EC, adenine 
nucleotides contents, and lactate production rates. Figure 3.8 (panel A) shows that lung 
ATP content decreased as EC decreased, whereas AMP content increased as EC 
decreased. Lung ADP content shows a biphasic behavior as a function of EC. As shown 
in Figure 3.8 (panel B), lung lactate production rate increased as lung EC decreased. 
However when EC dropped below 0.4, lung lactate production rate did not increase 
further. The two glycolytic enzymes HK and PFK require ATP as substrate. Model 
simulation shows that when EC falls below 0.4, ATP content becomes too low for these 
two enzymes to proceed. Therefore, under such conditions, most of the lactate produced 
by rat lung is from endogenous substrate such as alanine. As shown in Figure 3.8, model 
predictions using the estimated values of the model parameters in Table 3.4 are in good 
agreement with the measured experimental data. For model predictions, mitochondrial 
complex I and complex III activities were gradually decreased to simulate the inhibitory 
effects of rotenone and antimycin A on EC. Additional model simulations in Figure 3.8C 
show that as cytosolic ATP concentration decreases (due to decrease in complex I (CI) 
activity), cytosolic phosphate (Pi) concentration as well as cytosolic ADP + AMP 




ADP, and Pi as a function of complex I activity.   
The ATP hydrolysis potential, rGATPase, is a measure of the energy released by 
ATP hydrolysis and is more thermodynamically relevant than EC [105]. We calculated 
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where [ATPc], [ADPc] and [Pic] are concentrations of ATP, ADP and inorganic phosphate 
(Pi) in the cytosolic region, respectively; rG0ATPase, R and T are the standard Gibbs free 
energy of the reaction at pH = 7, gas constant, and temperature, respectively. Model 
simulations in Figure 3.8E and F show that decreasing CI activity leads to decrease in 
lung EC, decrease in cytosolic rGATPase, decrease in lung O2 consumption rate (OCR), 
and increase in lung rate of lactate (LAC) production.  The simulations in Figure 7E 
suggests a high correlation between EC and rGATPase, consistent with theoretical 









Figure 3.8: Relationship of lung fractional ATP, ADP and AMP contents, lung lactate 
(LAC) production rate, and energy charge. For the data (symbols) in panels A and B, 
lungs were isolated from male Sprague-Dawley rats (n = 36) and perfused with perfusate 
containing 5.5 mM glucose and 5% bovine serum albumin at 37°C. Isolated perfused rat 
lungs were exposed to single or combination of different treatments, including 20 μM 
rotenone (complex I inhibitor), 50 µM CoQ1 (reduced to CoQ1H2, an artificial electron 
donor), or 3.6 μM antimycin A (complex III inhibitor).These treatments induced different 







For model predictions (solid lines), mitochondrial complex I activity was incrementally 
decreased to simulate the inhibitor effects of rotenone on lung EC. In panel A, lung ATP 
amount decreased as EC decreased, while AMP amount increased as EC decreased. Lung 
ADP amount showed a biphasic behavior. In panel B, lung LAC production rate 
increased as lung EC decreased. Panel C shows model predicted relationships between 
CI activity and cytosolic concentrations of ATP, ADP, AMP and Pi. Panel D shows model 
predicted relationships between complex I (CI) activity and mitochondrial concentrations 
of ATP, ADP, and phosphate (Pi). Panel E shows model predicted relationships between 
CI activity and EC and cytosolic ATP hydrolysis potential (rGATPase). Panel F shows 
model predicted relationships between CI activity, lung oxygen consumption rate (OCR) 
and lung lactate (LAC) production rate.  
 
 
Bongard et al. also evaluated the effect of complex I inhibitor rotenone (20 µM) 
on lung ATP/ADP ratio and on lactate/pyruvate ratio in perfusate recirculated through 
isolated perfused rat lungs [16]. As shown in Figure 3.9, model simulations are in good 
agreement with the measured experimental data. For model predictions, rotenone 
inhibitory effect was simulated by decreasing mitochondrial Complex I activity by 85%, 
with the values of all the other model parameters set to those in Table 3.4. CO inhibitory 
effect was simulated by decreasing mitochondria complex IV activity by 99.7% at 10 
min, with the values of all the other model parameters set to those in Table 3.4.  
 
 
Figure 3.9: Effects of ROT on lung ATP/ADP ratio and LAC, PYR production. 
Effect of complex I inhibitor rotenone (ROT, 20 µM) on lung ATP/ADP (Panel A) ratio 
and LAC, PYR production rates (Panel B) in perfusate recirculated through isolated 
perfused rat lungs [16]. Experimental conditions are the same as those for data in Figure 
3.3. For model predictions, ROT effect was simulated by decreasing mitochondrial 







experimental data [16], values are mean ± SE (n = 4). Solid lines are model predictions. 
Panel C. Effect of complex IV inhibitor CO (carbon monoxide) on lung LAC, PYR 
production rates. In control condition, the lung was ventilated with 95% O2 and 5% CO2. 
At 5 min, the ventilation gas was changed to 95% CO and 5% CO2. For model 
predictions, CO effect was simulated by decreasing mitochondria complex IV activity by 
99.7%. Symbols are experimental data [22] and solid lines are model predictions. LAC 
production rate was multiplied by a factor of 2 since LAC production measured in [22] is 
50% lower than in [16]. 
 
 
Table 3.5: Model predicted and experimental lung tissue adenine nucleotide 
 Model 
predicted 
Bongard et al. 
[16] 




ATP/(ATP ADP AMP) 0.78 0.79 0.83 0.83 
ADP/(ATP ADP AMP) 0.19 0.16 0.12 0.12 
AMP/(ATP ADP AMP) 0.03 0.04 0.05 0.05 
ATP (mole/g dry wt) 6.64 5.66 ± 0.46 6.8 ± 0.5 12.8 ± 0.1 
ADP (mole/g dry wt) 1.85 1.17 ± 0.14 0.95 ± 0.05 1.8 ± 0.2 
AMP (mole/g dry wt) 0.29 0.31 ± 0.06 0.41 ± 0.02 0.8 ± 0.1 
 
 
Table 3.5 shows experimentally measured [16] and model predicted lung tissue 
adenine nucleotide fractions and content under control conditions. Model predictions are 
within the range of measured experimental data. 
 Staniszewski et al. and Sepehr et al. measured lung surface NADH (top panels) 
and FAD (middle panels) emission signals in isolated perfused rat lungs by placing a 
fiber optic probe against the pleural surface of the right lobe [26, 108]. Signals were first 
obtained under resting conditions, and then following the addition of inhibitors to the 
recirculating perfusate to induce changes in NADH and FAD redox status, and thus 
fluorescence intensities. Lung redox ratios were then calculated as the ratio 
(NADH/FAD) of NADH and FAD fluorescence intensities. As shown in Figure 3.10, 
rotenone (ROT, complex I inhibitor) caused a 20% increase in NADH intensity and 




caused 20% increase in NADH intensity as well as a 10% decrease in FAD intensity. The 
mitochondrial uncoupler pentachlorophenol (PCP) caused a 20% decrease in NADH 
intensity and negligible effect on FAD intensity. For model predictions, the ROT effect 
was simulated by decreasing mitochondrial Complex I activity by 85%, KCN effect was 
simulated by decreasing mitochondria complex IV activity by 99.7%, and PCP effect was 
simulated by increasing the proton leak activity (parameter Tmaxf,leak) by 5 times. As 





Figure 3.10: Experimental data and model prediction of normalized lung surface NADH 
(top panels), FAD (middle panels) and redox ratio (NADH/FAD, bottom panels) [26, 
109]. 
Lungs were isolated from male Sprague-Dawley rats (300-350 g) and perfused with 
perfusate containing 5.5 mM glucose and 3% bovine serum albumin at 37°C. NADH and 
FAD fluorescence intensities were measured using fluorometer with fiber optic probe 
placed against the pleural surface of the right lobe. Signals were first obtained under 
resting conditions, and then following the addition of inhibitors to the recirculating 
perfusate to induce changes in NADH and FAD redox status and thus fluorescence 
intensities. Lung redox ratios were calculated as the ratio (NADH/FAD) of NADH and 
















inhibitor) was added to the recirculating perfusate at 3 min. For panels D E, and F, 2 mM 
potassium cyanide (KCN, complex IV inhibitor) was added to the recirculating perfusate 
at 3 min. For panels G, H, and I, 3 mM protonophore (PCP, uncoupler) was added to the 
recirculating perfusate at 3 min. For model predictions, ROT effect was simulated by 
decreasing mitochondrial Complex I activity by 85%, KCN effect was simulated by 
decreasing mitochondria complex IV activity by 99.7%, and PCP effect was simulated by 
increasing proton leak activity by 5 times. Symbols are experimental data [26, 109], and 
solid lines are model predictions.  
 
3.5 Discussion 
We have developed and validated the first integrated computational model of the 
bioenergetics of isolated rat lungs. This model is an extension of our previously 
developed integrated computational model of the bioenergetics of isolated rat lung 
mitochondria [24] presented in Chapter 2. 
3.5.1 Parameter estimation results and sensitivity analysis 
As shown in Figure 3.3–Figure 3.5, the model was able to fit a wide range of 
published experimental data collected from isolated perfused rat lungs under various 
experimental conditions, including metabolic changes in response to different buffer 
glucose concentrations, lactate concentrations, oxygen partial pressures, as well as the 
effects of various metabolic inhibitors.  
Except for the maximum mitochondria proton leak activity (Tmaxf,leak), the values 
of model parameters for the mitochondria matrix and IMS regions were set to those 
estimated using our recent model of the bioenergetics of mitochondria isolated from rat 
lungs [24]. Our estimate of Tmaxf,leak from isolated mitochondria ranged between ~15 
nmol/min/mg and 36 nmol/min/mg mitochondria protein, depending on the quality of 




membranes [24]. For the whole lung, the value of Tmax,leak would be expected to be equal 
to or smaller than that estimated from isolated mitochondria, since mitochondria isolation 
process may cause damage to mitochondria membrane [24]. For the lung model, the 
estimated value of Tmaxf,leak was ~16 nmol/min/mg mitochondria protein which is close to 
the low end of the range of values estimated from isolated mitochondria [24]. 
For glycolytic enzymes, we used experimentally measured enzyme activities 
[101] as initial guesses for the unknown extrinsic model parameters, which significantly 
improved the efficiency of the parameter estimation method using genetic algorithm. 
Parameter estimation results show that most of the estimated Vmaxfs values that best fit 
model solution to the experimental data in Figure 3.3–Figure 3.5 are relatively close to 
the measured activities of the corresponding enzymes. This along with the ability of the 
model to predict quite well additional experimental data that were not used for model 
parameter estimation serve as validation of this integrated isolated rat lung bioenergetics 
model. 
A parameter with a relatively high normalized sensitivity coefficient is more 
likely to be the rate limiting step, since a small change in that parameter will result in 
relatively big change in the model output. Model sensitivity analysis revealed key 
information regarding the limiting step(s) in glycolysis. Consistent with enzyme studies 
in isolated rat lung cells [101], few glycolytic enzyme activities greatly exceeded the 
observed rate of glucose utilization. As such, the calculated normalized sensitivity 
coefficients are low for the glycolytic enzyme activity model parameters, including 
phosphoglucose isomerase (PGI) and phosphoglycerate kinase (PGK). In contrast, 




relatively high sensitivity coefficients, and hence are probably the glycolysis rate limiting 
steps in lung tissue.  
Flux control coefficient for a given enzyme or transporter is defined as the 
relative change in a pathway’s flux (e.g. glycolysis) with respect to a change in the value 
of a model parameter describing the activity of that enzyme or transporter in that pathway 
[110].  To gain more insights into the rate limiting step for glycolysis, we calculated the 
flux control coefficients [43, 110] for glycolytic enzymes and for the transporters that are 
affected by glycolysis (glucose transporter, lactate transporter and pyruvate transporter). 
The sum of those flux control coefficients should be one, as predicted by the metabolic 
control theory [43].  The results shown in Figure 3.11 (left panel) suggest that under basal 
condition, GLUT has the highest flux control coefficient, and hence is the rate limiting 
step for glycolysis. However Figure 3.11 (right panel) shows that when lung EC 
decreases, the flux control coefficients of the glycolytic enzymes HK and PFK increase 
significantly since they use ATP as a substrate, whereas that for GLUT decreases. Thus 






Figure 3.11: model predicted flux control coefficients for glycolytic enzymes and for the 
transporters that are affected by glycolysis. 
Left panel: model predicted flux control coefficients under basal conditions. Right panel: 
flux control coefficients as a function of energy charge (EC, defined in Equation 10). The 
flux control coefficient of the glucose transporter (GLUT) decreased as EC decreased, 
whereas flux control coefficients of the glycolytic enzymes phosphofructokinase (PFK) 
and hexokinase (HK) increased as EC decreased. For model simulations, mitochondrial 
complex I activity was incrementally decreased to induce a decrease in EC. 
 
3.5.2 Differences between the bioenergetics of mitochondria isolated from lungs and 
mitochondria in intact lungs 
The metabolic environment in isolated mitochondrial experiments is different 
from that in isolated perfused lung experiments. For instance, the environment in isolated 
mitochondria experiments is quite stable since the buffer volume is relatively large as 
compared to mitochondrial volume (ratio of mitochondrial volume to buffer volume is 
~1/1000) [24, 46]. For intact lungs, bioenergetics are more sensitive to metabolic control 
in isolated perfused rat lungs because of the relatively large mitochondria/cytosol volume 
Flux control coefficient


























ratio (mitochondria to cytosol volume ratio of ~1/50) [86].  
Mitochondrial respiratory substrates can inhibit glycolytic rate via increased 
citrate production from mitochondria [21]. For this study, conditions of abundant 
mitochondrial respiratory substrates were simulated using the proposed integrated lung 
tissue bioenergetics model by elevating cytosolic pyruvate concentration. The simulations 
in Figure 3.12 show that the fluxes of three TCA cycle reactions (namely PDH, CITS, 
and MDH) increased with increase in cytosolic pyruvate concentration. The fluxes of the 
other TCA cycle reactions (ICDH, AKGDH, SCAS and SDH) actually decreased with 
increase in cytosolic pyruvate concentration. As a result, excessive mitochondrial citrate 
produced by TCA cycle is released to cytosol, which in turn inhibits glycolysis.  
Previously we showed that the TCA cycle in mitochondria isolated from rat lung 
is functionally incomplete [24], with only half of the TCA cycle reactions (PDH, CITS, 
MDH) active while the other reactions are apparently inactive. However as Figure 3.12 
shows, a different TCA cycle behavior was observed in simulations generated using the 
integrated lung tissue bioenergetics model. For intact lung experimental conditions, the 
TCA cycle is complete and all the reactions are running at approximately equal rates. 
This difference in TCA cycle activity is potentially due to differences in the 
mitochondrial environment of the isolated mitochondrial preparation as compared to that 
in isolated perfused lung preparation. For instance in isolated perfused rat lung, the 
physiological pyruvate concentration is around 0.1 mM under normal conditions [98]. 
However, in isolated mitochondrial experiments, the buffer pyruvate concentration used 
(~5 mM) is much higher than the physiological pyruvate concentration, to ensure enough 





Figure 3.12: Model predicted mitochondrial TCA cycle fluxes as functions of cytosolic 
pyruvate (PYR) concentration.  
When cytosolic PYR concentration is clamped below 0.1 mM, TCA cycle is seen to be 
functionally complete (equal fluxes at steady state). As cytosolic pyruvate concentration 
increases, TCA cycle becomes increasingly functionally incomplete. PDH: Pyruvate 
dehydrogenase, CITS: Citrate synthase, ICDH: Isocitrate dehydrogenase, AKGDH: α-
ketoglutarate dehydrogenase, SCAS: Succinyl-coenzyme A synthetase, SDH: Succinate 
dehydrogenase, MDH: Malate dehydrogenase. 
 
Simulations using the lung tissue bioenergetics model provide a potential 
explanation for why the TCA cycle is apparently incomplete in isolated mitochondrial 
studies, but is complete in isolated perfused rat lung experiments. Higher cytosolic 
pyruvate concentration, as that used in isolated mitochondrial studies, results in higher 
NADH generation in mitochondria. Isocitrate dehydrogenase (ICDH) is known to be 
inhibited by NADH [24, 49], with the ICDH activity decreasing as mitochondrial 
NADH/NAD ratio increases. As such, increased amount of citrate is released into cytosol 
through the mitochondrial transporter tricarboxylate carrier (TCC) resulting in 
incomplete TCA cycle.  




mitochondria protein mass is around 13.1 mg in intact rat lung. This value is close to the 
estimated value using genetic algorithm (16.4 mg). Based on our previous study [5], 
mitochondria yield from lung tissue is around 2-3 mg/rat lung. That suggests that 80–
85% of rat lung mitochondria is lost/inactivated during the isolation process. 
3.5.3 Lactate regulation of glycolytic rate 
Experimental data showed that exogenous lactate has a regulatory effect on 
glycolytic rate (Figure 3.4D) [21, 103]. However, the underlying mechanism for such 
effect is not well understood. Different hypotheses have been proposed [21], including 
through alternations in cellular redox state or cellular energy states. However, 
mitochondrial control of the TCA cycle may also be contributing to lactate’s regulation of 
glycolytic rate. 
In the cytosol, pyruvate is always in equilibrium with lactate since the enzyme 
lactate dehydrogenase (LDH) activity is much higher than other glycolytic enzymes. 
Thus, increasing exogenous lactate concentration increases pyruvate concentration in 
cytosol, which in turn inhibits glycolysis. This is consistent with the data in Figure 3.4 
(panel D), which show that exogenous lactate has an inhibitory effect on rat lung 
glycolytic rates [21, 103, 104].  
Even though glucose utilization rate of rat lung is similar to that of heart and brain 
[18], isolated perfused rat lungs produce significantly higher lactate than hearts [18] and 
skeletal muscle [61]. 40–50% of glucose consumed by lungs is released as lactate [18]. 
Thus, a significant fraction of NADH produced in the glycolytic pathway is consumed by 
lactate dehydrogenase. Only ~10% of NADH produced by glycolysis is transported into 




MA-shuttle may have an important regulatory role on the bioenergetics of skeletal muscle 
and heart [46, 61]. However, simulations using the proposed integrated lung bioenergetics 
models suggest that the role of MA-shuttle may be less important in isolated rat lung. 
 
3.6 Conclusions and model limitations 
In conclusion, we have developed and validated an integrated mechanistic 
computational model of isolated perfused rat lung tissue bioenergetics by extending the 
model of isolated rat lung mitochondrial bioenergetics in chapter 2. The model was used 
to gain insights into how lung tissue glycolytic rate is regulated by exogenous substrates, 
such as glucose and lactate, and assess differences in the bioenergetics of mitochondria 
isolated from lung tissue and those of mitochondria in intact lungs.  
As shown in Figure 3.4 (panels B, C), model simulated endogenous lactate 
production underestimate the experimentally measured lactate production [23] when 
perfusate glucose concentration is low (0 to 0.5 mM). The model predicts that when 
exogenous glucose is low, lung mitochondria diverts more pyruvate from endogenous 
substrates (e.g. alanine), thus resulting in lower endogenous lactate production. However, 
Figure 3.4C shows the experimentally measured endogenous lactate production [23] is 
independent of perfusate glucose concentration. One possible reason for this could be that 
experimentally measured endogenous lactate production (Figure 3.4C) [23] is 
overestimated since pyruvate and lactate were extracted using ion-exchange 
chromatography [23, 71]. This method cannot differentiate between lactate and other 
small anions potentially present in the perfusate [71]. It is likely that the production rate 




Another possible reason for the inability of the model to account for the rate of 
lactate production under conditions of low perfusate glucose concentration could be that 
the activity of the enzyme alanine aminotransferase is dependent on ATP level. The 
rationale is that when glucose is low, protein degradation is stimulated in response to 
decreased ATP, resulting in more pyruvate formation from alanine. However, 
experimental data and model simulation in Figure 3.9 show that pyruvate production is 
decreased in the presence of rotenone (complex I inhibitor) which is known to decrease 
mitochondrial ATP [16].  
Glucose and alanine are considered major metabolic substrates for this rat lung 
bioenergetics model. Other substrates such as fatty acids and glycogen are not accounted 
for. Under normal conditions, fatty acid production accounts for less than 5% of glucose 
consumption in isolated perfused rat lungs [18]. Thus, the contribution of fatty acid is 
considered insignificant. However, under low energy conditions, fatty acid could become 
a significant alternative energy source. For example, fatty acid oxidation may be 
activated by AMPK (AMP-activated protein kinase) when glucose is low [112]. Fatty 
acids were not accounted for in the present model due to the scarcity of experimental data 
regarding fatty acid as a source of energy in intact lungs.  
Another limitation of the lung model is that it does not account for all ATP 
consumption processes, including consumption by active transporters, due to the scarcity 
of experimental data [7, 18, 20-24]. Instead, the ATP consumption rate is modeled as a 
passive process whose rate is only dependent on the concentrations of ATP, ADP, and 
inorganic phosphate. Accounting for all ATP consumption processes and their regulatory 




conditions of low glucose concentration.   
The model does not account for cation ions. This is a limitation since cation ions 
such as Ca2+ and Mg2+ s play an important role in lung tissue bioenergetics. A study by G. 
Nicolaysen demonstrated that normal Ca2+ and Mg2+ concentrations are essential for 
maintaining capillary barrier [113]. When Ca2+ or Mg2+ concentration in the perfusate 
recirculating through isolated rabbit lungs were reduced by added chelators to the 
perfusate, edema developed [113]. In addition, as discussed in chapter 2, Ca2+ has 
regulatory role on mitochondria bioenergetics. At low concentrations, Ca2+ activates 
dehydrogenase enzymes, whereas at high concentrations, Ca2+ inhibits mitochondria 
respiration [76]. Therefore, in order to incorporate Ca2+ and other cations into the current 
model, additional studies and data about transporters and buffering mechanisms for those 
ions, and about the interactions of these ions with other metabolites in the different 
regions of the model are required. Such data are not currently available, and collecting 





Chapter 4 : Effects of hyperoxia on lung tissue bioenergetics 
4.1 Introduction 
Normobaric hyperoxia (high O2 concentration) is an essential therapy for patients 
with hypoxemia (low blood oxygen partial pressure, PO2) and hypoxia (low tissue 
oxygenation) from any cause, including ALI/ARDS, to restore blood oxygen [7]. 
However, there is ample evidence that sustained exposure to hyperoxia causes lung 
injury, and hyperoxic lung injury is a widely accepted animal model of human 
ALI/ARDS [5, 7, 11, 107]. The objective of Aim 3 is to use the computational models 
developed under Aims 1 and 2 to quantify the impact of previously measured hyperoxia-
induced changes in specific mitochondrial processes on lung mitochondrial and tissue 
bioenergetics [5, 11, 26, 114-117]. This exercise will help in identifying potential 
therapeutic targets for ALI/ARDS. 
Previous studies have reported that specific mitochondrial and cytosolic processes 
pertinent to lung tissue bioenergetics are significantly altered in hyperoxia-exposed rats, 
and have suggested that these processes are important to lung hyperoxic lung injury and 
protection from this injury [16, 26, 117] . As described below, the computational models 
developed under Aims 1 and 2 allow us to determine the functional impact (e.g. effect on 
lung tissue bioenergetics) of changes in one or more of these processes.  
4.2 Hyperoxia-induced structural changes in rat lungs 
Exposure of rats to >95% oxygen is a well-documented animal model of clinical 
ALI/ARDS [11]. In a morphometric study, Crapo et al. observed no structural changes 




the lungs of rats exposed to 100% O2 for 60-h showed cellular and functional changes, 
including significant loss of capillary endothelial cells and cell surface area, infiltration of 
phagocytic leukocytes, and an increase in the thickness of the air-blood barrier [12]. 
Longer exposure periods resulted in additional loss of endothelial cells, enhanced 
microvascular capillary permeability, and severe hypoxemia and death within 64 to 72 
hours. For instance, the total number of endothelial cells, which was not changed for 
lungs of rats exposed to hyperoxia for up to 40 hours, decreased by ~31% in lungs of rats 
exposed to hyperoxia for 60 hours [12].   
4.3 Hyperoxia-induced changes in electron transport chain (ETC) 
enzymes in rat lungs 
Previous studies have demonstrated changes in mitochondrial redox state prior to 
evidence of respiratory distress in the pathogenesis of hyperoxia-induced lung injury [26, 
117]. For instance, Sepehr et al. used optical fluorometry to detect changes in the redox 
status of mitochondrial NADH and FAD at the surface of isolated perfused lungs from 
rats exposed to >95% O2 for 48 hours [26]. Those changes were consistent with decrease 
in complex I (77%) and complex II (63%) activities in lung homogenates of rats exposed 
to >95% O2 for 48 hours [26]. Audi et al. also demonstrated ~50% decrease in complex I 
activity in lungs of rats exposed to 85% O2 for 48 hours, but no effect on complex III 
activity [25]. Das et al. also reported a ~44% decrease in complex I activity in lungs of 
mice exposed to 90% O2 for 48 hours [116]. Bayir and Kagan have suggested that this 
decrease in complex I activity could be through the oxidation of cardiolipin [10], which is 
important for the function of mitochondrial complexes [26]. Another possible reason 




mtDNA, which are known to be highly sensitive to ROS, which play a key role in the 
pathogenesis of ALI/ARDS [26]. Mitochondrial dysfunction can alter lung tissue 
bioenergetics and hence key cellular functions since mitochondria is the major site of 
ATP production in cells, accounting for 80–85% of ATP in lung tissue [18]. Bongard et 
al. demonstrated that inhibition of mitochondria complex I decreased whole lung tissue 
ATP level by ~60% and compromised microvascular permeability as measured by an 
increase in pulmonary vascular endothelial filtration coefficient (Kf), a sensitive measure 
of pulmonary endothelial barrier function by 262% [16]. Moreover, they demonstrated 
that the decrease in lung tissue ATP and the increase in Kf can be reversed by adding an 
exogenous electron donor (reduced form of the quinone coenzyme Q1) which bypasses 
complex I to reduce complex III and restore mitochondrial bioenergetics. These results 
suggest that altering mitochondrial bioenergetics can reproduce one of the cardinal 
features of ALI, and hence suggest an important role for mitochondrial bioenergetics in 
the pathogenesis of ALI. Furthermore, the results suggest complex I as a potential 
therapeutic target for ALI/ARDS. 
4.4 Experimental data and model simulations of effects of hyperoxia 
(isolated mitochondria level) 
Hyperoxia-induced changes in the redox state of lung mitochondria are in big part 
due to hyperoxia-induced changes in the activities of mitochondrial complexes I and II. 
Simulations in Figure 4.1 and Figure 4.2, generated using the computational model of the 
bioenergetics of isolated mitochondria, show that changes in the activities of 
mitochondrial complexes I and II lead to changes in mitochondria membrane potential 




these changes are substrate dependent. Simulations with complex I substrates pyruvate + 
malate and complex II substrate succinate are shown in Figure 4.1 and Figure 4.2, 
respectively. For these simulations, model parameters describing the activities of 
complexes I and II were decreased from 100% to 20% of those measured in mitochondria 
from normoxic lungs. All other model parameters were fixed to those estimated for 
mitochondria from normoxic lungs (Table 2.4 in chapter 2) [24].  Figure 4.1 shows that 
when using pyruvate + malate as substrates, decreasing complex I activity resulted in a 
decrease  in m (depolarization) and maximum ATP generation rate, and an increase in 
NADH/NAD ratio and duration of state 3 respiration (as indicated by full width at half 
maximum (FWHM) of ADP-induced membrane potential depolarization). In contrast, 




donor to ETC when using pyruvate + malate as metabolic substrates.  
 
Figure 4.1: Model predicted effects of decreased complex I (CI) and/or complex II (CII) 
activities on mitochondria bioenergetics with PYR+MAL as substrates.  
Panel A: membrane potential (m) at state 2; Panel B: NADH/NAD ratio at state 2; 
Panel C: maximum ATP production rate at state 3 (ADP = 0.1 mM); Panel D: FWHM of 
state 3 (ADP = 0.1 mM). Simulations were generated using the isolated mitochondria 
model. Parameters describing the activities of CI and/or CII activities were altered. All 
other parameters were set to those estimated from mitochondria isolated from normoxic 
lungs (see Table 2.4 in chapter 2). PYR: pyruvate, MAL: malate, FWHM: Full width at 
half maximum. 
 
When using succinate (SUC) as metabolic substrate (Figure 4.2), decreasing 
complex II activity also resulted in a decrease in m, NADH/NAD ratio and in 
maximum ATP generation rate, and an increase in duration of state 3 (as indicated by full 
width at half maximum of ADP-induced membrane potential depolarization). In contrast, 







ETC when using SUC as metabolic substrate.  
 
 
Figure 4.2: Model predicted effects of decreased complex I (CI) and/or complex II (CII) 
activities on mitochondria bioenergetics with SUC as substrate.  
Panel A: membrane potential m) at state 2; Panel B: NADH/NAD ratio at state 2; 
Panel C: maximum ATP production rate at state 3 (ADP = 0.1 mM); Panel D: FWHM of 
state 3 (ADP = 0.1 mM). Simulations were generated using the isolated mitochondria 
model. Parameters describing the activities of CI and/or CII were altered. All other 
parameters were set to those estimated from mitochondria isolated from normoxic lungs 
(see Table 2.4 in chapter 2). SUC: succinate, FWHM: Full width at half maximum. 
 
 
4.4.1 Hyperoxia-induced changes in the membrane potential (m)  
The mitochondrial membrane potential (Ψm) plays a key role in mitochondrial 
ATP synthesis, apoptosis, and other functions [86]. Previously, we quantified Ψm in 







the cationic dye rhodamine 123 (R123) [72]. Figure 4.3 shows that the R123 emission 
signal dropped rapidly following the addition of mitochondria in the presence of pyruvate 
+ malate (complex I substrates), consistent with uptake and accumulation of R123 into 
mitochondria driven by Ψm [72].
 Addition of ADP (state 3) stimulated transient and 
reversible efflux of R123 from mitochondria consistent with partial depolarization of 
Ψm [72].
 Addition of the mitochondrial uncoupler carbonyl cyanide-4-
(trifluoromethoxy) henylhydrazone (FCCP) depolarized Ψm resulting in efflux of R123 
from mitochondria. Similar results were obtained with succinate (Figure 4.3, panel B), a 
complex II substrate [72]. One measure of the kinetics of ADP-stimulated Ψm 
polarization is the full width half maximum time (FWHM) for R123 return to baseline 
(state 2) [72]. Table 4.1 shows that rats exposed to hyperoxia (>95% O2 for 48 hrs) 
increased FWHM by 67%. This suggests that Ψm recovery from ADP-induced 
depolarization in mitochondria from hyperoxic lungs was substantially slower than that in 
normoxic lungs, which is consistent with hyperoxia-induced decreases in lung tissue 
complex I (77%) and II (64%) activities [26, 72]. What is not clear from the experimental 
results is whether the hyperoxia-induced changes in complexes I and II activities are 
sufficient to account for the measured hyperoxia-induced changes in Ψm as measured by 
the changes in FWHM from the R123 data. As shown below, the computational model of 





Figure 4.3: Averaged R123 emission signal in mitochondria isolated from lungs of 
normoxia and hyperoxia (>95% O2 for 48 hrs).  
Panel A: PYR + MAL; Panel B: SUC. 0.1 mM ADP and 0.05 mM ADP were added at 3 
min and 12 min, respectively. Uncoupler FCCP was added at 15 min [118]. One measure 
of the kinetics of ADP-stimulated m depolarization and repolarization is the full width 
at half maximum time (FWHM) for R123 return to baseline (state 4). PYR: pyruvate, 
MAL: malate, SUC: succinate.  
 
To evaluate the effect of a decrease in complexes I and II activities on 
mitochondrial membrane potential, simulations were performed with parameters 
describing complex I (Figure 4.4) or complex II (Figure 4.5) activities set at values 
ranging between 20% and 100% of those estimated from mitochondria isolated from 
normoxic lungs (Table 2.4 in chapter 2). Model simulations in Figure 4.4 and Figure 4.5 
show the effect of the addition of 0.1 mM and 0.05 mM ADP to buffer at 6 min and 14 
min, respectively, and FCCP at 15 min on R123 concentration in medium and on m.  
As shown in Figure 4.4, when using PYR + MAL as metabolic substrates for 
mitochondria, decreasing complex I activity leads to a proportional decrease 
(depolarization) in the steady state m at state 2 and state 4 (panel A), and a 
proportional increase in the duration of state 3 (panel B). When using SUC as metabolic 
substrate, decreasing complex I activity has little or no impact on m (panel C) or the 
ADP 













duration of state 3 (panel D). 
 
 
Figure 4.4: Model simulated effect of decreased complex I (CI) on m and R123  
dye concentration in buffer in the presence of PYR + MAL (panels A and B) or SUC 
(panels C and D). Simulations were performed using the isolated mitochondria model 
with parameter describing the activity of complex I activity set at 100%, 60% or 20% of 
that estimated for complex I activity in mitochondria from normoxic lungs. The values of 
other parameters were fixed to those estimated from mitochondria isolated from 



























Figure 4.5: Model simulated effect of decreased complex II (CII) on m and R123  
dye concentration in buffer in the presence of PYR + MAL (panels A and B) or SUC 
(panels C and D). Simulations were performed using the isolated mitochondria model 
with parameter describing the activity of complex II activity set at 100%, 60% or 20% of 
that estimated for complex II activity in mitochondria from normoxic lungs. The values 
of other parameters were fixed to those estimated from mitochondria isolated from 
normoxic lungs. PYR: pyruvate; MAL: malate; SUC: succinate.  
 
 
Similarly, as shown in Figure 4.5, when using SUC was the substrate, decreasing 
complex II activity resulted in a proportional decrease (depolarization) in the steady state 
m at state 2 and state 4 (panel C), and a proportional increase in the duration of state 3 


























Table 4.1: Measured and simulated membrane recovery time following ADP-induced 
depolarization in mitochondria isolated from lungs of rats exposed to normoxia or >95% 
O2 for 48 hrs 
Group FWHM (min), 
PYR+MAL 








Normoxia 1.98 ± 0.18 
(n=7) 





3.3 ± 0.26 * 
(n=6) 
2.7 ± 0.32 * 
(n=6) 
3.10 3.88 
Values are mean ± SE for experimental results [118]. FWHM indicates full width at half 
maximum for 0.1 mM ADP-stimulated depolarization of membrane potential. *different 
from normoxia. Model predicted FWHM times for normoxia and hyperoxia conditions 
were generated using the computational model for the bioenergetics of mitochondria 
isolated from rat lungs with the values of model parameters set to those in Table 2.4 for 
normoxia condition. For simulation of 48-h hyperoxia, the values of the parameters 
describing activities of complexes I and II were 77% and 64% lower than those for 
normoxia conditions. The values of the remaining parameters were set to those estimated 
for normoxia conditions (Table 2.4) [24].  
 
Sepehr et al. reported 77% and 64% decreases in the activities of complexes I and 
II, respectively, in lung homogenates of rats exposed to > 95% O2 for 48 hrs as compared 
to lung homogenates from normoxic rats [26]. Simulations in Figure 4.6 using the model 
of bioenergetics of isolated mitochondria, along with the pharmacokinetic model of R123 
disposition in isolated mitochondria, show the effects of simultaneously decreasing the 
values of model parameters describing complexes I and II activities by 77% and 64%, 
respectively, on m and the duration of ADP-induced state 3 as measured by the 
FWHM time. All other model parameters were fixed to those estimated from 
mitochondria isolated form normoxic lungs [24]. The results in Table 4.1 show that 
hyperoxia-induced changes in FWHM can be accounted for by hyperoxia-induced 
changes in complexes I and II activities. For succinate, model simulated FWHM increase 
is higher than experimentally measured FWHM after exposure to hyperoxia, could be 






Figure 4.6: Experimental data (panels A and B) and model predicted (panels (C-F) 
hyperoxia induced changes in mitochondria membrane potential.  
Simulations were generated using the isolated mitochondria model. For model-simulated 
hyperoxic conditions, parameters describing complex I (CI) and complex II (CII) 
activities were decreased by 77% and 64%, respectively, as compared to those estimated 
for mitochondria isolated from lungs of normoxic rats (Table 2.4 in chapter 2). All other 
parameters was set to those estimated from mitochondria isolated from lungs of normoxic 
rats (Table 2.4) [24]. Panels A and B show experimentally measured R123 dye 
concentration calculated from R123 fluorescence intensity. Panels C and D show model 

































isolated mitochondria model along with a pharmacokinetic model of R123 disposition in 
isolated mitochondria. Panels E and F show model simulated mitochondria membrane 
potential. 
 
4.4.2 Hyperoxia-induced changes in mitochondrial oxygen consumption rates  
 
 
Figure 4.7: Model-simulated mitochondrial oxygen consumption kinetic data and rates in 
mitochondria isolated from lungs of normoxic and 48-hr hyperoxic rats.  
Simulations were generated using the isolated mitochondria model, with malate + 
glutamate as metabolic substrates. For model-simulated hyperoxia condition, parameters 
describing complex I (CI) and complex II (CII) activities (Table 2.4) were decreased by 
77% and 64%, respectively, as compared to those estimated from mitochondria isolated 
from lungs of normoxic rats (Table 2.4 in chapter 2). All other parameters wet set to those 
estimated from mitochondria isolated from lungs of normoxic rats (Table 2.4) [24]. Panel 
A shows simulated oxygen concentration in the buffer. ADP was added into the buffer at 
1 min. Panel B shows calculated oxygen consumption rate (OCR) at state 2 and state 3. 
 










the effect of decreased activities of complexes I and II on mitochondrial oxygen 
consumption rate. As shown in Error! Reference source not found., hyperoxic c
onditions were simulated by decreasing mitochondria complex I and complex II activities 
by 77% and 64%, respectively. Hyperoxia resulted in slower state 2 and state 3 oxygen 
consumption rate.  RCI (calculated as state 3 OCR divide by state 2 OCR) decreased 
from 2.65 to 1.83. This result is consistent with our previously measured OCR data in 
mitochondria isolated from normoxic lungs (RCI = 2.58 ± 0.06 (SE), n = 4) [24], and 
unpublished results from 48-hr hyperoxic rats (RCI =1.84 ± 0.18, n=4) with malate + 
glutamate as substrates. 
The simulations of membrane potential in Figure 4.6, OCR in Error! Reference s
ource not found. and FWHM values in Table 4.1 demonstrate that the effect of 
hyperoxia on lung mitochondria membrane potential and oxygen consumption rate 
observed in isolated mitochondrial experiments can be accounted for by hyperoxia-
induced changes in the activities of complexes I and II. This is consistent with 
mitochondrial complexes I and II being potentially primary sites of hyperoxia-induced 
changes in lung tissue mitochondria. 
4.5 Experimental data and model simulations of effects of hyperoxia 
(intact lungs) 
 
4.5.1 Hyperoxia-induced changes in rat lung NADH and FAD surface fluorescence 
signals (redox status) 
Sepehr et al. evaluated the effect of rat exposure to hyperoxia (>95% O2 for 48 




NADH and FAD in the presence of rotenone (complex I inhibitor), potassium cyanide 
(complex IV inhibitor), and/or the mitochondrial uncoupler pentachlorophenol [26]. 
Experimental results (Table 4.2) show that rotenone- and cyanide-induced decrease in 
lung NADH signal was significantly smaller (63% for rotenone and 58% for cyanide) in 
hyperoxic lungs as compared to that in normoxic lungs. These results are consistent with 
hyperoxia-induced decrease in complex I activity (77%) in lung tissue homogenate [26]. 
Neither inhibitor had a significant effect on %FAD in hyperoxic lungs as compared to 
normoxic lungs.  However in the presence of the uncoupler pentachlorophenol (PCP), 
which fully oxidized the ETC, potassium cyanide effects on NADH and FAD surface 
signals were 65% and 55% lower respectively in hyperoxic as compared to normoxic 
lungs (Table 4.2). According to Sepehr et al., this is consistent with a more reduced ETC 
upstream from complexes I and II in hyperoxic lungs as compared to that in normoxic 
lungs, and with hyperoxia-induced decrease in complexes I and II activities in lung tissue 
homogenates [26]. 
 
Table 4.2: The effects of inhibitors on lung NADH and FAD signals [26]. 
Inhibitor/Uncoupler FAD % change NADH % change 
Normoxic Hyperoxic Normoxic Hyperoxic 
ROT 0.2 ± 0.2 -0.3 ± 0.3 20.2 ± 2.3 7.5 ± 1.0* 
KCN -6.8 ± 1.6 -5.2 ± 0.5 21.7 ± 2.5 9.2 ± 1.2* 
PCP 1.7 ± 0.8 -2.3 ± 1.4* -19.7 ±2.1     -20.8 ±1.2 
PCP + KCN -9.3 ± 1.0 -4.2 ± 0.7* 25.7 ± 2.6 9.0 ± 1.0* 
Values are mean ± SE. *significantly different from the corresponding normoxic value (t-






Figure 4.8: Experimental data and model simulated effect of hyperoxia on lung tissue 
NADH change in response to inhibitors. 
Experimental data and model simulated effect of hyperoxia on lung tissue NADH change 
in response to rotenone (ROT, panels A, B) and potassium cyanide (KCN, panels C, D). 
Inhibitor (ROT or KCN) was added at 3 min. Symbols are experimental data of NADH 
signal  from normoxic lungs (red symbols) and hyperoxic lungs (blue symbols). 
Simulations were generated using the intact lung model under normal conditions (values 
of model parameters fixed to the values in Table 3.4), or with the value of the model 
parameter describing complex I activity at 80%, 50% or 23% of the value under 
normoxic conditions (Table 3.4). 
 
Simulations were performed using the isolated rat lung model under the same 
experimental conditions as in Figure 3.10. For simulations of normoxic conditions, all 
parameters were fixed to the values in Table 3.4. For 48-hr hyperoxic conditions, 
parameters describing the activities of mitochondrial complexes I and II were decreased 









Model simulations in Figure 4.8 show that the ROT and KCN induced less 
changes in NADH signal in hyperoxic lungs than in normoxic lungs, suggesting that at 
normal condition (no inhibitor) NADH is more reduced in hyperoxic lungs. Simulations 
in Figure 4.9 show that PCP induced more changes in NADH signal, consistent with a 
more reduced NADH in hyperoxic lungs. Figure 4.8C and D show that PCP had no effect 
on FAD signal, and KCN induced a ~5% decrease in FAD signal. 
 
 
Figure 4.9: Experimental data and model simulated effect of decreased CI and CII on 
NADH and FAD signals in response to inhibitos. 
Experimental data and model simulated effect of decreased CI (B, E) or CII (C, F) on 
lung tissue NADH and FAD redox status in response to pentachlorophenol (PCP) and 
potassium cyanide (KCN).  Symbols are experimental data of NADH and FAD signal for 
normoxic lungs (red) and hyperoxic lungs (blue). Simulations were generated using the 
intact lung model under normal conditions (A, D, values of model parameters fixed to the 
values in Table 3.4), or with the value of the model parameter describing complex I 
activity (B, E) fixed at 80%, 50% and 23% of the value under normoxic conditions (Table 
3.4), or with the value of the model parameter describing complex II activity (C, F) fixed 
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Model simulation in Figure 4.8 and Figure 4.9 show that experimental data of 
NADH signal are more consistent with a 20% decrease in CI (i.e., 80% of CI activity in 
normoxic lung), much less than the 77% decrease in CI activity measured in lung 
homogenates by Sepehr et al. For simulations with 77% decreased CI activity, adding 
KCN after PCP failed to increase NADH signal (blue dash lines in Figure 4.9B, C).  In 
contrast, as shown in Figure 4.9C and E, model simulations show that decreased CII from 
80% to 20% had little or no effect on lung NADH and FAD signals. This observation 
indicates that for the intact lung, NADH is the major electron donor for ETC, while the 
contribution of FADH2 is low compared with NADH. 
4.5.2 Hyperoxia-induced changes in lung tissue glycolytic rates 
Since injury to the ETC enzymes impairs the ability of mitochondria to generate 
ATP, one would expect lung cells under such conditions to rely more on glycolytic ATP 
production. Fisher et al. reported 61%  increase in lactate production rate, an index of 
glycolytic ATP production, in lungs of rats exposed to >95% O2 for 48 hours [107]. 
Another study reported a 52% increase in the rate of glucose utilization and 99% increase 
in rate of lactate + pyruvate production in lungs of rats exposed to 100% O2 for 24 hours 
[115]. In addition, Bassett et al in [115] show that lung ATP content was not significantly 
altered following rat exposure to 100% O2 for 24 hours, which suggests that stimulation 
of glycolytic ATP production can compensate for the diminished mitochondrial ATP 
generation due to rat exposure to hyperoxia for 24 hrs. 
Model simulations were generated using the isolated perfused rat lung model to 
further understand the impact of decreased complexes I and II on lung tissue 




GLUT, panel A) and lactate production (as indicated by LACT, panel B) increase in 
response to decreased mitochondrial complex I, but no change is observed in response to 
complex II. This simulation suggests that even though complex II is important for 
mitochondria respiration in isolated mitochondria experiments when using SUC as 
substrate, it does not affect bioenergetics in the intact lungs. In contrast, decreased 
mitochondrial complex I resulted in decreased lung ATP/ADP and NADH/NAD ratios, 
which leads to stimulation of glycolysis in the cytosol to compensate for the impaired 
mitochondrial ATP generation capacity. 
 
 
Figure 4.10: Simulated effect of decreased CI and CII activities on lung tissue 
bioenergetics.  
Simulations were generated using the isolated rat lung model, with decreased CI and CII 
activities (range from 20% to 100% of activity under normoxic conditions). Other 
parameters were fixed to the values estimated for normoxic lungs (Table # in chapter 3). 






rate; Panel C: Lung ATP/ADP ratio; Panel D: Lung NADH/NAD ratio. 
 
 
Figure 4.11: Effects of hyperoxia on GLC consumption and PYR, LAC production of 
isolated perfused rat lung.   
Symbols in the figure are data of effect of 24-h hyperoxia exposure on lung glucose 
consumed (A) and PYR+LAC produced (B) in 100 minutes. Experiment data is compare 
with model simulation using whole lung model of control condition (red solid line), and 
decreasing complex I (CI) activity by 25% (solid blue line) and 50% (dash blue line), 
respectively. 
 
Fisher et al. [115] reported the effect of hyperoxia duration on lung pyruvate and 
lactate production rates, and lung ADP and ATP amount. As shown in Figure 4.12A, 
lactate and pyruvate production rate were measured in rat lungs after exposure to 
hyperoxia for 0 hours (control, normoxic), 18, 24 and 48 hours. Hyperoxia exposure 
significantly stimulated lactate production rate but had no effect on pyruvate production 
rate. This result is consistent with model simulation with increasingly decreased complex 
I activity from 100% to 50% (Figure 4.12B). By comparing Figure 4.12A and Figure 
4.12B, experimental data of 48-h hyperoxia rat lung lactate production are consistent with 
a ~50% decrease in complex I activity.  
Data and simulations in Figure 4.12 suggest that hyperoxia-induced injury to 




that CI is an early and major injury site. Even though mitochondrial ATP generation 
capacity is impaired experimental data [115] (Figure 4.4C) and model simulation show 
that (Figure 4.4D) lung ATP content can be maintained for up to 48 hours. However 
glycolytic ATP production is stimulated to compensate for the diminished mitochondrial 
ATP generation due to rat exposure to hyperoxia. 
 
 
Figure 4.12: Effect of hyperoxia exposure on lung lactate, pyruvate production and ATP, 
ADP. Lactate and pyruvate production rates (Panel A) and ATP, ADP amounts (Panel C) 
were measured in rat lung isolated after 0, 18, 24, 48 hours of hyperoxia exposure. Model 
simulations were performed with increasingly decreased complex I activity. 
 
Aconitase, a TCA cycle enzyme that catalyzes the isomerization of citrate to 
isocitrate, was also suggested to be altered early in the pathogenesis of hyperoxia-induced 






activity in rat lung after 24 hours of exposure to hyperoxia. However, as shown in chapter 
2, most of the generated citrate in TCA cycle is released into buffer. Therefore, 
decreasing aconitase activity has no effect on lung mitochondria bioenergetics. 
4.7 Discussion and conclusions 
Mitochondria electron transport chain is a primary and early target of injury 
during hyperoxia exposure (100% O2 for 48 hrs) as reflected by significant decreases in 
complexes I and II activities [26]. Longer membrane potential repolarization time [118] 
and slower oxygen consumption rates were observed in rat lungs after exposure to 
hyperoxia. Model simulations using isolated mitochondria model suggest that the 
changes in mitochondria membrane potential and oxygen consumption rates at states 2 
and 3 can be accounted for by a 77% decrease in complex I and a 64% decrease in 
complex II activities.  
At the isolated mitochondria level, model simulations suggest that hyperoxia-
induced changes in mitochondria complexes I and II activities can account for most 
observed hyperoxia-induced changes in mitochondrial bioenergetics. Decreasing complex 
I and complex II activities resulted in slower respiration in isolated mitochondria 
experiments when using pyruvate + malate, or succinate as substrates, respectively. 
Moreover, simulations in Figure 4.6 show that decreasing complex I results in higher 
FWHM value of ADP induced depolarization. Similarly, when using SUC as substrate, 
decreasing complex II resulted in slower repolarization. This indicates that both 
complexes I and complex II are essential to mitochondria respiration in isolated 
mitochondria, depending on the metabolic substrates used.  




II activity might be less important to lung bioenergetics as compared to that with a 
decrease in complex I activity. Simulations using isolated perfused rat lung model 
(Figure 4.10) show that lung ATP/ADP ratio and NADH/NAD ratio are altered in 
response to a change in  mitochondria complex I activity, but not to a change in complex 
II activity. Thus, complex I activity appears to be more important than complex II in 
intact lungs, and hence might be a potential therapeutic target for hyperoxia-induced lung 
injury. 
In addition, simulations using isolated perfused rat lung model suggest that the 
hyperoxia-induced decrease in complex I activity might be less than that measured in the 
isolated mitochondrial preparation. Both NADH/FAD simulations and glycolytic rate 
simulations show that a smaller decrease in complex I activity (20% - 50%) than the 77% 
reported by Sepher et al. is needed to account for the hyperoxia-induced changes in lung 
surface NADH/FAD and glycolytic rate.  Simulations in Figure 4.8 and Figure 4.9 show 
that NADH and FAD signal changes measured in hyperoxic lungs are consistent with 
model simulations with only a 20%-50% decrease in mitochondria complex I. 
Simulations in Figure 4.12 also show that hyperoxia-induced increase in lactate 
production after 48 hours is consistent with  ~50% decrease in complex I activity. One 
possible explanation of this inconsistency between isolated mitochondria and intact lungs 
is that complex I activity is reduced more in lung homogenates than in intact lungs. 
Another explanation is that in intact lungs, other pathways changes, such as energetic 





Chapter 5: Summary, conclusions and future directions 
5.1 Summary and conclusions 
A key outcome of this dissertation is the development and validation of two 
thermodynamically constrained integrated models of the bioenergetics of rat lung 
mitochondria and the bioenergetics of an intact rat lung. These models incorporate major 
metabolic pathways/components in rat lung mitochondrial/tissue bioenergetics, including 
glycolysis and pentose phosphate pathway in cytosol, and TCA cycle, electron transport 
chain, ATP phosphorylation in mitochondria. This resulted in the estimation of kinetic 
parameters describing those pathways, including intrinsic parameters (binding constants) 
and extrinsic parameters (Vmaxs/Tmaxs) for various enzymes and transporters. For each 
model, the same set of model parameters were able to fit well a wide range of new and 
existing data from isolated rat lung mitochondria and/or isolated perfused rat lungs, 
including mitochondrial oxygen consumption, TCA cycle metabolites 
consumption/production, lung glucose consumption rate, and lactate/pyruvate production 
rates. For validation, each model was capable of predicting well experimental data not 
used for the estimation of the model parameters. As such, these two models provide a 
basic structure for building more complex model, and for integration and interpretation of 
experimental data collected at different levels of biological organization, including 
isolated enzyme data, isolated mitochondria data and isolated perfused lung data. Such 
models can also allow us to predict the functional impact of a change in one or more of 
mitochondrial or cytosolic processes on bioenergetics under pathophysiological 
conditions such as rat exposure to hyperoxia. Simulations using these models provided 




they differ from those of other organs. For instance, citrate production is much higher in 
isolated lung mitochondria than in cardiac mitochondria. The high citrate production 
results in an incomplete TCA cycle, since no enough intermediates are left for the TCA 
cycle reactions. Thus, only half of TCA cycle reactions are active in isolated rat lung 
mitochondria. Additional simulations in our whole lung model show that completeness of 
TCA cycle in rat lung mitochondria is dependent on substrate concentrations. 
The developed models can also be used to test hypotheses with respect to the 
regulation of metabolic pathways. For example, the models were used to evaluate how 
substrates concentration (PYR, LAC, etc) regulate glycolysis and TCA cycle. 
Moreover, the developed models can be used to evaluate the effect of altered 
enzyme activities on lung bioenergetics. For example, the effect of the overexpression of 
a specific enzyme or transporter can be simulated by increasing the value of the 
Vmax/Tmax parameter that describe the activity of that enzyme or transporter. The effect 
gene knockout or injury to a specific enzyme or transporter can be simulated by 
decreasing the value of the Vmax/Tmax parameter that describe the activity of that enzyme 
or transporter. Using these two models, we were able to evaluate the impact of hyperoxia-
induced-decreases in the activities of mitochondrial ETC enzymes on mitochondrial 
membrane potential, coenzymes NADH and FAD redox status, lung glucose 
consumption, and lung lactate and pyruvate production rates. Both isolated mitochondria 
model and isolated lung model suggest that hyperoxia-induced decreases in mitochondria 
complexes I and II are sufficient to account for experimentally measured changes in 
mitochondrial membrane potential, and the redox status of the coenzymes NADH and 




they showed that 1) inhibition of mitochondria complex I decreased whole lung tissue 
ATP level and comprised microvascular permeability as measured by an increase in 
pulmonary vascular endothelial filtration coefficient (Kf), a sensitive measure of 
pulmonary endothelial barrier, and 2) that the decrease in lung tissue ATP and the 
increase in Kf can be reversed by adding an exogenous electron donor (reduced form of 
the quinone coenzyme Q1) which bypasses complex I to reduce complex III and restore 
mitochondrial bioenergetics [16].  
5.2 Future directions 
As mentioned in the limitation sections in chapters 2 and 3, cations such as Ca2+ 
and Mg2+ are not included in the current bioenergetics models, even though they play an 
important regulatory role in rat lung bioenergetics [76]. It is known that dehydrogenases 
are activated by Ca2+ at nM level (~100–300 nM). However, Fisher et al. reported that 
mitochondrial oxygen consumption rates are inhibited as Ca2+ concentration increases to 
µM–mM ranges [76]. In addition, high mitochondria matrix Ca2+ concentration is known 
to stimulate permeability transition pore (PTP) opening, allowing small molecules (such 
as TCA intermediates and NADH) in mitochondria matrix to pass across mitochondria 
inner-membrane, resulting in loss of mitochondrial intermediates and membrane potential 
depolarization [120]. This provides a possible explanation for the inhibitory effect of high 
Ca2+ on respiration [120]. Besides the inhibitory effect of Ca2+, Fisher et al. also observed 
a loss of free NAD(P)H (drop from 2.3 nmol/mg to 0.3 nmol/mg) in the presence of high 
Ca2+ (0.2 mM) [76]. This observation is consistent with the hypothesis of PTP opening. 
However, in order to account for Ca2+ in the computational models, additional studies and 




concentration and kinetics behavior for PTP opening. In a computational study, Chapa-
Dubocq et al. recently developed a mitochondrial model of PTP to study Ca2+  induced 
mitochondria swelling in cardiac cells [121]. In order to include Ca2+ into the current 
computational model, two aspects of Ca2+ effects need to be considered. At low 
concentrations, Ca2+ is important for ion homeostasis, and Ca2+ stimulates mitochondrial 
respiration by activating dehydrogenase enzymes. Computational models of Ca2+ 
transportation and buffering in mitochondria developed by Dash and coworkers [31, 122, 
123] need to be integrated into current models. At high concentrations, Ca2+ stimulates 
PTP opening and induces mitochondrial dysfunction. Mathematical equations describing 
PTP opening need to be included. 
Mitochondrial Ca2+ influx and increased ROS production are early events in the 
pathogenesis of ALI/ARDS [124].  In addition, increased mitochondrial ROS production 
or oxidative stress plays a key role in the pathogenesis of other lung diseases [125, 126]. 
Mitochondria are not only the key site of ROS production, but also the key sites for ROS 
detoxification, and hence a primary target of oxidative stress (excess ROS production 
with low ROS detoxification capacity). Both the computational models developed here 
do not account for ROS production and scavenging under physiological or 
pathophysiological conditions, and the impact of ROS on the activities of key cellular 
processes. Therefore, one future direction for this work is to include ROS production into 
current bioenergetics models. There is a wealth of data about ROS production and 
scavenging in isolated mitochondria [127-131]. In cardiac cells, mitochondria complex I 
and complex III are major sites for mitochondrial ROS production. Computational 




complex III [130]. Similarly in a series of studies, Dash and colleagues have developed 
detailed kinetics/mechanistic models of mitochondrial ROS scavenging by the 
glutathione and thioredoxin ROS scavenging systems [127-129].  
For rat lung tissue, mitochondria complex II might also be an important source of 
ROS production [132]. Using Amplex red and optical imaging, Audi et al. showed that 
complex II accounted for 76% of the rate of H2O2 production in the isolated perfused rat 
lung [132]. In addition, they showed that lung ventilation with high O2 gas mixture (acute 
hyperoxia) increased H2O2 production from non-mitochondrial source, potentially via 
NADPH oxidase, but did not increase mitochondrial H2O2 production. Incorporating the 
ROS production data in lung tissue into the two computational models of lung tissue 
mitochondrial bioenergetics along with ROS scavenging would help in furthering our 
understanding of the interrelationship between lung tissue and mitochondrial ROS 
production, oxidative stress, and hyperoxia-induced ALI/ARDS.   
Another future direction is to look at lung bioenergetic changes due to another rat 
model of clinical ALI, namely lipopolysaccharide (LPS)-induced lung injury, a model of 
clinical sepsis which is one of the main causes of ALI/ARDS. LPS-induced lung injury 
and hyperoxia induced lung injury share common pathways, including injury to capillary 
endothelium and cell apoptosis [11].  In order to evaluate the effect of LPS on 
mitochondrial bioenergetics, mitochondria membrane potential data and NADH/FAD 
fluorescence need to be collected in LPS-exposed rat lungs, and simulations using the 
two computational models developed under Aims 1 and 2 can be used to further our 
understanding of the role of lung tissue and mitochondrial bioenergetics in the 
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Appendix I: Glossary 
 
Terms Description 
Subscript r Reservoir region 
Subscript b Lung vascular (blood) region 
Subscript c Cytosolic region 
Subscript m Mitochondria matrix region 
Subscript i Inter-membrane space 
Species Description 
ADP Adenosine diphosphate 
ATP Adenosine triphosphate  
ALA Alanine 
ACoA  Acetyl-coenzyme A 
ASP Aspartate 
AKG α-ketoglutarate (2-oxoglutarate) 
BPG 1,3-Bisphosphoglyceric acid 
CoA Coenzyme A 
CIT Citrate 
CytCr Reduced form of cytochrome c 
CytCo Oxidized form of cytochrome c 
DHAP Dihydroxyacetone phosphate 
F16BP Fructose 1,6- bisphosphate 
F6P Fructose 6-phosphate 
FUM Fumarate 
FAD Oxidized form of flavin adenine dinucleotide 
FADH2 Reduced form of flavin adenine dinucleotide 








AKGDH α-ketoglutarate dehydrogenase 
CITS Citrate synthase 
CITDH Lumped reaction of aconitase and isocitrate dehydrogenase 
CI Complex I 
CII Complex II 
CIII Complex III 
CIV Complex IV 
CV Complex V 
FH Fumarate hydratase 
GOT Glutamate oxaloacetate (or Aspartate aminotransferase) 
GDP Guanidine diphosphate 
G6P Glucose-6-phosphate 







PEP Phosphoenolpyruvic acid 
Pi Inorganic phosphate 
SUC Succinate 
SCoA Succinyl-coenzyme A 
UQH2  Reduced form of ubiquinone 




AA Alanine Aminotransferase 
AK Adenylate kinase 
ALD Lumped reaction of Aldolase and triose phosphate isomerase 
HEX Hexokinase 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
G6PDH Glucose-6-phosphate dehydrogenase 
GSR Glutathione reductase 
GPx Glutathione peroxidase 
LDH Lactate dehydrogenase 
PFK Phosphofructokinase 
PGI Phosphoglucose isomerase 
PGK Phosphoglycerate kinase 




MDH Malate dehydrogenase 
NDK Nucleoside diphosphokinase 
PDH Pyruvate dehydrogenase 
SCAS Succinyl-coenzyme A synthetase 
SDH Succinate dehydrogenase 
Transporters Description 
ANT Adenine nucleotide translocase 
DCC Dicarboxylate carrier 
GAE Glutamate-aspartate exchanger 
GLUH Glutamate-hydrogen co-transporter 
GLCT (b-c) Glucose transporter between blood and cytosol 
LACT (b-c) Lactate transporter between blood and cytosol 
LEAK Passive proton leak from inter-membrane space to mitochondria matrix 
OME α-ketoglutarate (2-oxoglutarate) malate exchanger 
PYRT (b-c) Pyruvate transporter between blood and cytosol 
PIC (c-m) Inorganic phosphate carrier (cytosol to mitochondria) 
PIT (b-c) Inoganic phosphate-Na cotransporter (blood to cytosol) 
PYRH Pyruvate-hydrogen co-transporter 
TCC Tricarboxylate carrier 







Appendix II: Derivation of the generalized metabolic reaction and 
transport flux equations: 
 
One-substrate one-product enzymatic reactions 

E
S P  
The general scheme for a reversible one-substrate one-product enzymatic reaction 
[133] is shown in Figure A1,  
 
 
Figure A1. General scheme for one substrate and one product enzymatic reactions 
where E is the enzyme, S is the substrate, P is the product, and ESP is a hypothetical 
enzyme-substrate-product complex that binds both substrate and product, KS is the 
dissociation constant of ES complex, and KP is the dissociation constant of EP. For 
simplicity and to reduce the number of unknown parameters, two assumptions were made 
to derive the general flux equations. First, we assumed rapid equilibrium conditions, i.e., 
all the enzymatic complex dissociation reactions are considered extremely rapid 
compared to the interconversion of ES and EP, which is the only rate limiting reaction 
step.  Second, we assumed that the binding of S does not affect the binding of P.  
Under the above assumptions, the flux equation for the reversible one-substrate one-
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  (C.14) 
where Et is the total concentration of the enzyme, and Vmaxf = kp.Et and Vmaxr = k-p.Et are 
the maximum forward and reverse reaction velocities, respectively. The denominator of 
Eq (C.13)reflects all four species in this system, namely E, ES, EP, and ESP. However, 
under the assumption that both the substrate and product do not bind to the enzyme at the 
same time, the ESP complex does not form, and hence [ESP] = 0. Under this assumption, 
the flux equation for the reversible one-substrate one-product enzymatic reaction can be 
reduced to: 
 
   















  (C.15) 
We note here that the flux expression (C.15) for a reversible one-substrate one-
product enzymatic reaction contains two intrinsic model parameters (enzymatic complex 
dissociation constants KS and KP; also referred to as binding constants), and two extrinsic 
model parameters (forward and reverse reaction maximal velocities Vmaxf and Vmaxr). The 
intrinsic parameters are assumed to be independent of tissue source of enzymatic 
reaction, while the extrinsic model parameters are assumed to be dependent on tissue 
source of enzymatic reaction. Specifically, the extrinsic model parameters are assumed to 




several cellular factors, such as enzyme expression, concentration, post-translational 
modifications, physiological state of the tissue, etc.  
Two-substrates two-products enzymatic reactions 
1 2 1 2  
E
S S P P
 
 
Figure A2. General scheme for two substrates two products enzymatic reactions 
 
The general scheme (a random rapid-equilibrium binding scheme) for a reversible 
two-substrate two-product enzymatic reaction is shown in Figure A2. With the similar 
assumptions, as described for a reversible one-substrate one-product enzymatic reaction, 
the flux equation for a reversible two-substrate two-product enzymatic reaction can be 
derived as: 
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Considering that    and    share the same binding site on the enzyme, and    and    
share a different binding site on the enzyme, as usually is the case for reaction cofactors 
(such as NADH and NAD+, ATP and ADP, GTP and GDP, etc.), the flux equation can be 
modified to exclude the contributions of [  ][  ] or [  ][  ] product terms: 
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The flux expression (C.18) for a reversible two-substrate two-product enzymatic 
reaction contains four intrinsic model parameters (binding constants KS1, KS2, KP1 and KP2) 
and two extrinsic model parameters (forward and reverse reaction maximal velocities Vmaxf 
and Vmaxr), having the similar tissue-independent and tissue-dependent characteristics, as 
described above for the one-substrate one-product enzymatic reaction.  
Multi-substrates multi-products enzymatic reactions  
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where Si is i
th substrate, Pj is j
th product, NS and NP are number of substrates and products 
in the reaction, respectively, and αi and βj are the corresponding stoichiometric 
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  (C.20) 
where KSi and KPj are the binding constants (intrinsic model parameters) corresponding to 
substrates and products, respectively, and Vmaxf and Vmaxr are the forward and reverse 
reaction velocities (extrinsic model parameters). 
Thermodynamic constraints for enzymatic reactions:  
To maintain the thermodynamic consistency of an enzymatic reaction, the 
forward and reverse reaction velocities are constrained by the Haldane relationship [46]. 
At equilibrium, the net reaction flux is zero (J = 0), which gives the following 
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  (C.21) 
where eqK   is the apparent equilibrium constant for the reaction, which is the value of the 
reaction equilibrium-state quotient (i.e. ratio of product of product concentrations over 




temperature, ionic strength, and pH). The apparent equilibrium constant at pH = 7 (
0 (pH 7))eq eqK K   is calculated as: 
 
0Δ /0 rG RT
eqK e
    (C.22) 
where 
0ΔrG , R and T are the standard Gibbs free energy of the reaction at pH = 7, gas 
constant, and temperature, respectively. The standard Gibbs free energy of reactions in 
the mitochondrial bioenergetics model was obtained from references [46, 56, 68], and are 
listed in Part C. 
With the Haldane constraint (C.21), Vmaxr can be calculated from Vmaxf  and 
0
eqK   to 
reduce the number of unknown model parameters. Thus, the reaction flux expression for 
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  (C.23) 
Under the assumption that the substrate and product representing a co-factor pair 
bind with a given enzyme at the same binding site, one can show that the resulting 
reaction flux equation does not include the corresponding substrate and product terms. 
Since in the proposed integrated bioenergetics model all the co-factor pairs (e.g. 
NADH/NAD+, ATP/ADP/Pi, GTP/GDP/Pi and CoA/ACoA/SCoA) are assumed to bind 






Most of the metabolite transporters in the proposed integrated bioenergetics 
model involve the transport of two different metabolites or a metabolite and an ion. In 
general, there are two different types of such transporters: a co-transporter (symporter) 
that transports two different substances from one side to the other side of the inner 
mitochondrial membrane (IMM), and an antiporter (exchanger) that transports two 
different substances across the IMM in the opposite directions [133]. There are also 
uniporters, which transport one substance across the IMM, such as a Ca2+ uniporter, 
which is not considered in the present integrated bioenergetics model.  
For generality, a random-ordered rapid-equilibrium binding mechanism is 
assumed for all the transporters, i.e., the transporter can bind to the two substrates in an 
arbitrary order, similar to that described for a reversible two-substrate two-product 
enzymatic reactions. Thus, the transport flux equations for various transporters can be 
derived similarly.  
The general scheme for a co-transporter is shown below in Figure A3: 
 
 
Figure A3. General scheme for a co-transporter 
 
 
   
   
   
        
     




Here  𝑖 and  𝑖 are two distinct substrates at side i of the membrane (i =1, 2). The 
free transporter (E) binds to the two substrates in an arbitrary order before undergoing 
conformational changes. All association and dissociation processes are assumed to be 
reversible and rapid-equilibrium reactions. The rate limiting steps are the conformational 
changes in the substrate-bound transporters resulting in the transport of the substrates 
across the membrane. 
Assuming rapid equilibrium, the general flux equation for a co-transporter is 
given by 
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  (C.24) 
where Tmaxf and Tmaxr are the maximum forward and reverse transport rates, respectively. 
The general scheme for an anti-porter is shown below in Figure A4: 
 
 
Figure A4. General scheme for an anti-porter 
 
The anti-porters bind to the substrates from both sides of the membrane. The 
general flux equation for an anti-porter is similarly given by: 
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  (C.25) 
For all the metabolite transporters, the internal and external binding constants are 
assumed to be equal (KA1 = KA2 and KB1 = KB2). Therefore: 
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For non-electrogenic transporters, Tmaxf =Tmaxr and Keq = 1. For electrogenic 
transporters, such as the glutamate-aspartate exchanger (GAE) and the adenine nucleotide 
translocase (ANT), equilibrium constants are dependent on membrane potential, 
determined based on the Nernst equation. Detailed transport flux expressions for such 





Appendix III: Flux expressions for metabolic reactions and transport 
processes for the isolated mitochondria model 
In the proposed mitochondrial bioenergetics model, metabolic reaction and 
transport flux equations are derived based on thermodynamically-constrained enzymatic 
reaction and transport kinetic mechanisms [75, 133]. As described below, the intrinsic 
model parameters, such as binding constants (K’s), were either determined using 
previously published isolated enzyme and transporter kinetic data or set to well-
established published values. Most of the enzyme kinetic data were measured using 
isolated mitochondrial enzymes purified from the heart or liver tissue, as no such kinetic 
data are available for lung tissue. The assumption is that differences in the intrinsic 
properties of the mitochondrial enzymes, such as binding constants (K’s), between the 
heart, liver and lung are relatively small [75], under fixed experimental conditions 
(temperature, pH, and ionic strength). With the intrinsic model parameters K’s known, 
the extrinsic model parameters, such as the maximum reaction and transport velocities 
(Vmaxs and Tmaxs), of the integrated bioenergetics model for isolated lung mitochondria 
were then estimated using previously published and newly measured experimental data 
from isolated rat lung mitochondria as described in the Results section of the main paper. 
The extrinsic model parameters are assumed to be dependent on the activities of the 
enzymes and transporters in a particular tissue, which is dependent on several cellular 
factors, such as enzyme and transporter expressions, concentrations, post-translational 
modifications, and physiological state of the tissue. Particularly the mitochondrial 
enzyme and transporter activities in non-excitable lung tissue is expected to be 




In what follows, we provide the flux expressions for different enzymes and 
transporters used in the proposed integrated bioenergetics model. These flux expressions 
are determined based on the generalized flux expressions derived in the previous section. 
These flux expressions are then fitted to available experimental data on the kinetics of 
specific enzymes and transporters to estimate the associated parameter values (i.e. K’s, 
Vmax’s, Tmax’s). This is done using the “fmincon” algorithm in the MatLab optimization 
toolbox. Kinetic parameters for some of the enzymes and transporters are fixed at the 
well-established published values for which suitable kinetic data could not be identified. 
Only the values (estimated or fixed) of the intrinsic model parameters, such as binding 
constants K’s, are used in the integrated bioenergetics model. All extrinsic model 
parameters, such maximal reaction and transport velocities (Vmax’s and Tmax’s), were re-
estimated based on fittings of the integrated bioenergetics model to available and new 
experimental data from isolated rat lung mitochondrial experiments. 
Reaction 1: Pyruvate dehydrogenase (PDH) 
PYRm + CoAm + NADm ⇌ ACoAm + CO2 + NADHm + Hm+ 
For this reaction, the reactant concentrations are denoted as A = [ ]mPYR , B = [ ]mCoA , 
C = [ ]mNAD , D = [ ]mACoA , E = 2,[ ]mCO , F = [ ]mNADH . CO2 concentration is set at 
1.32×10-5 M based on Henry’s law and is assumed to be constant. The participating co-
factor pairs in the above reaction are NADH/NAD and CoA/ACoA. Thus, the overall 
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  (C.28) 
The above PDH-catalyzed reaction involves the generation of one proton. Thus, the 
pH-dependent apparent equilibrium constant for this reaction is defined as: 
 
' 0 7Δ / 10 mPDHr
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eqK e
    (C.29) 
where mpH  is pH in the mitochondrial matrix, and
0
r PDHG  is the transformed Gibbs free 
energy of the reaction catalyzed by PDH at pH = 7. Since the CO2 concentration is 
assumed constant, the factor  1 / EE K  in the denominator reduces to a constant value. 
Figure A5 shows the PDH reaction flux measured in isolated enzyme over a range 
of PYR, CoA, or NAD concentrations [134]. The model parameters (Table A4) were 
estimated by simultaneously fitting the solution of equation (C.28) to all the data in 
Figure A5 using the MATLAB “fmincon” optimizer. The solid lines in Figure A5 are the 
fits of equation (C.28) to the data.  
Even though the binding constant of PYR for PDH is estimated to be ~25 M in 
isolated enzyme experiments (as shown in Figure A5 and Table A1), the experimental 
data at the whole mitochondria level show that the apparent binding constant of PYR for 
PDH is around ~3-5 mM. This apparent inconsistency is caused by the enzyme pyruvate 
dehydrogenase kinase (PDK) [75]. PDH is known to be inhibited by the PDK, and PDK 
is inhibited by PYR. Thus, the apparent binding constant of PYR for PDH is affected by 
PDK. Therefore, for simplicity, only the apparent binding constant of PYR for PDH is 





Table A1: PDH model kinetic parameters 
Parameters Definition Value Source 





Estimated using data 
in Figure A5 
AK  
PYR binding 
constant in isolated 
PDH* 
52.52 10  M  Estimated using data 




51.49 10  M  Estimated using data 




53.50 10  M  Estimated using data 




51.49 10  M  Assumed to be the 




53.50 10  M  Assumed to be the 
same as KC 
'0Δr PDHG  
Gibbs free energy of 
the reaction (pH=7) 
-38.64 kJ/mol 
[68] 
*The binding constant of PYR for PDH is affected by the enzyme pyruvate dehydrogenase kinase 




Figure A5: Symbols: Reaction fluxes of pyruvate dehydrogenase (PDH) measured in 
isolated PDH in reference [134]. In these experiments, around ~16–20 µg PDH enzyme 
was used to catalyze the reaction. Reaction fluxes are plotted with three substrates 
varying at the concentrations as shown in the figures. (A) PYR concentration was varied 
from 0 to 0.6 mM, with CoA concentration fixed at 0.2 mM (red), 0.1 mM (blue), 0.07 
mM (green), or 0.05 mM (cyan), respectively; NAD concentration was fixed at 0.05 mM. 
(B) CoA concentration was varied from 0 to 0.3 mM, with NAD concentration fixed to 
0.5 mM (red), 0.25mM (blue), 0.1 mM (green), or 0.05 mM (cyan), respectively; PYR 
concentration was fixed at 0.25mM. (C) NAD concentration was varied from 0 to 0.6 




0.05 mM (cyan), respectively; CoA concentration was fixed at 0.1 mM. The solid lines 
are the fits of equation (C.28) to the data. 
 
Reaction 2: Citrate synthase (CITS) 
ACoAm+OXAm ⇌ CoAm+ CITm +2Hm+ 
For this reaction, the reactant concentrations are denoted as A = [ ]mACoA , B = 
[ ]mOXA , C = [ ]mCoA , D = [ ]mCIT .  Since CoA and ACoA are co-factor pairs, the overall 
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  (C.30) 
The reaction catalyzed by CITS generates two protons. Thus, the pH-dependent 
apparent equilibrium constant for this reaction is defined as: 
 





    (C.31) 
Figure A6 shows the CITS reaction flux measured in isolated enzyme over a range of 
ACoA, OXA, CIT, or CoA concentrations [48]. The model parameters in Table A5 were 
estimated by simultaneously fitting the solution of equation (C.30) to all the data in 
Figure A6 using the MATLAB “fmincon” optimizer. The solid lines in Figure A6 are 





Figure A6: (A) Forward flux as a function of substrates ACoA and OXA. The 
concentrations of OXA was 2.5 μM (green), 5.0 μM (blue), or 10 μM (red). (B) Forward 
reaction flux as a function of substrates OXA and ACoA.  ACoA concentration was 
2.5μM (green), 5.0μM (blue), or 10μM (red). (C) Reverse reaction flux as a function of 
CoA and CIT. CoA concentration was 20 μM (green), 33 μM (cyan), 50 μM (blue), or 
100 μM (red). (D) Reverse reaction flux as a function of concentrations of CoA and CIT. 
CIT concentration was 1.0 mM (green), 2.0 mM (cyan), 4.0 mM (blue), or 10 mM (red). 
This reaction was fit using data from reference [48] on forward reaction fluxes (Figure 
A6A and A6B) and reverse reaction fluxes (Figure A6C and A6D). The solid lines are the 
fit of equation A18 to the data. All data were obtained at 28°C, pH = 8.1. 
 
 
Table A 2: CITS model kinetic parameters 
Parameters Definition Value Source 





Estimated using data in Figure 
A6 
KA ACoA binding 
constant 
63.90 10  M  Estimated using data in Figure 
A6 
KB OXA binding 
constant 
64.53 10  M  Estimated using data in Figure 
A6 
KC CoA binding 








KD CIT binding 
constant 
34.30 10  M  Estimated using data in Figure 
A6 
'0Δ CITSrG  
Gibbs free energy of 




Reaction 3: Aconitase and Iso-citrate dehydrogenase (CITDH) 
The reactions catalyzed by aconitase and isocitrate (ISOCIT) dehydrogenase are: 
 Aconitase: CIT ⇌ ISOCIT + H2O 
  Isocitrate dehydrogenase: ISOCIT +NAD + H2O ⇌ AKG + NADH + 
CO2 
Under the assumption that the reaction catalyzed by aconitase is rapidly equilibrating, 
the reactions catalyzed by aconitase and isocitrate can be lumped into the following 
reaction 
CITm +NADm ⇌ AKGm + NADHm +CO2 
For this reaction, the reactant concentrations are denoted as A = [ ]mCIT , B = 
[ ]mNAD , C = [ ]mAKG , D = [ ]mNADH , and E = 2, [ ]mCO , which is assumed to be 
constant. 
 









A C B D E
K K K K K
 
   

     
         
     
  (C.32) 
The production of CO2 results in the generation of bicarbonate ions and one 
proton. Thus, the equilibrium constant for this reaction is defined as: 
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of NAD or NADH concentrations. The model parameters in Table A6 were estimated by 
simultaneously fitting the solution of equation (C.32) to the data in Figure A7 using the 
MATLAB “fmincon” optimization program package.  
 
 
Figure A7:  Symbols are reaction fluxes of isocitrate dehydrogenase measured in isolated 
enzyme experiments from reference [49]. Reaction fluxes are plotted with NAD and 
NADH concentrations varying at the concentrations shown in the figure. (A) Enzyme 
activity as a function of NAD in the absence (blue, triangle) or presence of 0.039 mM 
NADH (red, asterisk). (B) Inhibition effect of NADH on enzyme activity. Percent 
inhibition was calculated as 100(v0-v)/v0, where v0 and v are the enzyme flux rates in the 




Table A3: CITDH model kinetic parameters 
Parameters Definition Value Source 
Vmaxf Maximum forward 
reaction rate 
63.6 10 nmol 
/min/mg 
enzyme 
Estimated using data in Figure 
A7 
KA CIT binding 
constant 
31.30 10  M  Estimated using data in Figure 
A7 
KB NAD binding 
constant 
6500 10  M  Estimated using data in Figure 
A7 
KC AKG binding 
constant 
63.50 10  M  Estimated using data in Figure 
A7 
KD NADH binding 
constant 





'0Δ CITDHrG  
Gibbs free energy 
of the reaction 
(pH=7) 
2.81 KJ/mol [68] 
 
Reaction 4: AKG dehydrogenase (AKGDH) 
AKGm + CoAm + NADm ⇌ SCoAm+NADHm+CO2 
For this reaction, the reactant concentrations are denoted as A =[ ]mAKG , B = 
[ ]mCoA , C = [ ]mNAD , D = [ ]mSCoA , E = [ ]mNADH , and F = 2[ ]CO . The participating 
co-factor pairs in the above reaction are CoA/ACoA, and NADH/NAD. Thus, the overall 
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  (C.34) 
Since the CO2 produced results in the generation of a bicarbonate ion and one 
proton, the equilibrium constant for this reaction is defined as 
 




     (C.35) 
Figure A8 shows the AKGDH flux measured in isolated enzyme over a range of 
AKG, COA or NAD concentrations. The model parameters in Table A4 were estimated 
by simultaneously fitting the solution of equation (C.34) to the data in Figure A8 using 
the MATLAB “fmincon” optimization program package. The solid lines are model fits 
the data. 
Table A4: AKGDH model kinetic parameters 










Estimated using data in Figure 
A8 
KA 
AKG binding constant 685.9 10  M  
Estimated using data in Figure 
A8 
KB CoA binding constant 61.63 10  M  
Estimated using data in Figure 
A8 
KC NAD binding constant 646.6 10  M  









67.14 10  M  
Estimated using data in Figure 
A8 
'0Δ AKGDHrG  
Gibbs free energy of 






Figure A8: AKGDH activity as a function of substrate and product concentrations. (A) 
Forward reaction fluxes as a function of AKG concentration as shown at x axis. And 
concentrations of NAD and CoA were set to 0.033 mM and 0.005 mM (cyan), 0.066mM 








Forward reaction fluxes as a function of CoA concentration shown on the x axis. The 
concentrations of AKG and NAD were set to 0.025 mM and 0.02 mM (cyan), 0.05 mM 
and 0.04 mM (blue), 0.1 mM and 0.08 mM (green), 0.5 mM and 0.4 mM (red). (C) 
Forward reaction fluxes as a function of NAD concentration shown on the x axis. The 
concentrations of AKG and CoA were set to 0.05 mM and 0.005 mM (cyan), 0.1 mM and 
0.01mM (blue), 0.2 mM and 0.02 mM (green), 0.5 mM and 0.05 mM (red). (D) Net 
reaction fluxes as a function of NAD concentration shown on the x axis. AKG and CoA 
concentrations were fixed to 0.5 mM and 0.05 mM, respectively. The NADH 
concentration was set to 0 mM (red), 0.01 mM (green), 0.02 mM (blue), 0.05 mM (cyan). 
The symbols are experimental data [135] and solid lines are model fits to the data. 
 
Reaction 5: SCoA synthetase (SCAS) 
SCoAm + GDPm + Pim ⇌ SUCm + GTPm + CoAm + Hm+ 
For this reaction, the reactant concentrations are denoted as A = [ ]mSCoA , B = 
[ ]mGDP , C = [ ]mPi , D = [ ]mSUC , E =[ ]mGTP , and F = [ ]mCoA . The participating co-
factor pairs in this reaction are SCoA/CoA, ADP/ATP, ATP/Pi, and SCoA/SUC. 
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        (C.36) 
This reaction involves the generation of one proton, thus, the equilibrium constant 
for this reaction is defined as 
 




     (C.37) 
Figure A9 shows the SCAS flux measured in isolated enzyme over a range of 
GTP, GDP or SCA concentrations. The model parameters in Table A5 were estimated by 
simultaneously fitting the solution of equation (C.36) to the data in Figure A9 using the 




model fits to the data. 
Table A5: SCAS model kinetic parameters 
Parameters Definition Value Source 





Estimated using data in Figure 
A9 
KA SCoA binding 
constant 
612.5 10  M  Estimated using data in Figure 
A9 
KB GDP binding 
constant 
65.70 10  M  Estimated using data in Figure 
A9 
KC Pi binding constant 32.10 10  M  Estimated using data in Figure 
A9 
KD SUC binding 
constant 
6451 10  M  Estimated using data in Figure 
A9 
KE GTP binding constant 623.1 10  M  Estimated using data in Figure 
A9 
KF CoA binding constant 617.7 10  M  Estimated using data in Figure 
A9 
'0Δ SCASrG  
Gibbs free energy of 








Figure A9: SCAS activity as a function of substrate and product concentrations [50]. (A) 
Reverse reaction fluxes as a function of GTP concentration shown on the x axis. SUC 
concentrations were fixed at 0.4 mM (red), 1 mM (green), 10 mM (blue), 50 mM (cyan), 
while CoA was fixed to 0.1 mM. (B) Forward reaction fluxes as a function of GDP 
concentration as shown at x axis. The concentrations of GTP was set to 0 mM (red), 0.05 
mM (green) and 0.1 mM (blue), while inorganic phosphate (Pi) concentration fixed at 50 
mM and SCoA concentration fixed at 0.1mM. (C) Forward reaction fluxes as a function 
of SCoA concentration shown on the x axis. The concentrations of CoA were set to 0 mM 
(red), 0.02 mM (green), 0.04 mM (blue). (D) Forward reaction fluxes as a function of 
SCoA concentration shown on the x axis. SUC concentration were fixed to 0 mM (blue), 
0.5 mM (green), 2 mM (red). While phosphate concentration and GDP concentrations are 
fixed at 1 mM and 0.05 mM, respectively. 
 
Reaction 6: Nucleoside diphosphokinase (NDK) 
GTPm+ADPm ⇌ GDPm+ATPm 
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Table A6: NDK model kinetic parameters 
Parameters Definition Value Source 
KA GTP binding constant 6111 10  M                                   [46]
KB ADP binding constant 6100 10  M [46] 
KC GDP binding constant 6260 10  M [46] 
KD ATP binding constant 6278 10  M [46] 
'0Δr NDKG  




Parameters in this reaction do not affect the simulations in the main paper since the 
reaction is rapidly equilibrating.  
 
Reaction 7:  Succinate Dehydrogenase (SDH) 
SUCm + FADm ⇌ FUMm + FADH2,m, 
For this reaction, the reactant concentrations are denoted as A = [ ]mSUC , B = [
mFAD ], C = [ ]mFUM ,  and D = 2, ][ mFADH , and the participating co-factor pairs are 
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Figure A10 shows reaction fluxes for different concentrations of SUC and the 
exogenous electron acceptor phenazine methosulphate. The model parameters in Table 
A7 were estimated by simultaneously fitting the solution of equation (C.39) to the data in 




lines in Figure A10 are the fits of equation (C.39) to the data. 
 
Figure A10: SDH activity as a function of succinate and electron acceptor (phenazine 
methosulphate) concentrations [136]. Succinate concentration is indicated on the x axis, 
and electron acceptor concentrations are 0.067 (red), 0.10 (blue), 0.167 (yellow), 0.30 
(cyan), and 2 mM (black), respectively. 
 
Table A7: SDH model kinetic parameters 
Parameters Definition Value Source 
Vmaxf Maximum forward 
reaction rate 
6
6001.20 10  / min
   Estimated using 
data in Figure 
A10 
KA SUC binding 
constant 
31.80 10  M  Estimated using 
data in Figure 
A10 
KB FAD mimic binding 
constant 
6140 10  M  Estimated using 
data in Figure 
A10 
KC FUM binding 
constant 
31.80 10  M  Assumed the 
same as KA 
KD FADH2 binding 
constant 
62.45 10  M  Estimated using 
data in Figure 
A10 
'0Δr SDHG  
Gibbs free energy of 







Reaction 8: Fumarate Hydratase (FH) 
 FUMm + H2O ⇌ MALm  
For this rapidly equilibrating reaction, the reactant concentrations are denoted as A = 
[ ]mFUM , and B = [ ]mMAL . The reactant H2O is ignored in this reaction since its 
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Table A8: FH model kinetic parameters 
Parameters Definition Value Source 
KA FUM binding constant 31.8 10  M  fixed 
KB MAL binding constant 31.8 10  M  fixed 
'0Δr FHG  





Reaction 9: Malate Dehydrogenase (MDH) 
   MALm + NADm ⇌ OXAm + NADHm + Hm+ 
For this reaction, the reactant concentrations are denoted as A = [ ]mNAD , B = 
[ ]mMAL , C = [ ]mOXA , D = [ ]mNADH , the participating co-factor pairs are NADH/NAD, 
and MAL is known to be competitive inhibitor of OXA [137]. Thus, the overall reaction 
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The above reaction involves the generation of one proton, thus, the equilibrium 
constant for this reaction is defined as 
 
' 0 7Δ / 10 mMDHr
pHG RT
eqK e
    (C.42) 
Figure A11 shows reaction fluxes over different concentrations of NAD, OXA, 
and NADH. The model parameters in Table A9 were estimated by simultaneously fitting 
the solution of equation (C.41) to the data in Figure A11 using the MATLAB “fmincon” 
optimization program package. The solid lines in Figure A11 are the fits of equation 
(C.41) to the data. 
 
Figure A11: MDH activity [137] as a function of substrate and product concentrations 
(A) Forward reaction flux as a function of NAD and MAL. NAD concentrations are 
indicated on the x axis. MAL concentrations are fixed to 0.33 mM (green), 0.5 mM 
(magenta), 0.67 mM (cyan), 1 mM (yellow), 2 mM (blue), 4 mM (red). Product 
concentrations are set to zero. (B) Reverse reaction flux as a function of OXA and NADH 
concentrations. NADH concentrations are fixed at 0.0067 mM (cyan), 0.015 mM (blue), 
0.02 mM (green), 0.05 mM (red). (C) Reverse reaction flux as a function of NADH and 
MAL. NADH concentrations are indicated on the x axis and MAL concentrations were 
fixed to 0 mM (red), 1.5 mM (magenta), 3 mM (cyan), 4.5 mM (yellow), and 6 mM 
(blue). 
 
Table A9: MDH model kinetic parameters 
Parameters Definition Value Source 





data in Figure A11 
KA MAL binding constant 6155 10  M  Estimated using 







KB NAD binding constant 31.10 10  M  Estimated using 
data in Figure A11 
KC OXA binding constant 63.38 10  M  Estimated using 
data in Figure A11 
KD NADH binding 
constant 
636.1 10  M  Estimated using 
data in Figure A11 
'0Δr MDHG  
Gibbs free energy of 
the reaction (pH=7) 
28.83 KJ/mol [68] 
 
Reaction 10: Glutamate oxaloacetate transaminase (GOT) 
    ASPm +AKGm ⇌ GLUm + OXAm 
For this reaction, the reactant concentrations are denoted as A = [ ]mASP , B = 
[ ]mAKG , C = [ ]mGLU , D = [ ]mOXA , and the overall reaction flux equation is given by: 
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  (C.43) 
The equilibrium constant for this reaction is: 
 
' 0Δ /r GOTG RT
eqK e
    (C.44) 
Table A 10: GOT model kinetic parameters 
Parameters Definition Value Source 
KA ASP binding constant 33.9 10  M  [46] 
KB ΑKG binding constant 6430 10  M  [46] 
KC GLU binding constant 38.9 10  M  [46] 
KD OXA binding constant 688 10  M  [46] 
'0Δr GOTG  
Gibbs free energy of 




Reaction 11: Complex I (CI)  
   NADHm + UQm + Hm ⇌ NADm + UQH2m + 4ΔH 




from the mitochondria matrix into the inter-membrane space. Thus, this reaction flux is 
dependent on proton motive force defined as  [ / [] ]H i mG F RTln H H    , where F 
is the Faraday’s constant and   is the mitochondrial membrane potential. To take this 
dependency into account, the kinetic parameters was modified to be dependent on 
membrane potential [74, 138].  
For this reaction, the reactant concentrations are denoted as A = [ ]mNADH , B = 
[ ]mUQ , C = [ ]mNAD , D = 2[ ]mUQH , and the participating co-factor pairs in this 
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  (C.45) 
The model parameters in  
 
Table A11 were estimated by simultaneously fitting the solution of equation (C.45) to 
the data in Figure A11 using the MATLAB “fmincon” optimization program package. The 





Figure A12: CI activity [131] as a function of substrate and product concentrations (A) 
NADH concentrations are varied as shown on the x axis. UQ concentrations was set to 25 
µM (cyan), 50 µM (blue), 100 µM (green), 200 µM (red). Product concentrations are set 
to zero. (B) NADH concentrations are varied as shown on the x axis. UQ concentration 
was set to 100 µM and NAD concentration was fixed to 0 µM (red), 200 µM (green), 400 
µM (blue), 600 µM (cyan). (C) NADH concentrations are varied as shown on the x axis. 
UQ concentrations was set to 100 µM and UQH2 concentrations were set to 0 µM (red), 
100 µM (blue), 200 µM (green). (D) UQ concentrations are varied as shown on the x 
axis. NADH concentration was fixed to 10 µM and NAD concentration was set to 0 µM 
(red), 400 µM (blue), 600 µM (green). 
 
Table A11: CI model kinetic parameters 






Estimated using data 
in Figure A12 
KA NADH binding constant 61.50 10  M  
Estimated using data 
in Figure A12 
KB UQ binding constant 
658.1 10  M  
Estimated using data 
in Figure A12 
KC NAD binding constant 6428 10  M  
Estimated using data 






KD UQH2 binding constant 6519 10  M  
Estimated using data 
in Figure A12 
βCI 
Complex I free energy 
barrier 
0.5 Fixed 
'0Δr CIG  




Reaction 12: Complex II (CII) 
FADH2,m + UQm ⇌ FADm + UQH2,m 
For this reaction, the reactant concentrations are denoted as A = 2,[ ]mFADH , B = 
[ ]mUQ , C = [ ]mFAD , D = 2,[ ]mUQH , and the participating co-factor pairs are FAD/ 
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Table A12: CII model kinetic parameters 




61.50 10  M  
Assume the same as NADH 




658.1 10  M  
Assume the same as UQ binding 




6428 10  M  
Assume the same as NAD 




6519 10  M  
Assume the same as UQH2 
binding constant in CI 
'0Δr CIIG  
Gibbs free 
energy of the 
reaction (pH=7) 





Reaction 13: Complex III (CIII)  
UQH2m + 2CytCo + 2Hm ⇌ UQm + 2CytCr + 4ΔH 
For this reaction, the reactant concentrations are denoted as A = 2,[ ]mUQH , B = 
[ ]CytCo , C = [ ]mUQ , D = [ ]CytCr , and the participating co-factor pairs are 
UQm/UQH2,m, and CytCr/CytCo. In addition, the above reaction catalyzed by complex III 
involves pumping four protons from mitochondria matrix into inter-membrane space. 
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Table A13 were estimated by simultaneously fitting the solution of equation (C.47) to the 
data in Figure A13 using the MATLAB “fmincon” optimization program package. The 
solid lines are model fits to the data. 
 
Figure A13: CIII activity [130] as a function of substrate and product concentrations as 
indicated in the figures. (A) Oxidized form of cytochrome c concentrations were varied 
as shown on the x axis. UQH2 concentrations were set to 25 µM (cyan), 15 µM (blue), 10 
µM (green), 7 µM (red). Product concentrations are set to zero. (B) Oxidized form of 
cytochrome c concentrations were varied as shown on the x axis. Reduced form of 
cytochrome c concentrations were set to 0 µM and 10 µM, respectively. UQ 
concentration was fixed to 20 µM. (C) UQH2 concentrations were varied as shown on the 
x axis. Reduced form of cytochrome c concentrations were set to 0 µM (cyan), 5 µM 
(blue), 10 µM (green), 15 µM (red). (D) UQH2 concentrations are varied as shown on the 
x axis. Oxidized form of cytochrome c concentrations were fixed to 7 µM (cyan), 12 µM 











Table A13: CIII model kinetic parameters 
Parameters Definition Value Source 




Estimated using data in Figure 
A13 
KA UQH2 binding 
constant 
64.66 10  M  Estimated using data in Figure 
A13 
KB CytCo binding 
constant 
63.76 10  M  Estimated using data in Figure 
A13 
KC UQ binding constant 64.08 10  M  Estimated using data in Figure 
A13 
KD CytCr binding 
constant 
64.91 10  M  Estimated using data in Figure 
A13 




'0Δ CIIIrG  
Gibbs free energy of 




Reaction 14: Complex IV (CIV) 
2CytCr+0.5O2+2Hm ⇌ 2CytCo+H2O+2ΔH 
For this reaction, the reactant concentrations are denoted as A = [ ]CytCr , B = 2[ ]O
, C =[ ]CytCo , and the participating co-factor pair is CytCr/CytCo. In addition, two protons 
arepumped from the matrix side to the inter-membrane space. Another two protons are 
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  (C.48) 
The model parameters in Table A14 were estimated by simultaneously fitting the solution 
of equation (C.48) to the data in Figure A14 using the MATLAB “fmincon” optimization 






Figure A14: CIV activities as a function of the substrate cytochrome c and membrane 
potential (A), or oxygen (B) [139, 140]. In Figure 14A, CIV enzyme turnover numbers 
were measured under different fractions of reduced cytochrome c and membrane 
potentials. In Figure 14B, CIV reaction fluxes were measured under different oxygen 
concentrations. 
Table A14: CIV model kinetic parameters 






Estimated using data in 
Figure A14 
KA CytCr binding constant 6680 10  M  
Estimated using data in 
Figure A14 
KB    Oxygen binding constant 65.4 10  M  
Estimated using data in 
Figure A14 
KC CytCo binding constant 6680 10  M  Assumed the same as KA 
βCIV 
Complex IV free energy 
barrier 
0.5 Fixed 
'0Δr CIVG  




Reaction 15: Complex V (CV) 
ADPm + Pim +3Hi + Hm
+  ⇌ ATPm + 3Hm+ 
For this reaction, the reactant concentrations are denoted as A = [ ]mADP , B = [ ]mPi , C 
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  (C.49) 
Table A15: CV model kinetic parameters 
Parameters Definition Value Source 
KA ADP binding constant 610 10  M  Fixed 
KB Pi binding constant 30.5 10  M  Fixed 
KC ATP binding constant 31 10  M  Fixed 
𝛽𝐶𝑉 Complex V free energy barrier 0.5 Fixed 
'0Δr CVG  





Metabolic Transport Fluxes across the Mitochondrial Inner Membrane: 
Transport 1: Pyruvate-Hydrogen Cotransporter (PYRH)  
PYRe + He
+ ⇌ PYRm + Hm+ 
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  (C.50) 
Table A16: PYRH model kinetic parameters 
Parameters Definition Value Source 
KPYR PYR binding constant 30.24 10  M  [141] 
KH H
+ binding constant 1 × 10 7 M Fixed 
 
Transport 2: Glutamate-Hydrogen Cotransporter (GLUH) 
GLUe + He
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Table A17: GLUH model kinetic parameters 
Parameter Definition Value Source 
KGLU GLU binding constant 30.5 10  M  Fixed 
KH Proton binding 
constant 
71 10  M  Fixed 
 
Transport 3&4: Dicarboxylate Carrier (DCC) 
DCC (SUC): Pie + SUCm
 ⇌ Pim + SUCe 
DCC (MAL): Pie + MALm
 ⇌ Pim + MALe 
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Table A18: DCC model kinetic parameters 
Parameter Definition Value Source 
KPi Pi binding constant 30.93 10  M  [141] 
KMAL MAL binding constant 31.17 10  M  [141] 




Transport 5: Tricarboxylate Carrier (TCC) 
TCC is non-electrogenic, only 𝐻𝐶𝐼𝑇   and 𝑀 𝐿   are accepted as transport species of 
TCC. One proton must bind to CIT for transport process to occur. 
HCITe + MALm
 ⇌ HCITm + MALe 
 
 
The flux equation for this antiporter is:  
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Table A19: TCC model kinetic parameters 
Parameter Definition Value Source 
KCIT CIT binding constant 31 10  M  Fixed 
KMAL MAL binding constant 30.25 10  M  [141] 
KH Proton binding constant 71 10  M  Fixed 
 
Transport 6: AKG-MAL Exchanger (OME) 
AKGe + MALm
 ⇌ AKGm + MALe 
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Table A20: OME model kinetic parameters 
Parameter Definition Value Source 
KAKG AKG binding constant 30.24 10  M  [141]* 
KMAL MAL binding constant 31 10  M  [141]* 
KH Proton binding constant 71 10  M  Fixed 
*External binding constant and internal binding constant for AKG are reported to be 0.31 
mM and 0.17 mM, respectively [141]. For simplicity, internal binding constant and 
external binding constant are assumed the same in this model. So an average value of 




1.36 mM and 0.71 mM, respectively. Thus an average value of 1 mM is used as MAL 
binding constant. 
 
Transport 7: ASP-HGLU Exchanger (GAE) 
ASPe + HGLUm
 ⇌ ASPm + HGLUe 
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Table A21: GAE model kinetic parameters 
Parameter Definition Value Source 
KASP ASP binding constant 30.12 10  M  [141] 
KGLU GLU binding constant 30.25 10  M  [141] 
KH Proton binding constant 71 10  M  Fixed 
 
Transport 8: ATP-ADP Anti-Transporter (Adenine Nucleotide Translocase, ANT): 
ADPe + ATPm
 ⇌ ADPm + ATPe 
Free ATP carries four negative charges while free ADP carries three negative 
charges. Therefore, the transport process catalyzed by ANT is affected by membrane 
potential. The flux equation was modified based on [46] to account for the effect of 
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Table A22: ANT model kinetic parameters 
Parameters Definition Value Source 
KADP ADP binding constant 610 10  M  [141] 
KATP ATP binding constant 610 10  M  [141] 
βANT ANT free energy barrier 0.6 [46] 
 
Transport 9: Inorganic Phosphate Carrier (PIC) 
Pie + He
+ ⇌ Pim + Hm+ 
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Table A23: PIC model kinetic parameters 
Parameters Definition Value Source 
KPi Pi binding constant 39.4 10  M  [141] 
KH H
+ binding constant 71 10  M  Fixed 
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Table A24: Proton leak model kinetic parameters 
Parameters Definition Value Source 
KH H





Appendix IV: Governing mass balance equations for the isolated 
mitochondria bioenergetics model 
Buffer region: 
( ) ( )
[ ]e
e PIC DCC MAL DCC SUC
d Pi
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dt
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Mitochondrial matrix region: 
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[ ]m
m CI CII CIII
d UQ
V J J J
dt
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2[ ] [ ]m m
m m
d UQH d UQ
V V
dt dt
     (C.97) 
Mitochondria membrane potential: 
 
1
4 2 4 3CI CIII CI ANT HLEAKV ANT
imm
d
J J J J J J
dt C

        (C.98) 
where immC  is capacitance of the inner mitochondrial membrane. 
Oxygen consumption: 
     For membrane potential experiments, the chamber is open to the atmosphere, and 
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      For oximetry experiments, the chamber is a closed system, and oxygen is consumed 
by the mitochondria at complex IV. Therefore, 
  2
[ ]
0.5m e i CIV
d O
V V V J
dt





Appendix V: Flux expressions for transport process and reactions for 
the isolated rat lung bioenergetics model 
Cytosolic region 
Reaction 1: Hexokinase (HK) 
GLCc + ATPc ⇌ G6Pc+ ADPc + Hc 
For this reaction, the reactant concentrations are denoted as A = [ ]cGLC , B =
[ ]cATP , C = [ ]6 cG P , D = [ ]cADP , and ATP/ADP is considered a co-factor pair. In 
addition, this enzyme is known to be inhibited by its product, G6P [61, 99]. The flux 
equation is modified based on [61] to account for the inhibitor effect. The overall reaction 
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Table A25: HK model kinetic parameters 
Parameter Definition Value Source 
KA GLC binding constant 1×10
-4 M [142] 
KB ATP binding constant 1.16×10
-4 M [142] 
KC G6P binding constant 1×10
-4 M Assumed the same as 
KA 
KD ADP binding constant 1.26×10
-4 M [142] 
KiC G6P inhibition constant 27.8×10
-3 M [61] 
'0Δr HKG  




Reaction 2: Phosphoglucose isomerase (PGI) 
G6Pc ⇌ F6Pc 
For this reaction, the reactant concentrations are denoted as A =[ ]6 cG P , B =
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Table A26: PGI model kinetic parameters 
Parameter Definition Value Source 
KA G6P binding constant 30.59 10  M  [144] 
KB F6P binding constant 30.095 10  M  [144] 
'0Δr PGIG  





Reaction 3: Phosphofructokinase (PFK) 
F6Pc + ATPc ⇌ F16BPc+ADPc+H+ 
The reactant concentrations are denoted as A = [ ]6 cF P , B = [ ]cATP , C = 
[ ]16 cF BP , D = [ ]cADP .  
PFK is the key regulatory enzyme for glycolysis. It follows sigmodial kinetics 
with respect to F6P. ATP allosterically inhibits PFK by decreasing its affinity for F6P 




allosteric site and reverse the inhibitory action of ATP [99]. In addition, PFK is inhibited 
by cytosolic citrate [61, 99].  
Thus, the reaction flux equation is modified to account for the regulatory effects 
of ATP, ADP, AMP and citrate based on [145]. The proportion of PFK in active state (R 
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Even though fructose 2,6-bisphosphate is also an activator of PFK, its 
physiological concentration (30 µM) is sufficient to fully activate PFK (half maximal 
activation occurs at ~2µM) [100]. Thus, its effect is not considered in this model. 
The overall reaction flux equation 
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The activation constants or inhibition constants were estimated based on available 
data from rat lung PFK shown in Figure A15. In Figure A15, symbols are experimental 






Figure A15: (A) Effect of citrate concentration on normalized enzyme activities measured 
in isolated adult rat lung. Symbols are experimental data obtained from [146] and solid 
lines are model fits of Equation (C.105) to the data. (B) Effect of ATP concentration on 
apparent S0.5 of F6P measured in rat lung. S0.5 is defined as the concentration by which 
half maximal velocity is achieved. (C) Effect of AMP and ADP inhibition on normalized 
enzyme activity. Symbols in (B) and (C) are experimental data obtained from [100] and 
solid lines are model fits. (D) Predicted cooperative feature of PFK with respect to F6P 
under different ATP concentrations. 
 
Table A27: PFK model kinetic parameters 
Parameter Definition Value Source 
KA F6P binding constant 30.032 10  M  [147] 
KB ATP binding constant 30.020 10  M  [147] 
KC F16BP binding constant 30.032 10  M  Assumed the same as KA 
KD ADP binding constant 30.020 10  M  Assumed the same as KB 
KiCIT CIT inhibition constant 35.5 10  M  Estimated from Figure A15 
KiATP ATP inhibition constant 64.9 10  M  Estimated from Figure A15 
KaAMP AMP activation constant 61.75 10  M  Estimated from Figure A15 
KaADP ADP activation constant 63.5 10  M  Estimated from Figure A15 
n Hill coefficient 2.3 Estimated from Figure A15 







Reaction 4: Aldolase and triose phosphate isomerase (ALD) 
F16BPc ⇌ 2GAPc 
This is a lumped reaction of F16BP aldolase and triose phosphate isomerase  
   F16BP Aldolase: F16BP ⇌ GAP + DHAP 
   Triose phosphate isomerase:  DHAP ⇌ GAP 
The reactant concentrations are denoted as A = [ ]16 cF BP , B = [ ]cGAP . The 
overall reaction flux equation 
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Table A 28: ALD model kinetic parameters 
Parameter Definition Value Source 
KA F16BP binding constant 61.7 10  M  [148] 
KB GAP binding constant 61.7 10  M  Assumed the same as KA 
'0Δr ALDG  





Reaction 5: Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) 
GAPc + Pic + NADc ⇌ BPGc + NADHc + Hc 
The reactant concentrations are denoted as A = [ ]cGAP , B = [ ]cPi , C =[ ]cNAD , D 
= [ ]cBPG , E =[ ]cNADH . NAD/NADH are considered cofactor pairs. The overall 
reaction flux equation 
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Table A29: GAPDH model kinetic parameters 
Parameter Definition Value Source 
KA GAP binding constant 620.7 10  M  [149] 
KB Pi binding constant 32.9 10  M  Set to initial concentration 
KC NAD binding constant 617.8 10  M  [149] 
KD BPG binding constant 620.7 10  M  Assumed the same as KA 
KE NADH binding constant 617.8 10  M  Assumed the same as KC 
'0Δ GAPDHrG  





Reaction 6: Phosphoglycerate Kinase (PGK) 
BPGc + ADPc ⇌ PEPc + ATPc 
The reactant concentrations are denoted as A = [ ]cBPG , B = [ ]cADP , C =[ ]cPEP
, D = [ ]cATP . ADP/ATP is considered a cofactor pair. Thus, the overall reaction flux 
equation 
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Table A30: PGK model kinetic parameters 
Parameter Definition Value Source 
KA BPG binding constant 30.01 10  M  [150] 
KB ADP binding constant 30.4 10  M  Assumed the same as KD 
KC PEP binding constant 30.01 10  M  Assumed the same as KA 
KD ATP binding constant 30.4 10  M  [150] 
'0Δr PGKG  




Reaction 7: Pyruvate Kinase (PK) 




The reactant or regulator concentrations are denoted as A = [ ]cPEP , B = [ ]cADP , 
C =[ ]cPYR , D = [ ]cATP . E=[ ]16 cF BP .ADP/ATP is considered a cofactor pair. The 
enzyme is known to be strongly activated by low concentration of F16BP [151, 152].  
The overall reaction flux equation 
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Table A31: PK model kinetic parameters 
Parameter Definition Value Source 
KA PEP binding constant 30.26 10  M  [151] 
KB ADP binding constant 30.40 10  M  [151] 
KC PYR binding constant 30.26 10  M  Assume the same as KA 
KD ATP binding constant 30.40 10  M  Assume the same as KB 
KaE F16BP activation constant 61 10  M  [151] 
'0Δr PKG  





Reaction 8: Lactate Dehydrogenase (LDH) 
PYRc + NADHc + Hc ⇌ LACc + NADc+ 
The reactant concentrations are denoted as A = [ ]cPYR , B = [ ]cNADH , C =
[ ]cLAC , D = [ ]cNAD . NAD/NADH is considered a cofactor pair. Thus, the overall 
reaction flux equation 
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Table A32: LDH model kinetic parameters 
Parameter Definition Value Source 
KA PYR binding constant 30.052 10  M  [153] 
KB NADH binding constant 60.68 10  M  Fixed to initial 
concentration 
KC LAC binding constant 34.934 10  M  [153] 
KD NAD binding constant 6340 10  M  Fixed to initial 
concentration 
'0Δr LDHG  





Reactions 9 and 10: Pentose phosphate pathway reactions (PPP) 
6-Phosphogluconate Dehydrogenase (6PGDH) 
G6Pc + 2NADPc ⇌ R5Pc + 2NADPHc+ 2Hc+ CO2; '0ΔrG  =-20.66 kJ/mol 





; '0ΔrG =-34.23 kJ/mol 





⇌ 2CO +2NADPH +2Hc c ; '0Δr PPPG =-54.89 kJ/mol 
The reactant concentrations are denoted as A = [ ]6 cG P , B = [ ]cNADP , C = 2[ ]CO , 
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Table A33:PPP model kinetic parameters 
Parameter Definition Value Source 
KA G6P binding constant 636 10  M  [154] 
KB NADP binding constant 64.8 10  M  [154] 
KC PG6 binding constant 636 10  M  [154] 
KD NADPH binding constant 64.8 10  M  [154] 
'0Δr PPPG  








Reaction 11: Glutathione reductase (GSR) 
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Table A34: GSR model kinetic parameters 
Parameter Definition Value Source 
KA GSSG binding constant 661 10  M  [156] 
KB NADPH binding constant 67.6 10  M  [156] 
KC GSH binding constant 661 10  M  Assumed the same as KA 
KD NADP binding constant 67.6 10  M  Assumed the same as KB 
'0
,eq GSRK  Equilibrium constant (pH=7) 0.075 
[157] 
Reaction 12: GSH Peroxidase (GPx) 
2GSHc + H2O2,c ⇌ GSSGc + 2H2O 
The reactant concentrations are denoted as A = [ ]cGSH , B = 2 2[ ]H O , C =
[ ]cGSSG .The reactant H2O is ignored for this reaction. Thus, the overall reaction flux 
equation 
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Table A35: GPx model kinetic parameters 
Parameter Definition Value Source 
KA GSH binding constant 33 10  M  [158] 
KB H2O2 binding constant 61 10  M  [158] 
KC GSSG binding constant 33 10  M  Assumed the same as KA 
'0Δr GPxG  
Gibbs free energy of the 







Reaction 13: ATPase  
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Table A36: ATPase model kinetic parameters 
Parameter Definition Value Source 
KA ATP binding constant 31 10  M  Fixed 
KB ADP binding constant 6100 10  M  Fixed 
KC Pi binding constant 31 10  M  Fixed 
'0Δ ATPaserG  





Reaction 14: Adenylate kinase (AK) 
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Table A37: AK model kinetic parameters 
Parameter Definition Value Source 
KA ATP binding constant 31 10  M  [112] 
KB AMP binding constant 610 10  M  [112] 
KC ADP binding constant 6100 10  M  [112] 
'0Δr AKG  




For this rapidly equilibrating reaction,Vmaxf was set to be 1e7 nmol/min/lung. 
Reaction 15: Alanine Aminotransferase (AA) [61] 
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Table A38: AA model kinetic parameters 
Parameter Definition Value Source 
KA ALA binding constant 31 10  M  [61] 
KB PYR binding constant 6100 10  M  [61] 




For the mitochondrial regions, the reaction flux equations are the same as those in our 
integrated model of the bioenergetics of mitochondria isolated from rat lungs [24]. 
Values of pertinent parameters were set to those estimated for our mitochondria model 




Appendix III: Flux expressions for metabolic reactions and transport processes for 
the isolated mitochondria model. 
Transport Fluxes 
Transport 1: Glucose transporter (GLUT)  
Glucose transport between blood and cytosol is controlled by AMPK (AMP-
activated protein kinase). As energy charge falls, glucose transport is activated by 
AMPK. Thus, the flux equation is modified to account for the cytosolic AMP effect on 
glucose transport. 
GLCb



































  (C.117) 
Table A 39:GLUT model kinetic parameters 
Parameter Definition Value Source 





30.21 10  M  
Fixed to AMP initial 
concentration 
 
Transport 2: Pyruvate transporter (PYRT) 
This transport process is catalyzed by the enzyme monocarboxylate transporter 
(MCT). Km for pyruvate and lactate are 0.1 mM and 0.7 mM, respectively [159]. 
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Table A40: PYRT model kinetic parameters 
Parameters Definition Value Source 
KPYR PYR binding constant 30.1 10  M  
[159] 
 
Transport 3: Lactate transporter (LACT)  
LACb
 + Hb
+ ⇌ LACc + Hc+ 
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Table A 41: LACT model kinetic parameters 
Parameters Definition Value Source 
KLAC LAC binding constant 30.7 10  M  
[159] 
 
Transport 4: Phosphate transporter (PIT) 
Phosphate is co-transported with sodium ions (Na+) between blood and cytosol. 
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Table A42: PIT model kinetic parameters 
Parameters Definition Value Source 
KPi Pi binding constant 
32 10  M  
Fixed 
Transport 5-11 are the same as in the mitochondria model.  
Transport 12: Malate-Aspartate Shuttle (MAS) 
Four reactions and two transport fluxes are involved in Malate-aspartate shuttle, 




mitochondrial GOT, OME and GAE. For simplicity and in order to reduce number of 
unknown parameters, the overall process is treated as one transporter. 
NADHc + NADm
+ ⇌ NADHm + NADc+ 
The transporter GAE is driven by membrane potential. In addition, the 
equilibrium constants of MDH is affected by pH. Therefore, the apparent equilibrium 
constant for MA shuttle is  
 , , , 1 , 2 exp 10
m cpH pHm
eq MA eq GAE eq MDH eq MDH
F
K K K K
RT
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The overall flux equation is defined as 
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Table A43: MAS model kinetic parameters 
Parameters Definition Value 
KNADH KNAD 
Product of NADH binding constant and NAD 
binding constant 
61 10  M  
 
Transport 13: Passive Proton Leak [46], is the same as the mitochondria model  
Appendix VI: Governing mass balance equations for the lung tissue 
bioenergetics model 
Reservoir region:  
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     (C.133) 






V J J J
dt
































     (C.139) 
[ ]c
PK LDH PYRT PYRHc
d PYR
V J J J J
dt












    (C.142) 
( )
[ ]c












     (C.144) 
[ ]c
PK LDH PYRT PYRHc
d PYR
V J J J J
dt

































    (C.150) 
( ) ( )
[ ]c
PIT PIC DCC SUC DCC Mc AL GAPDH ATPase
d Pi
V J J J J J J
dt






     (C.152) 
[ ]
2c HK PFK PGKc PK AK ATPase ANT
d ADP
V J J J J J J J
dt
          (C.153) 
[ ]c
HK PFK PGK PK AK ATPase Ac NT
d ATP
V J J J J J J J
dt




V J J J
dt
      (C.155) 
[ ] [ ]c c
c c
d NAD d NADH
V V
dt dt
     (C.156) 
[ ]




      (C.157) 
[ ] [ ]c c
c c
d NADP d NADPH
V V
dt dt






      (C.159) 
[ ]


















    (C.162) 
Mitochondria region 
The ordinary differential equations in mitochondria are the same as in the 


















     (C.165) 
[ ]m
m MDH CITS GOT
d OXA
V J J J
dt





m CITS ICDH TCC
d CIT
V J J J
dt






V J J J
dt






     (C.169) 
DH ( )
[ ]m
m SCAS S DCC SUC
d SUC
V J J J
dt







     (C.171) 
( )
[ ]m
m FH MDH DCC MAL TCC
d MAL
V J J J J
dt






     (C.173) 






     (C.174) 
DH
[ ]m
m MAS P ICDH AKGDH MDH CI
d NADH
V J J J J J J
dt
        (C.175) 
[ ] [ ]m m
m m




    (C.176) 
[ ]m
m ANT NDK CV
d





       (C.177) 














     (C.179) 












     (C.181) 
DH DH
[ ]




V J J J J
dt
CoA
      (C.182) 
(( ) )
[ ]






























J J J J J










   










m CI CII CIII
d UQ
V J J J
dt
       (C.185) 
2[ ] [ ]m m
m m
d UQH d UQ
V V
dt dt






4 2 4 3CI CIII C CV HLEAKIV ANT MAS
imm
d




       (C.187) 
Oxygen consumption: 





   (C.188) 
 
